Benedetti, E. L., (A) 343
Benjamins, J. A., (A) 722
Bennike, T., (A) 135
Bera, D. K., (O) 198
Berasina, S. F., (A) 695
Berenberg, J., (A) 327
Berger, T. G., (A) 148
Berhan, T. Y., (A) 333
Bernardi, C. D. V., (A) 691
Berreman, J. M., (A) 512
Betts, R. P., (A) 694
Bhanu, B. V., (A) 499
Bharadwaj, V. P., (A) 510, 670, 686, 688
Bharathi, R., (A) 671
Bhargava, D. K., (A) 360
Bharija, S. C., (A) 332
Bhate, R. D., (A) 668
Bhatia, V. N., (A) 327
Bhatki, S., (A) 328
Bhatnagar, A., (A) 505
Bhutani, L. K., (A) 143, 339, 339, 340, 504
Bierther, M., (O) 64, 70, (A) 685
Binford, C. H., (O) 1, (A) 169, 175, 176, (O) 269, (A) 351, 351, 352, 353, 684
Birch, M. C., (A) 133
Birdi, T. J., (A) 144, 680
Blank, A., (A) 331
Bloom, B. R., (A) 180, 181, 335, 678, 680, 699, 727
Bloombaum, M., (B) 129
Bobhate, S. K., (A) 331
Boddingius, J., (A) 138
Boere, W. A. M., (A) 699
Bogaert, D. H., (A) 151
Bonhomme, J., (A) 500
Bonnici, E., (A) 134
Boon, J. J., (A) 348
Boonthanom, A., (A) 672
Borua, P. C., (A) 498
Bose, C., (A) 334
Bottorff, M. B., (A) 497
Bouckaert, A., (O) 461
Bourland, J., (O) 517
Bradley, D., (A) 356, 356, 511
Bragina, V. S., (A) 494
Brand, P. W., (A) 513
Brandsma, J. W., (B) 129, (A) 359, 513
Brantley, P., (A) 162
Brantley, P. J., (O) 251
Brennan, P. J., (A) 139, 176, 178, 180, 180, 343, (C) 484, 487, (A) 680, 680, 683, 685, 712, 715, 721, 727
Brett, S. J., (A) 139, (O) 211, (A) 349, 349
Britton, S., (A) 359
Brodthagen, H., (A) 514
Brosman, C., (A) 335
Brown, A., (A) 163, 354
Brown, A. A., (O) 559
Brown, H. L., (O) 1
Brown, I. N., (A) 698
Brown, S., (A) 343
Browne, S. G., (N) 122, 125
Brubaker, M. L., (O) 517
Bruyninckx, W. J., (A) 726
Buchanan, T. M., (A) 178, 182, (O) 262, (A) 335, 679, 684, 684, 713, 715
Bueno Marco, G., (A) 361
Bulakh, P. M., (A) 673
Bullock, W. E., (A) 144, (O) 559
Burchard, G.-D., (O) 64, 70, (A) 685
Bure, N. P., (A) 673

Campbell, P. B., (A) 184
Campos-Outcalt, D., (A) 493, 666
Carayon, A., (B) 663
Cartel, J.-L., (O) 15
Casal, M. J., (A) 361
Casas, J. G., (A) 682
Cassou, M., (A) 139
Castets, M., (A) 149
Caticha-Alfonso, O., (C) 483
Cavalcanti, Z. M. de O., (A) 142
Chacko, C. J. G., (C) 116, 120
Chaise, F., (A) 694, 694
Chakinis, C., (A) 354
Chakrabarty, A. K., (A) 505, 676
Chakrabarty, N., (A) 499
Chakravarti, R. N., (A) 510, 689
Chalopin, J. M., (A) 500
Chandorkar, A. G., (A) 673
Chandorkar, R. K., (A) 334
Chandrakar, K. P., (A) 692
Chang, P. H. C., (A) 167, (E) 289, (A) 347
Chaparas, S. D., (A) 353
Charuwichitratana, S., (A) 672
Chatterjee, B., (A) 669
Chatterjee, B. R., (A) 685
Chatterjee, D., (A) 715
Chattopadhyay, S. P., (A) 498
Chaudhary, R. C., (A) 512
Chaudhuri, S. K., (A) 679
Chaudhury, S. K., (A) 669
Chawhan, R. N., (A) 332
Chawla, T. C., (A) 360
Chehl, S. K., (A) 167, 720
Chen, J., (A) 134, 357
Chen, J., *et al.*, (A) 136
Chen, R., (O) 56
Chernysheva, L. M., (A) 494
Chidambaram Pillai, S., (A) 511
Chiewsilp, P., (O) 28
Ching, C. Y., (A) 163
Ching, N., (A) 163
Chiracharyavej, T., (O) 28
Cho, S.-N., (A) 139, 715, 717
Choudhary, S. K., (A) 512
Chovet, M., (A) 330
Christian, M., (O) 19, (A) 356, 356, 499, 511, (O) 524, (N) 660, 660, 660, 660, 692
Christie, J. D., (A) 358
Christy, S. A., (A) 165
Chutha, S., (A) 672

Clark-Curtiss, J. E., (A) 170, 344, 711
Clement, F., (A) 344
Closs, O., (A) 351
Cocito, C., (A) 712
Coghill, G., (O) 582
Cohn, Z. A., (A) 337, 708, 725
Cole, G. W., (A) 152
Coleman, W. C., (O) 255
Colizzi, V., (A) 140
Collings, L. A., (A) 505, 678
Collins, F. M., (A) 149, 697, 698
Colston, M. J., (A) 140, 337, 342
Conalty, M. L., (A) 671
Connolly, S. M., (A) 153
Connor, D. H., (A) 684
Convit, J., (A) 148, 181, 358, 680
Cook, J. L., (A) 361
Cordero, C. F. A., (A) 147
Corn, J., (A) 140
Corsey, R., (A) 151
Costa Cordova, H., (O) 595, (A) 689
Cottenot, F., (A) 133
Cottler-Fox, M., (A) 359
Courtright, P., (A) 137
Cree, I. A., (O) 582
Crepon, M.-O., (C) 481
Cross, G. M., (A) 361
Crouse, D. T., (A) 358
Curtis, J., (A) 144, 146, 503
Curtiss, R., III, (A) 170, 344, 711
Cutler, E., (A) 183
Cynamon, M. H., (A) 165

Daffé, M., (A) 342, 346
Daneshmend, T. K., (A) 494
Dang Duc Trach, (A) 343
Danguy, E., (A) 357
Daniel, T. M., (A) 360
Dao, A. H., (A) 132
Date, A., (O) 455
Datta, A. K., (O) 45, (A) 686, 688
Datta, G., (O) 428
Dauguet, C., (A) 344
Dave, D. S., (A) 354
David, H. L., (A) 145, 340, 342, 343, 344, 344, 345, 346, 352, 685
Davis, R., (A) 183
Davis, R. W., (A) 699
Daya, H., (A) 697
de Almeida, R. G., (A) 666
de Almeida, S. M. R., (A) 137
de Almeida Neto, E., (A) 137
de Bracco, M. M. de E., (O) 218
de Chastellier, C., (A) 336
de Herrera, M., (O) 595, (A) 689
De Jonge, S., (A) 338
de la Barrera, S. S., (O) 218
de la Cruz, F., (A) 336
de la Cruz Castillo, F., (A) 336
de la Solana Dumas, J., (A) 147
de Lange, G., (A) 355
de Latini, M. D. S., (A) 360
de Oliveira, N. R., (A) 137
De Ridder, K., (A) 687
de Souza, Z. W. T., (A) 142
de Vries, J. L., (A) 355
de Vries, R. R. P., (O) 56, (A) 148, 358, 502
del Hoyo, M., (O) 410
Delaha, E. C., (A) 695
Della Bruna, C., (A) 135
Deo, M. G., (A) 502
Deo, S. S., (A) 342
Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences, (A) 133, 134
Depasquale, G., (A) 134
Desikan, K. V., (O) 39, 395, (A) 498, 501, 510, 668
Devanandan, M. S., (A) 675
Dharma Rao, T., (A) 679
Dhople, A. M., (A) 166, (O) 365, (A) 507, 687
Diaz, M. L., (A) 150
Dickinson, J. M., (A) 695
Dobson, G., (A) 345, 686, 687
Docherty, M. A., (A) 170, 344, 711
Dols, M. W., (A) 132
Dong, L., (A) 357
Dongre, V. V., (A) 355
Dorken, E., (A) 149
Douglas, J. T., (A) 180
Douglas-Jones, A. G., (O) 412
Doyle, J. A., (A) 153
Draper, P., (A) 139, (O) 211, (A) 345, 345, (O) 441, (A) 686, 687
Drupa, I., (A) 361
Duckworth, T., (A) 694
Dugan, E., (O) 404
Duncan, M. E., (A) 336, (E) 468
Dunia, I., (A) 343
Durai, V., (A) 332
Durairaj, V., (A) 498
Durgambal, K., (A) 493
Dwivedi, P. D., (A) 504
Dyachina, M. N., (A) 336, 502, 506, 508
Dykhno, M. M., (A) 695

Ebeid, O., (A) 361
Edwardsson, C.-A., (A) 359
Efremova, T. V., (A) 495
Eggelte, T. A., (A) 338
Ekambaram, V., (A) 331
Eksioglu, M., (A) 696
El-Ansary, E. H., (A) 149
El-Gholmy, Z. A., (A) 669
El-Khordagui, L. K., (A) 669
Ellard, G. A., (O) 587
Ellis, B. P. B., (C) 114
Enarson, D. A., (A) 149
Engardt, M., (A) 359
Engleman, E. G., (A) 178, 680, 717
Eremeev, V. V., (A) 360

Ermolin, G. A., (A) 336, 506
Esca, S. A., (A) 498
Eshchanov, T. B., (A) 140, 502
Eshetu Lema, (A) 362
Estrada-Parra, S., (A) 150, (O) 262, (A) 691
Eustis-Turf, E. P., (A) 722
Evstratova, V. A., (A) 494, 498, 506
Eyckmans, L., (A) 334

Fadeeva, N. I., (A) 695
Faulstich, M. E., (A) 674
Fei, H., (O) 56
Ferluga, J., (A) 140
Ferrante, A., (A) 140
Ferreira, J., (A) 691
Festou, P., (A) 149
ffytche, T. J., (A) 137, 674
Fieldsteel, A. H., (A) 172, 349
Fine, P. E. M., (A) 356
Finkelstein, E., (A) 675
Fiscus, J., (A) 151, 726
Flaguel, B., (A) 133
Fleury, R. N., (A) 331
Fliess, E. L., (A) 140
Fohn, M. J., (A) 684, 684
Folse, D. S., (A) 358
Forstrom, L., (A) 360
Foucauld, J., (A) 327
Foung, S. K. H., (A) 178, 717
Fox, H., (A) 336
Franceschi, G., (A) 135
Fredricks, C. W., (Ob) 641
Frehel, C., (A) 145, 346, 346
Freire-Maia, D. V., (A) 140, 141
Frias Iniesta, J. F., (A) 361
Fritschi, E. P., (B) 129
Frutos, V., (A) 667
Fuentes, A., (A) 356
Fujikawa, R., (A) 163
Fujimiya, Y., (A) 707
Fujiwara, T., (A) 139, 727
Fukunishi, Y., (O) 75, 247, 447
Furukawa, F., (A) 137, (C) 647

Gad, S. M., (A) 502
Gadi, S., (A) 676
Gaines, S., (A) 167
Gaither, J. M., (A) 514
Gallo, M. E. N., (A) 137
Ganapati, R., (N) 123, (A) 355, 501
Ganatra, R. D., (A) 514
Ganguly, N. K., (O) 233, (A) 510, 689
Ganter, B., (A) 696
Garagusi, V. F., (A) 695
Garcia, N., (O) 595, (A) 689
Garcia Montelongo, R., (A) 150
Gardner, I. D., (A) 146
Garg, B. R., (A) 501
Garnier, J.-P., (A) 329
Gaylord, H., (A) 712
Geertzen, H. G. M., (O) 225
Geffner, J., (O) 218
Gelber, R. H., (A) 139, 171, 172, 178, 180, (C) 311, (A) 328, 349, (C) 643, (A) 680, 715, 717
Gerbase, A. C., (A) 691
Gerhard, L., (A) 506
Gerone, P. J., (O) 1, (A) 176, 351, 352
Ghei, S. K., (A) 498, 504
Ghosh, M., (A) 501
Gibson, J. B., (A) 328
Gidoh, M., (A) 714
Gigase, P., (A) 334
Gigli, I., (A) 184, 683
Gilliland, B. C., (A) 182, 713
Gillis, S., (A) 503
Gillis, T. P., (A) 178, 679, 718
Girdhar, A., (A) 668
Girdhar, B. K., (O) 39, (A) 498, (N) 663, (A) 668
Girgia, H. S., (A) 672
Gnenjuk, T. S., (A) 494, 494, 496
Godal, T., (A) 141, 141, (O) 385
Golyshevskaya, V. I., (A) 150
Gomez Mampaso, E., (O) 410
Gomez-Pedraja, J. F., (A) 669
Gomez-Salazar, M. D., (A) 669
Gonen, B., (A) 331
Gonzales de Canales Cerisola, F., (A) 511
Gonzalez, N. M., (A) 148, 358
Gonzalez, V., (A) 356
Gonzalez-Abreu, E., (A) 336
Gonzalez-Abreu Castells, E., (A) 336
Gonzalez-Amaro, R., (O) 201
Gonzalez Herrada, C., (A) 361
Gonzalez-Mendoza, A., (O) 373
Gonzalez-Segredo, A., (A) 336, 336
Gonzalez Vazquez, R., (A) 328
Goodfellow, M., (A) 687
Goren, M. B., (A) 150, 151, 726
Gormus, B. J., (O) 1, (A) 169, 175, 176, (O) 269, (A) 351, 351, 352, 353
Graham, L., (A) 146
Grange, J. M., (A) 149, 150, 151, 361
Green, R., (A) 137
Gregory, D. W., (A) 132
Grimont, F., (A) 344
Groothuis, D. G., (A) 348
Grosset, J. H., (O) 15, (C) 118, (A) 134, (C) 481
Grosskinsky, C. M., (A) 335, 699
Grzybowski, S., (A) 149
Guelpa, C.-C., (C) 481
Guelpa-Lauras, C. C., (A) 352
Guessennd, G., (A) 357
Gugelyk, T., (B) 129
Guha, S. K., (O) 206
Guidet, M., (A) 139
Guill, M. A., (A) 361
Guizar-Vazquez, J., (A) 356
Gupta, C. M., (A) 499, 499, 668
Gupta, G., (A) 499
Gupta, N. K., (A) 328

Gupta, O. P., (A) 332, 499, 499
Gupta, P. K., (A) 328
Gupta, S. K., (A) 503
Gurnani, S., (O) 428
Gutierrez de la Solana Dumas, J., (A) 353
Gutierrez-Rodriguez, O., (A) 151

Ha, D. K. K., (A) 146
Hackel, C., (O) 533
Hadfield, T. L., (O) 1, (A) 351, 684, 692
Hagstad, H. V., (A) 147, 175
Haile, R. W. C., (A) 356
Haimanot, R. T., (O) 238
Hamashima, Y., (A) 137, (C) 647
Hansen, S., (A) 359
Hanson, W. L., (A) 153
Harboe, M., (O) 1, (A) 144
Hardas, U. D., (A) 695
Hardy, R., (A) 363
Haregewoin, A., (A) 141, (O) 385
Harihar, S., (O) 455
Harkness, R. A., (A) 336
Harmsen, T., (A) 699
Harnisch, J. P., (A) 182, 713
Harris, D., (A) 183
Harris, E. B., (A) 165, 168, 508, 688, 723
Hastings, R. C., (E) 101, (A) 165, 166, 167, 175, 179, 350, 502, 688, 690, 710, 720, 723
Haugen, O. A., (A) 351
Hazra, S. K., (A) 669, 679
Head, E. C., (A) 176
Heifets, L. B., (A) 361
Heifetz, L., (A) 726
Heine, H. S., (A) 169
Heiskala, M., (A) 360
Helle, I., (A) 141
Hempstead, R. W., (A) 332
Henika, P. R., (A) 328
Her Hsin Tsai, (A) 674
Heritage, R. W., (A) 497
Hernanz Hermosa, J. M., (A) 361
Heroman, B., (A) 162
Heroman, M. W., (O) 251
Herzenberg, L. A., (A) 363, 363
Hibino, T., (A) 350, 709
Hirata, T., (O) 433, 577
Hoang Thuy Long, (O) 225
Hoang, L. T., (A) 355
Hobbs, E. R., (A) 332
Hoffeld, J. T., (A) 353
Hoffenbach, A., (A) 138, 348, 349, 510, 679
Hoffmann, T., (A) 683
Hofman, F. M., (A) 503
Hokama, Y., (A) 163
Holborow, E. J., (A) 140
Holub, M., (A) 362
Hooper, M., (A) 134, 494
Hopewell, P. C., (A) 696
Horney, D. A., (A) 514
Horwitz, D. A., (A) 338, 503, 707
Hoyer, H., (A) 514
Hsu, P.-S., (A) 350, 709
Hugh-Jones, M. E., (A) 175
Huikeshoven, H., (E) 474
Humber, D. P., (C) 656
Humphres, R. C., (A) 172, 174, 349
Hunter, S. W., (A) 139, (C) 484, 487, (A) 712
Husmann, L. A., (A) 503

Ibegbu, C., (A) 173
Ibraimov, M., (A) 502
Imaeda, T., (O) 1, (A) 170, 342, 358
Imamura, S., (A) 137
Imes, G. D., Jr., (O) 1
Imkamp, F. M. J. H., (C) 313
Ingty, K., (A) 675
Insanov, A. B., (A) 360
Inverso, J. A., (A) 152
Irgens, L. M., (A) 326, (O) 524, (E) 610
Irtuganova, O. A., (A) 494, 507
Irulegui, I., (A) 142
Iselius, L., (A) 356
Iseman, M. D., (A) 361
Isozaki, Y., (A) 350
Isturiz, M. A., (O) 218
Ito, T., (O) 421, (A) 706
Ivanyi, J., (O) 33, (A) 681, 699
Izaki, M., (A) 350, 709
Izaki, S., (A) 350, 709
Izumi, S., (A) 675, 727

Jacobs, W. R., (A) 170, 344, 711
Jacobson, R. R., (A) 162, (O) 554
Jagadisan, T. N., (C) 658
Jagannathan, R., (A) 495, 507
Jain, A. P., (A) 332, 499, 499
Jain, G. L., (O) 206
Jain, R. K., (A) 333
Jain, V. K., (A) 676
Jajoo, U. N., (A) 332, 499
Jayaraman, J., (A) 339
Jayaraman, T., (A) 340
Jayaraman, V. S., (A) 695
Jeevan, A., (A) 502
Jenkins, J. S., (A) 362
Jenner, P. J., (O) 587
Jesudasan, J., (O) 19
Jesudasan, K., (A) 356, 356, 499, 511, 692
Jeyavarthini, S. E., (O) 455
Jhol, J. S., (A) 340
Ji, B., (A) 134, 357
Ji, B., *et al.*, (A) 668
Ji, Z., *et al.*, (A) 141
Job, C. K., (A) 166, 179, 350, (O) 554, (A) 690, 720, 723
Johnson, F. B., (O) 447
Jones, R. L., (A) 337
Jopling, W. H., (A) 134
Jorg, J. R., (A) 506

Joseph, A., (A) 511
Joshi, J. V., (A) 328
Joshi, U. M., (A) 328
Joshua-Raghavar, A., (B) 323
Jumar, B., (A) 510
Juscenko, A. A., (B) 492, (A) 495, 507, 507, 508, 510

Kachel, D. L., (A) 696
Kadantsev, N. D., (A) 495
Kadivl, G. V., (A) 514
Kaipbergenov, U. K., (A) 499
Kale, H. D., (A) 332
Kandamuthan, M., (A) 511
Kaneda, K., (A) 342
Kannan, K., (A) 498
Kannan, K. B., (A) 686, 688
Kant, M., (A) 333, 694
Kant, V. P., (A) 511
Kanwar, A. J., (A) 332
Kaplan, G., (A) 337, 708, 725
Kapur, B. M. L., (A) 360
Kar, H. K., (A) 334, 495, 669
Kardjito, T., (A) 151, 361
Katayama, I., (A) 503
Kato, H., (A) 152, 363
Kato, L., (A) 686
Katoch, K., (O) 45, (A) 498, 510, 686
Katoch, V. M., (O) 45, (A) 686, 688
Katoh, M., (A) 347
Kaur, P., (A) 694
Kaur, S., (O) 233, (A) 510, 689
Kazda, J., (A) 166
Kearney, G. P., (O) 447
Keeler, R. F., (A) 329
Kelly, J. W., (A) 135
Kemp, M., (A) 151
Khalil, S. A. H., (A) 669
Khan, N., (A) 499
Khandke, L., (A) 142, 337, (C) 487
Khanolkar, S. R., (A) 679, 684
Kherdekar, M. A., (A) 331
Khotko, N. I., (A) 692
Kim, K.-S., (A) 343
Kingston, A. E., (A) 337
Kiran, K. U., (A) 136, 674
Kirkpatrick, C. H., (A) 514
Kitabatake, S., (A) 342
Klatser, P. R., (A) 338
Klein, N., (A) 508
Kliemann, T. A. E., (A) 142
Koffi, J. K., (A) 357
Kogan, V. R., (A) 495
Kohler, W., (A) 361
Kohsaka, K., (O) 421, 600, (A) 706
Kojima, F., (A) 348
Kolk, A. H. J., (A) 338
Korolev, M. B., (A) 150
Koseki, Y., (A) 348
Koster, F., (A) 721
Koster, F. T., (A) 683
Koteeswaran, A., (A) 498
Kowale, C. N., (A) 673
Kozbor, D., (A) 677
Kozminska-Kubarska, A., (A) 145
Kraaijeveld, C. A., (A) 699
Krahenbuhl, J. L., (A) 184, 340, 720
Kreysel, H. W., (A) 500
Krishnan, S. A. R., (A) 513
Krotoski, W. A., (A) 177, 502
Kuba, B., (A) 167
Kuba, B. A., (A) 347
Kubin, M., (A) 362
Kuijper, S., (A) 338
Kulkarni, G. R., (A) 332
Kumar, A., (A) 332, 493
Kumar, B., (O) 233, (A) 689
Kumar, D. S., (A) 675
Kumar, G. V., (A) 669
Kumar, K., (A) 332, 333, 499, 694
Kundu, S. K., (A) 669, 679
Kurkcuoglu, N., (A) 696
Kuzina, Z. A., (A) 499, 503
Kuznetsouva, L. V., (A) 698
Kvach, J. T., (A) 169

Laal, S., (A) 504
Lad, S. J., (A) 144
Lagadec, R., (A) 330
Lagrange, P. H., (E) 278, (A) 349, 510, 679
Lahuerta-Palacios, J. J., (A) 669
Laing, A. B. G., (A) 333
Lakshmana Rao, S. S., (A) 679
Lamas-Robles, C., (O) 373
Lamba, P. A., (A) 675
Lambert, A., (O) 461
Lancaster, R. D., (O) 587
Lanéelle, M.-A., (A) 342, 343, 346
Lang, T., (A) 336
Lang-Stevenson, A. I., (A) 694
Lanier, L., (A) 363
Larrick, J. W., (A) 680
Larsson, L., (O) 441
Latini, O. A., (A) 360
Lauer, R., (A) 514
Lawton, J. W. M., (A) 146
Lazovskaya, A. L., (A) 508
Lechat, M. F., (O) 461
Lefford, M. J., (A) 690, 722
Leguizamon, O., (A) 667
Leiker, D. K., (A) 141
Leung, K.-P., (A) 726
Levis, W. R., (A) 183, 329, 341, 708
Levy, L., (C) 118, (A) 350, (C) 653, (A) 669, 690
Levy-Frebault, V., (A) 344
Li, F. T., (A) 670
Li, H.-Y., (O) 79
Li, W., (A) 495
Li, X., (O) 565
Li, Y., (A) 357
Li, Z., (O) 565

Liano, F., (O) 410
Liew, F. Y., (A) 362
Lim, M., (A) 363
Lindholm-Levy, P. J., (A) 361
Lindner, B., (O) 365
Lipinskas, B. R., (A) 698
Littlewood, S. M., (A) 362
Liu, L., *et al.*, (A) 142
Liu, Q., (O) 565
Loesch, J., (A) 184
Loginov, V. K., (A) 496, 500
Lombardi, C., (A) 357
Long, E. G., (A) 176, 358
Longley, J., (O) 385
Lopez, D. A., (A) 184
Loredo, C. E., (O) 201
Loudon, J., (A) 497, 497
Loui, W., (A) 163
Lovik, M., (A) 351
Lowe, C., (A) 139
Lucht, F., (A) 500
Ludosky, M. A., (A) 343
Lukehart, S. A., (A) 182, 713
Luniya, A. K., (A) 328
Lutsky, I., (A) 690
Lyons, N. F., (C) 114
Lyzhin, A. A., (A) 506

Ma, B., (A) 495
Ma, J., (A) 357
Ma, Y., (A) 360
Ma, Z., (O) 565
Macedo, P. M., (A) 347
Mack, T. M., (A) 724
Mackett, M., (A) 353
Macotela, E., (A) 356
Madrigal, D. R., (A) 162, (O) 251, 255
Magna, L. A., (A) 138
Magnin, P. H., (A) 682
Magnusson, M., (A) 687
Mahadevan, P. R., (A) 142, 144, 337, (C) 487, (A) 495, 507, 508, 509, 671
Maitra, A., (A) 328
Makino, M., (O) 600
Makonkawkeyoon, S., (O) 559
Malaty, R., (A) 176, (O) 269
Malkova, J., (A) 509
Malvi, H., (A) 496
Manchester, K., (B) 326
Mangal, H. N., (A) 503
Manglani, P. R., (A) 692
Mani, K., (A) 513
Mankar, M. V., (A) 507
Marks, R., (A) 135
Marks, S. C., (A) 501
Marolia, J., (A) 508
Marshall, J. T., (N) 319
Marsili, I., (A) 135
Martin, L. N., (O) 1, (A) 169, 175, 176, (O) 269, (A) 351, 351, 352, 353
Martin, W. J., II, (A) 696
Martinez, D., (A) 151
Martinez, E. L. W., (A) 142
Mascali, J. J., (A) 514
Maslov, A. K., (A) 508
Massalski, W., (A) 145
Matejka, M., (A) 509
Mathur, A., (A) 670
Mathur, N., (A) 503
Mathur, P. N., (A) 514
Mathur, R. S., (A) 503
Matsuo, O., (A) 350
Matsuo, Y., (A) 345, 347
Matthew, R. C., (A) 503
Matthiesen, T., (A) 330, 672
Maurice, P. D. L., (A) 362
McCormick, G. T., (A) 177, 690
McDougall, A. C., (O) 238, (A) 333, 337, (O) 582, (A) 674
McKee, L. C., (A) 132
McKenzie, D. K., (A) 697
Meeker, H. C., (A) 341
Mehra, V., (A) 180, 335, 678, 680, 707, 727
Mehta, L. N., (A) 338
Mejia-Arreguin, S., (O) 373
Mende, V. B., (A) 500
Mendez, E. V., (O) 540
Mendez, I., (O) 258
Mengistu, G., (O) 189
Merryman, C. F., (A) 514
Mesquita, A. P., (A) 148
Mester de Parajd, L., (A) 329, 670
Mester de Parajd, M. A., (A) 670
Metah, D., (A) 682
Meyers, W. M., (O) 1, (A) 169, 175, 176, (O) 269, (A) 351, 351, 352, 353, (O) 447, 517, (A) 684, 692
Michalany, J., (A) 142, 143
Michalany, N. S., (A) 142, 143
Millard, P. R., (A) 333
Miller, R. A., (A) 178, 182, 679, 713
Minagawa, F., (A) 715
Mineeva, E. I., (A) 512
Mines, J. S., (A) 724
Minh, H. L., (A) 338
Minnikin, D. E., (A) 345, 348, 686, 687
Miranti, C., (A) 151
Misra, N. P., (A) 496
Misra, R. S., (A) 333, (O) 571
Misson, C. B., (O) 461
Mistry, N. F., (A) 680
Mistry, Y., (A) 508
Mitchell, D. N., (A) 151
Mitchison, D. A., (A) 150, 695
Mittal, A., (A) 671
Miyachi, Y., (A) 330
Miyaji, I., (A) 715
Miyata, Y., (O) 600, (A) 706
Mizuguchi, Y., (A) 696
Modlin, R. L., (A) 181, 338, 389, (O) 404, (A) 503, 707, 709

Moghe, K. V., (A) 499
Mohagheghpour, N., (A) 178, 680, 717
Mohammed, H. A. A., (A) 513
Mohammed, K. N., (A) 329
Mohelska, H., (A) 362
Moncada, B., (O) 201
Monferrer Guardiola, J. F., (A) 497
Monferrer Guardiola, R., (A) 497
Montalban, M. A., (A) 669
Mookerjee, B. K., (A) 697
Mor, N., (A) 690
Morales, M. J., (A) 166
Mori, T., (O) 600, (A) 706
Morton, A., (A) 143
Morton, N. E., (A) 356
Moss, B., (A) 353
Mshana, R. N., (A) 136, (O) 238
Mukerjee, C. M., (A) 697
Mukherjee, A., (A) 333, (O) 571
Mukherjee, R., (A) 508, 687
Mukul, (A) 503
Munnell, J. F., (A) 153
Murmu, R., (A) 136
Murray, R. I., (A) 697
Murthy, N. N., (A) 334
Musa, S., (A) 363
Mustafa, A. S., (A) 141

Naafs, B., (C) 114
Nagai, M., (A) 348
Nagata, K., (A) 706
Nagata, Y., (O) 421
Naidu, B., (A) 331
Naik, G., (A) 334
Naik, S. S., (O) 428, (N) 490, (A) 496
Nair, I., (A) 671
Nakami, N., (A) 136
Nakamura, K., (A) 719
Nakamura, M., (O) 52, (A) 687
Nandy, A., (A) 679
Narayanan, R. B., (O) 39, (A) 143, 339, 504
Nath, I., (A) 143, 339, 339, 340, (O) 378, (A) 504, 671, 725
Nathan, C. F., (A) 708
Naudillon, Y., (O) 15
Naumov, V. Z., (A) 500
Navalkar, R. G., (A) 146, 173
Nazarov, K. I., (A) 494, 502
Neafie, R. C., (A) 684
Neelan, P. N., (C) 115, (A) 327, 497
Negrel, A. D., (A) 330
Nelson, K., (A) 163, 354, 719
Nelson, K. E., (O) 559
Neubert, T. A., (A) 169
Neupani, K., (A) 497
Neva, F. A., (A) 151
Neves, R. G., (B) 131
Neville, J., (N) 321
Nguyen, H. T. D., (A) 355
Nguyen Diem Hong, (O) 225
Nguyen Van Man, (A) 343
Nielsen, H., (A) 135
Nilakanta Rao, M. S., (A) 671
Niwa, Y., (A) 330
Noda Carera, A., (A) 150
Nomaguchi, H., (A) 706
Nomura, T., (A) 347
Norins, A. L., (A) 514
Novales, J., (A) 676
Nozawa, R. T., (A) 152, 363
Nsibambi, J., (A) 333
Nsibami, D., (O) 385
Numela, T., (A) 360
Nunez, C., (A) 356
Nye, P., (A) 143

Oates, C., (A) 341
O'Connor, R. J., (N) 664
Ogawa, M., (A) 696
Ohkawa, S., (A) 675, 681
Ohkuma, M., (A) 709
Ohshio, G., (C) 647
Ojha, K. S., (A) 512
Okamura, H., (A) 706
Olcen, P., (A) 144
Oltra, A., (O) 258, 262
Oppenheim, J. J., (A) 353
Opromolla, D. V. A., (A) 331
Orme, I., (A) 698
Orme, I. M., (A) 697
Ortiz, M. C., (A) 140
Ortuno, J., (O) 410
O'Sullivan, J. F., (A) 671
Ottenhoff, T. H. M., (A) 148, 502
Ozaki, M., (A) 137, 330, 675

Padierna, J., (A) 150
Padilha-Goncalves, A., (A) 153
Padilla, M. A., (A) 340
Palande, D. D., (A) 352
Paldino, A. M., (A) 330
Palmer, G., (A) 165
Pan, Y.-L., (O) 79
Pandian, T. D., (A) 671
Pandit, S., (A) 513
Pandya, S. S., (N) 123
Paoletti, E., (A) 698
Papa, F. P., (A) 345
Paradkar, S., (A) 496
Pareek, S. S., (A) 500
Parker, D., (A) 144
Parvez, K., (A) 499
Pasricha, J. S., (O) 206
Patil, K. M., (N) 319
Patil, S. A., (A) 504
Pattengale, P. K., (A) 707
Pattyn, S. R., (A) 330, 334, 347, 496, 687
Pauly, J. L., (A) 697
Pavithran, K., (C) 645
Payne, S. N., (A) 139, (O) 211

Pearson, J. M. H., (A) 136, 674
Pearson, M., (A) 358
Pena, F., (A) 356
Pennec, J., (A) 133
Penumarti, N., (A) 142
Perez Batista, C., (A) 147, 353
Perez-Suarez, G., (O) 373
Perkus, M. E., (A) 698
Perry, B. H., (A) 355
Pervukhin, Y. V., (A) 502
Petchclai, B., (O) 28
Petersen, E. A., (A) 151
Petri, V., (A) 142, (O) 540
Pfau, R., (A) 358, 512
Picard, B., (A) 346
Piccini, A., (A) 698
Piccoro, J. J., Jr., (A) 497
Pilarski, R., (A) 137
Pinchuck, L. M., (A) 508
Pineau, P., (A) 149
Pineda Jimenez, J. M., (A) 511
Pinto, W., Jr., (A) 138
Piper, L., (A) 166
Pirila, V., (A) 360
Pitchenik, A. E., (A) 135
Podoplelov, I. I., (A) 498, 498, 501
Pollack, M., (A) 163
Polnikorn, N., (A) 672
Portaels, F., (A) 170, 346, 347, 348, (O) 441, (A) 687
Portier, H., (A) 500
Poulter, L. W., (A) 505, 678
Powell, R. J., (A) 362
Pozo Roman, T., (A) 361
Prabhakara Rao, V., (A) 331
Prabhakaran, K., (A) 165, 168, 508, 688
Prakash, O., (A) 144
Praputpittaya, K., (A) 681
Prasad, H. K., (A) 688
Prioleau, E., (A) 132
Prioli, R. P., (A) 698
Prokop, O., (A) 361
Puavilai, S., (A) 672
Pukhov, E. B., (A) 512
Purohit, M. G., (A) 134
Pust, R. E., (A) 493, 666

Quereda, C., (O) 410
Quesada-Pascual, F., (O) 262, (A) 691
Quintanar, E., (A) 356

Rada, E., (A) 680
Radhabai, K., (A) 498
Raj, D. V., (A) 675
Rajan, M. A., (A) 677
Rajan, R., (A) 679
Ramalho, A. S., (A) 138
Ramanan, C., (A) 692
Ramanathan, U., (A) 498
Ramanathan, V. D., (A) 144, 681
Ramirez-Almaraz, J. A., (A) 691
Rammasoota, T., (O) 28
Ramu, G., (O) 33, (A) 144, 498, 501, 504, 510, 668, 670, 671, 681
Ranade, S. M., (A) 673
Rao, K. N., (A) 676
Rao, P. R., (A) 679
Rastogi, N., (A) 145, 340, 342, 343, 344, 346, 346, 352, 685
Rathore, B. S., (A) 498
Ratledge, C., (B) 664
Rauzier, J. Y., (A) 345
Ravettini, B. A., (A) 682
Ravisse, P., (A) 352
Rea, T. H., (A) 139, 181, 338, 389, (O) 404, (A) 503, 707, 709, 715, 724
Reboa, F., (A) 150
Reddy, B. N., (C) 115, (A) 148, 497
Reddy, N. B. B., (A) 513
Reed, S. G., (A) 152
Rees, R. J. W., (C) 118, (A) 336, (O) 378, (A) 670
Reeser, P., (A) 363
Reichart, P. A., (A) 682
Reichert, E., (A) 163
Reinhardt, V., (A) 506
Revankar, C. R., (A) 355, 501
Rezaev, A. A., (A) 495
Ridel, P. R., (A) 340
Ridley, D. S., (A) 341
Ridley, M. J., (A) 134, 341
Rifle, G., (A) 500
Riley, D. N., (A) 326
Ritchie, L. R., (A) 344
Robertson, I., (A) 675
Rocamora, A., (O) 410
Roder, J. C., (A) 677
Rodgers, G. C., Jr., (A) 497
Rodriguez, F. C., (A) 361
Rodriguez, H., (A) 356
Rodriguez Garcia, R., (A) 353
Roger, B., (A) 694
Rojas-Espinosa, O., (A) 146, (O) 258, 262, (A) 691
Romanova, R. Y., (A) 360
Rook, G. A. W., (O) 22, (A) 143, (O) 211
Rose, J. K., (A) 353
Rostenberg, I., (A) 356
Rowden, G., (A) 389
Roy, R. G., (A) 327, 334, 495, 669
Rozzo, S. J., (A) 514
Rubin, L., (A) 719
Rullan, P. P., (A) 152
Ryan, S., (A) 163, 354
Ryter, A., (A) 346
Ryzen, E., (A) 675
Ryzhova, N. Y., (A) 496, 501

Saha, K., (B) 131, (A) 505, 505, 676
Sakane, T., (A) 330
Salgame, P. R., (A) 144, 337
Samuel, A. M., (A) 514

Samuel, N., (A) 143
Samuel, N. M., (A) 136, (O) 395, (A) 497, 497
Samuel, S., (A) 136, 497, 497
Sanchez, J. L., (A) 340
Sanchez, R. M., (A) 350, 690
Sanchez, R. S., (A) 179
Sanchez-Hernandez, M., (A) 696
Sandhu, H. S., (A) 334
Sandland, M., (A) 135
Sanfilippo, A., (A) 135
Sankaran, K., (A) 353
Sankolli, G., (A) 328
Sansarricq, H., (A) 330
Sarojini, P. A., (A) 136
Sasaki, D. T., (A) 680
Sasiain, M. del C., (O) 218
Sathish, M., (A) 339, 340, (O) 378
Sato, D., (A) 163
Satpathy, S. K., (A) 513
Saul, A., (A) 676, 676
Schauf, V., (A) 163, 354, 719
Schirren, C., (A) 677
Schlagel, C. J., (O) 1, (A) 351, 692
Schlegerova, D., (A) 362
Schlinwinski, U., (A) 506
Schreiber, R., (A) 184, 683
Schroder, J. M., (A) 672
Schroh, R. G., (A) 682
Schuller-Levis, G., (A) 183
Schwab, B. W., (A) 330
Schwerer, B., (A) 341
Scocozza, J. B., (A) 360
Scollard, D. M., (A) 163, 354, (O) 559, (A) 719
Scott, J., (A) 135
Seang Hoo Nah, (A) 501
Sebille, A., (C) 481
Seckl, M. J., (E) 618
Sedel, L., (A) 694
Sedig, K., (A) 359
Segal-Eiras, A., (O) 218
Sehgal, V. N., (A) 505, 676
Sekita, K., (A) 137
Selezneva, S. P., (A) 501, 505
Sen, P. C., (C) 113, (O) 198, (A) 668, 672, 673
Sengupta, U., (O) 33, 39, (A) 144, 498, 501, 504, 681
Seres-Clavel, S., (A) 344
Serrano-Espinosa, A., (A) 666
Sersen, G., (A) 341
Seshadri, P. S., (A) 327, (O) 378, (A) 671
Seydel, U., (O) 365
Shah, A., (A) 359, 513
Shandas, G. J., (A) 669
Shankar, P., (C) 649
Shannon, E. J., (A) 165, 175, 502, 710, 720
Sharma, A. K., (A) 143, 339, 339, 340, 504
Sharma, A. M., (O) 571
Sharma, D. R., (A) 496
Sharma, L., (A) 672
Sharma, P., (A) 681
Sharma, P. K., (A) 683
Sharma, V. D., (O) 45, (A) 686, 688
Sharma, V. K., (A) 505
Sharp, A. K., (A) 341, 342
Sharrad, W. J. W., (A) 694
Shatrov, V. A., (A) 698
Shepard, C. C., (C) 118, (O) 587, (C) 653
Sheskin, J., (A) 138, 331
Shipstone, A. C., (A) 503
Shivannavar, C. T., (A) 686, 688
Shochina, M., (A) 331
Shoji, K., (A) 706
Shriniwas, (A) 360
Shu, H., (O) 565
Silva, M. T., (A) 347
Sim, V. S., (A) 494
Simon Marco, E., (A) 497
Singer, F. R., (A) 675
Singh, G., (C) 113, (A) 668, 673, 694
Singh, I. P., (A) 668
Sinha, S., (O) 33, (A) 504
Siqueria, L. F. de G., (A) 666
Sirumban, P., (A) 332, 669
Sisodia, S. M., (A) 331
Sithambaram, M., (A) 671
Skinsnes, O. K., (A) 167, (E) 289, (A) 347
Skukla, R. R., (A) 145
Smith, D., (A) 363
Smith, J. H., (A) 176, 358
Smith, J. S., (A) 176
Smith, K. A., (O) 385
Smith, N. J., (A) 362
Smith, P. G., (A) 356, 356, 511
Smith, T., (A) 163, 354
Smucuy, J. A., (A) 137
Snippe, H., (A) 699
Sommerfelt, H., (O) 524
Sorg, T. B., (A) 165
Spencer, P. S., (A) 330
Srinivasan, H., (A) 359
Srinivasan, T., (A) 513
Sriram, S., (A) 363
Srivastava, G., (A) 505
Stach, J. L., (E) 278
Stanford, J., (A) 362, (B) 664
Stanford, J. L., (A) 143, (O) 395, 546
Stanley, J. N., (A) 674
Stanley, J. N. A., (A) 136
Steffen, C., (A) 608
Stein, G., (A) 500
Steinman, L., (A) 363
Steinman, R. M., (A) 708, 725
Stewart, C., (C) 484, (A) 712
Stewart-Tull, D. E. S., (A) 666
Storrs, E. E., (A) 166
Strickland, N. H., (E) 86
Subramaniam, K., (A) 501
Sugi, H., (A) 363
Sukhenko, L. T., (A) 336, 506
Sula, L., (A) 509, 509
Sulova, J., (A) 509, 509

Sultan Sheriff, D., (A) 138
Sundararaj, G. D., (A) 513
Suryawanshi, N., (A) 674
Svendsen, C. L., (A) 151
Sweetser, D., (A) 727
Swendson, L. S., (A) 726

Tala, E., (A) 360
Talati, S., (A) 509
Talhari, S., (B) 131
Tandon, B. N., (A) 360
Tandon, H. D., (A) 360
Tang, Q., (A) 357
Tanji, O., (A) 709
Tanna, A., (A) 698
Tao, M., (A) 495
Tapia, F. J., (A) 181
Tasanapradit, P., (A) 672
Tausk, F., (A) 184, 683
Taylor, C. R., (A) 338, 389, 503
Teruel, J. L., (O) 410
Teuscher, C., (A) 683, 721
Thalliath, G. H., (A) 672
Thangavel, N., (A) 493
Thirugnanam, T., (A) 677
Thomas, D., (A) 699
Thomas, D. A., (A) 724
Thomas, D. C., (A) 724
Tidman, N., (A) 678
Timpatanapong, P., (A) 672
Tiwari, M. L., (A) 328
Tiwari, V. D., (A) 499, 693
Tokairin, S., (A) 709
Tolson, T. A., (A) 184
Tomiyasu, I., (A) 342
Trautman, J. R., (A) 326
Truman, R. W., (A) 165, 175, 710
Tsukiyama, F., (A) 347
Tsutsumi, S., (A) 714
Tung, K. S., (A) 505
Tung, K. S. K., (A) 683, 719, 721
Turk, J. L., (A) 144, 146, 503
Tutakne, M. A., (A) 499, 499, 683, 693

Udou, T., (A) 696
Umerov, G. G., (A) 506, 506, 506
Umezaza, H., (A) 348
Umland, E., (A) 354, 719, 721
Ungheri, D., (A) 135
Uotila, K., (A) 360
Uphouse, W., (A) 327
Uplekar, M., (A) 680
Urbina, R., (O) 201
Urlyapova, N. G., (A) 494, 494
Uyemura, K., (A) 709

Vaccaro, S. E., (A) 338
Vadiee, R., (A) 165
Vaishnavi, C., (O) 233, (A) 510, 689
Valdez, R. P., (O) 595, (A) 689
Van Den Broek, H., (A) 148
Van der Weyden, M. B., (A) 135
van Eden, W., (A) 358, 502
van Eede, P., (A) 355
van Leeuwen, A., (O) 56
van Leeuwen, F., (A) 355
Van Leeuwen, J., (A) 338
Van Loo, L., (A) 330
van Rood, J. J., (A) 148, 358
van Tiel, F. H., (A) 699
Vanderveken, M., (O) 461
Vargas Molguin, S. M., (A) 497
Vazquez, C., (A) 356
Veitia, M. C., (O) 251
Velasco Castrejon, O., (A) 150
Vellut, C., (O) 461
Vemuri, N., (C) 487, (A) 508
Venkataraman, V., (A) 498
Venkatsan, K., (A) 670
Vera-Roman, J. M., (A) 497
Verma, R. N., (A) 683
Vieregge, P., (A) 506
Vigevani, A., (A) 135
Viktorov, I. V., (A) 506
Vinnik, L. A., (A) 502
Vioglio, S., (A) 135
Vishnevetsky, F. E., (A) 500
Vithayasai, P., (A) 719
Vithayasai, V., (A) 354, (O) 559, (A) 719
Vivancos Gallego, G., (A) 150
Vlug, A., (O) 225
von Ballestrem, W., (A) 667
Vorobyeva, Z. G., (A) 502

Wada, T., (A) 348
Wagner, D., (A) 719
Waldor, M. K., (A) 363
Wallach, D., (A) 133, (C) 649
Walsh, G. P., (O) 1, (A) 169, 175, 176, (O) 269, (A) 351, 351, 352, 353, (O) 447
Wang, C., (A) 134, 357
Wang, H., (A) 495
Wang, H., *et al.*, (A) 689
Wang, Y., (O) 79
Warndorff, T., (A) 144
Warndorff van Diepen, T., (O) 189, (A) 333, (O) 385
Wastiaux, K., (A) 133
Waters, M. F. R., (A) 141, 341, 505, (O) 546
Watson, J. D., (O) 412
Watson, S. R., (A) 144
Wear, D. J., (A) 684
Weiner, J. M., (A) 675
Weinstein, D. E., (A) 708
Weldon, J. S., (A) 153
Wendling, D., (A) 139
Weshler, Z., (A) 138
West, D. P., (A) 148
Whiting, J., Jr., (O) 447
Wieten, G., (A) 348
Williams, K., (A) 162

Winkelmann, R. K., (A) 153
Winters, M. A., (A) 174
Witmer, M., (A) 725
Wolf, J., (A) 331
Wolf, R. H., (O) 1, (A) 169, 175, 176, (O) 269, (A) 351, 351, 352, 353
Wong, C., (A) 163
Wong, L., (A) 707
Wong, P., (A) 497
Wongwaisayawan, H., (A) 672
Woodward, W., (A) 667
Worobec, S., (A) 719
Wright, E. P., (O) 225
Wright, P., (A) 355
Wright, S., (A) 677
Wu, Q., (O) 565
Wu, Q., *et al.*, (A) 145
Wulff, C. H., (A) 514

Xia, G., (A) 134
Xu, K., (O) 56
Xu, K., *et al.*, (A) 359

Yada, A., (A) 330
Yamazaki, T., (A) 348
Yanagahara, D., (A) 721
Yanagihara, D., (A) 683
Yano, I., (A) 342
Ye, D., (A) 357
Ye, G.-Y., (O) 56, (N) 122, 318, (A) 495, (O) 565, (N) 659
Ye, S., *et al.*, (A) 509
Yellapurkar, M. V., (A) 671
Yemaneberhan, T., (O) 385
Yengui, M., (A) 693
Yilma, T., (A) 353
Yobouet, P., (A) 357
Yoder, L. J., (A) 166, 184, (O) 554
Yogi, Y., (A) 719
Yokota, T., (A) 152, 363
Yoshida, H., (A) 137
Yoshino, Y., (A) 715
Young, D. B., (A) 679, 684, 684
Young, R., (A) 727
Young, R. A., (A) 699
Yu, R., (A) 148
Yushchenko, A. A., (A) 336
Yushin, M. Y., (A) 506

Zacharia, A. G., (C) 643
Zahaf, A., (A) 693, 693
Zajcev, R. A., (A) 506, 506
Zawar, P. C., (A) 332
Zelger, J., (A) 498
Zemskova, Z. S., (A) 150
Zhang, J., (A) 357
Zhang, Y., (A) 495
Zhou, L., (O) 565
Zhou, Y., (A) 673
Zimmerman, L. E., (A) 176

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

Acid, fatty,
Essential fatty acids in the plasma phospholipids of patients with leprosy. Wright, S. ..(A) 677
Fatty acids in *M. leprae* purified from the tissues of the animals with experimental leprosy. Pinchuck, L. M., *et al.* ....(A) 508
Quantitative comparison of the mycolic and fatty acid compositions of *Mycobacterium leprae* and *M. gordonae.* Minnikin, D. E., *et al.* ....(A) 687

Adenosine triphosphatase (ATP),
Application of ATP assays to patient care in leprosy. Dhople, A. M. ....(A) 507
Rapid methods for counting mycobacteria—comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assay. Prioli, R. P., *et al.* ....(A) 698
Results from cation and mass fingerprint analysis of single cells and from ATP measurements of *M. leprae* for drug sensitivity testing: a comparison. Seydel, U., *et al.* ....(O) 365

Africa,
Leprosy in Africans. A Pictorial Documentation Based on Photographs Selected and Annotated by W. K. Jacyk. ....(B) 130

Anemia,
Dapsone and aplastic anemia. Foucauld, J., *et al.* ....(A) 327
Incidence of anemia in leprosy patients tested with dapsone. Puavilai, S., *et al.* ....(A) 672

Antibody(ies),
A monoclonal antibody against *Mycobacterium lepraemurium* which recognizes a cross-reacting mycobacterial antigen. Bach, M.-A. and Hoffenbach, A. ....(A) 138
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. ....(O) 22
Affinity purification of a 65,000 dalton protein of *Mycobacterium gordonae* using a monoclonal antibody which recognizes a shared epitope on the homologous protein of *Mycobacterium leprae.* Gillis, T. P. ....(A) 718
Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., *et al.* ....(A) 503
Anti-*Mycobacterium leprae* antibodies in urine from lepromatous patients examined by crossed immunoelectrophoresis and radioimmunoassay. Olcén, P., *et al.* ....(A) 144
Anti-*Mycobacterium leprae* antibodies induced by lepromin injection as demonstrated by indirect immunofluorescence. Gonzalez-Abreu, E., *et al.* ....(A) 336
Antibodies to *Mycobacterium leprae* detected by enzyme linked (ELISA) and radio (RIA) immunoassay: comparison among families with leprosy patients. Chakinis, C., *et al.* ....(A) 354
Antibody response to phenolic glycolipid-I in inbred mice immunized with *Mycobacterium leprae.* Teuscher, C., *et al.* ....(A) 683
Antimycobacteria antibodies in *M. lepraemurium* murine infection. Bach, M. A. and Hoffenbach, A. ....(A) 348
Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients. Andreoli, A., *et al.* ....(O) 211
Characterization of competitive-antibody-binding assay with a radiolabeled monoclonal antibody specific for *Mycobacterium leprae.* Gillis, T. P., *et al.* ....(A) 178
Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of *M. leprae.* Truman, R. W., *et al.* ....(A) 175
Determination of antibodies in dried blood from earlobes of leprosy patients by enzyme-linked immunosorbent assay—a preliminary report. Wu, Q., *et al.* ....(O) 565
Determination of inhibitory concentrations of antiviral agents in cell culture by use of

an enzyme immunoassay with virus-specific, peroxidase-labeled monoclonal antibodies. van Tiel, F. H., *et al.* ..... (A) 699
Diagnostic test systems based on enzyme-linked immunosorbent assay for detection of anti-*M. leprae* antibodies. Sukhenko, L. T., *et al.* ..... (A) 506
Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., *et al.* ..... (A) 137
Effect of thalidomide on induction of antibody synthesis in mice to a T-independent antigen. Shannon, E. J., *et al.* ..... (A) 165
Evaluation of tubercular antigen and antitubercular antibodies in pleural and ascitic effusions. Samuel, A. M., *et al.* ..... (A) 514
Fibronectin in leprosy lesions: observations using monoclonal antibodies to human fibronectin. Narayanan, R. B., *et al.* ..... (A) 339
Human monoclonal antibodies against *Mycobacterium leprae.* Atlaw, T., *et al.* ..... (A) 677
IgM antibodies against phenolic glycolipid-I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* ..... (A) 341
In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin-2 and its receptor. Modlin, R. L., *et al.* ..... (A) 503
Inhibition of antibody-dependent, cell-mediated cytotoxicity by serum from lepromatous leprosy patients. de la Barrera, S. S., *et al.* ..... (O) 218
Monoclonal antibodies and recombinant DNA technology: present and future uses in leprosy and tuberculosis. Seckl, M. J. ..... (E) 618
Monoclonal antibodies to a 28,000 mol. wt protein antigen of *Mycobacterium leprae.* Young, D. B., *et al.* ..... (A) 684
Myelinotoxic effect of serum antibodies from leprosy patients. Umerov, G. G., *et al.* ..... (A) 506
Neural auto-antibodies in leprosy. Eustis-Turf, E. P., *et al.* ..... (A) 722
Production and characterization of monoclonal antibodies to *Mycobacterium tuberculosis.* Kolk, A. H. J., *et al.* ..... (A) 338
Production of human antibodies to *Mycobacterium leprae.* Mohagheghpour, N., *et al.* ..... (A) 717
Production of human monoclonal antibodies to *Mycobacterium leprae.* Mohagheghpour, N., *et al.* ..... (A) 178
Results of a World Health Organization-sponsored workshop on monoclonal antibodies to *Mycobacterium leprae.* ..... (A) 682
Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Waldor, M. K., *et al.* ..... (A) 363
Salivary anti-*M. leprae* antibodies of household contacts and inhabitants in a leprosy-endemic area. Abe, M., *et al.* ..... (A) 715
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* ..... (A) 360
Serological survey of leprosy and control subjects by a monoclonal antibody-based immunoassay. Sinha, S., *et al.* ..... (O) 33
Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. ..... (A) 715
Strain variation of lymphokine production and specific antibody secretion in mice infected with *Mycobacterium lepraemurium.* Hoffenbach, A., *et al.* ..... (A) 510
The molecular basis of positive treponemal antibody, antinuclear antibody, and immune complex tests among Hansen's disease patients. Miller, R. A., *et al.* ..... (A) 713
The sensitivity and specificity of fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with *Mycobacterium leprae.* Ji, B., *et al.* ..... (A) 357
The study of antibodies to DNA in the patients with complicated lepromatous leprosy. Kuzina, Z. A. ..... (A) 499
Use of human skin to demonstrate antinuclear antibodies in lepromatous leprosy patients. Lamas-Robles, C., *et al.* ..... (O) 373

Antigen(s),
A comparative study of antigens from human peripheral nerves and *M. leprae* antigens. Umerov, G. G. ..... (A) 506
A monoclonal antibody against *Mycobacterium lepraemurium* which recognizes a cross-reacting mycobacterial antigen. Bach, M.-A. and Hoffenbach, A. ..... (A) 138

Detection of an antigen (MY4) common to *M. tuberculosis* and *M. leprae* by "tandem" immunoassay. Praputpittaya, K. and Ivanyi, J. ..... (A) 681
Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of *M. leprae*. Truman, R. W., *et al.* ..... (A) 175
Dissection of *Mycobacterium tuberculosis* antigens using recombinant DNA. Young, R. A., *et al.* ..... (A) 699
Effect of thalidomide on induction of antibody synthesis in mice to a T-independent antigen. Shannon, E. J., *et al.* ..... (A) 165
Evaluation of tubercular antigen and antitubercular antibodies in pleural and ascitic effusions. Samuel, A. M., *et al.* ..... (A) 514
Host responses to the phenolic glycolipid-I antigen of *M. leprae*. Truman, R. W., *et al.* ..... (A) 710
Immunologic assessment of *Mycobacterium leprae* antigens using isoelectric focusing and chromatofocusing separation. Navalkar, R. G. and Ibegbu, C. ..... (A) 173
In vivo responses to *Mycobacterium leprae*: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., *et al.* ..... (O) 385
Isolation and preliminary characterization of the major intracellular carbohydrate-containing antigens of *Mycobacterium leprae*. Hunter, S. W., *et al.* ..... (A) 712
Monoclonal antibodies to a 28,000 mol. wt protein antigen of *Mycobacterium leprae*. Young, D. B., *et al.* ..... (A) 684
Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. Kirkpatrick, C. H., *et al.* ..... (A) 514
New-found glycolipid antigens of mycobacteria. Brennan, P. J. ..... (A) 343
Occurrence of antigen BCG 60 in leprosy-derived corynebacteria and other coryneforms. Papa, F. P., *et al.* ..... (A) 345
Parasitism of antigen presenting cells in hyperbacillary leprosy. Poulter, L. W., *et al.* ..... (A) 505
Protective properties of some bacterial antigens in experimental leprosy. Zajcev, R. A. and Umerov, G. G. ..... (A) 506
Recombinant DNA clones expressing *M. leprae* and *M. tuberculosis* antigens: potential new tools for immunodiagnosis and prophylaxis. Mehra, V., *et al.* ..... (A) 727
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* ..... (A) 360
Strain variation in murine immune response to the *M. leprae* glycolipid antigen, phenolic glycolipid-I. Tung, K. S. K., *et al.* ..... (A) 721
Use of an artificial antigen containing the 3,6-di-*O*-methyl-β-D-glucopyranosyl epitope for the serodiagnosis of leprosy. Cho, S.-N., *et al.* ..... (A) 139

Argentina,
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* ..... (A) 360

Armadillo(s),
A possible mode of transmission of armadillo leprosy in the wild and a simple method to conduct a random survey of its prevalence. Job, C. K., *et al.* ..... (A) 723
Armadillo exposure among Mexican-born patients with lepromatous leprosy. Thomas, D. A., *et al.* ..... (A) 724
Biochemical alterations in the serum of armadillos (*Dasypus novemcinctus*) infected with *Mycobacterium leprae*. A preliminary report. Rojas-Espinosa, O., *et al.* ..... (O) 262
Cultivable mycobacteria isolated from organs of armadillos uninoculated and inoculated with *Mycobacterium leprae*. Portaels, F., *et al.* ..... (A) 687
Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of *M. leprae*. Truman, R. W., *et al.* ..... (A) 175
Experimental leprosy in the armadillo and nude mice: comparative histobacteriology and ultrastructure. Ravisse, P., *et al.* ..... (A) 352
Experimental reproduction of leprosy in seven-banded armadillos (*Dasypus hybridus*). Balina, L. M., *et al.* ..... (O) 595
First lesion in experimental armadillo leprosy. Job, C. K., *et al.* ..... (A) 690

Leprosy in wild armadillos (*Dasypus novemcinctus*) of the Texas Gulf Coast. Smith, J. H., *et al.* ..... (A) 358
Manifestation of experimental leprosy in the armadillo. Job, C. K., *et al.* ..... (A) 350
Phagocytosis of *Mycobacterium leprae* and *M. avium* by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. ..... (A) 340
Presence of "difficult-to-grow" mycobacteria in armadillos. Dhople, A. M., *et al.* ..... (A) 166
Purification of phenolic glycolipid-I from armadillo and human sources. Hunter, S. W., *et al.* ..... (C) 484
Reversal reactions in *M. leprae*-infected nine-banded armadillos. Juscenko, A. A. ..... (A) 510
The adenosine triphosphate content and death rate of *Mycobacterium leprae* isolated from armadillo tissue by Percoll buoyant density centrifugation. Kvach, J. T., *et al.* ..... (A) 169
The free lipids of *Mycobacterium leprae* harvested from experimentally infected nine-banded armadillos. Minnikin, D. E., *et al.* ..... (A) 686
Ultrastructure of sciatic nerve of armadillo infected with *Mycobacterium leprae*. Mehta, L. N. and Antia, N. H. ..... (A) 338
Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. avium/intracellulare*, and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* ..... (O) 441

Armed Forces,
Epidemiological and clinical aspects of leprosy in Indian Armed Forces. Tiwari, V. D. and Tutakne, M. A. ..... (A) 693
Leprosy in the Armed Forces of the United States: newly reported cases from 1970 to 1983. Schlagel, C. J., *et al.* ..... (A) 692

Arthritis,
Thalidomide. A promising new treatment for rheumatoid arthritis. Gutierrez-Rodriguez, O. ..... (A) 151

Asia,
Proceedings of the 5th International Workshop on Leprosy Control in Asia. Leprosy Control in Urban Community. ..... (B) 323
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. ..... (A) 697
Specific health problems of Southeast Asian refugees in middle Tennessee. Dao, A. H., *et al.* ..... (A) 132

Assay(s) (see also ELISA),
Application of ATP assays to patient care in leprosy. Dhople, A. M. ..... (A) 507
Characterization of a competitive-antibody-binding assay with a radiolabeled monoclonal antibody specific for *Mycobacterium leprae*. Gillis, T. P., *et al.* ..... (A) 178
Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of *Mycobacterium leprae* sensitivity/resistance to dapsone. Sathish, M., *et al.* ..... (O) 378
Deoxyribonucleic acid relatedness among *Mycobacterium leprae, Mycobacterium lepraemurium*, and selected bacteria by dot blot and spectrophotometric deoxyribonucleic acid hybridization assays. Athwal, R. S., *et al.* ..... (A) 342
Determination of antibodies in dried blood from earlobes of leprosy patients by enzyme-linked immunosorbent assay—a preliminary report. Wu, Q., *et al.* ..... (O) 565
Diagnostic test systems based on enzyme-linked immunosorbent assay for detection of anti-*M. leprae* antibodies. Sukhenko, L. T., *et al.* ..... (A) 506
Rapid methods for counting mycobacteria—comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assay. Prioli, R. P., *et al.* ..... (A) 698
Rapid, radiometric *in vitro* assay for the evaluation of the anti-leprosy activity of clofazimine and its analogues. Mittal, A., *et al.* ..... (A) 670
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* ..... (A) 360

B663 (see Clofazimine)

Bacilli,
Electron microscopic observations of acid-fast bacilli in nasal mucosal biopsies of lepromatous leprosy patients. Hirata, T. ..... (O) 577
Electron microscopic observations of cell wall and cytoplasmic membrane in murine and human leprosy bacilli. Hirata, T. ..... (O) 433
Proprionibacterium, Corynebacterium, Mycobacterium and lepra bacilli. Barksdale, L. and Kim, K.-S. ..... (A) 343
Skin-test sensitization by tubercle bacilli and by other myobacteria in Ethiopian school children. Eshetu Lema and Stanford, J. ..... (A) 362

Bacterial index (BI),
Effect of levamisole on bacterial index in BL and LL leprosy. Bera, D. K. and Sen, P. C. ..... (O) 198
IgM antibodies against phenolic glycolipid-I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* ..... (A) 341

BCG (bacille Calmette-Guérin),
Does infection with environmental mycobacteria suppress the protective response to subsequent vaccination with BCG? Smith, D., *et al.* ..... (A) 363
Effect of *Mycobacterium bovis* (BCG) infection on the kinetics of the mononuclear cell response within the lung. Collins, F. M. and Auclair, L. K. ..... (A) 149
Efficacy of *Mycobacterium bovis* BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Orme, I. M. and Collins, F. M. ..... (A) 697
Occurrence of antigen BCG 60 in leprosy-derived corynebacteria and other coryneforms. Papa, F. P., *et al.* ..... (A) 345
Prophylactic effect in mice of BCG vaccination against nontuberculous mycobacterial infections. Orme, I. and Collins, F. M. ..... (A) 698

Biochemistry,
Biochemical alterations in the serum of armadillos (*Dasypus novemcinctus*) infected with *Mycobacterium leprae*. A preliminary report. Rojas-Espinosa, O., *et al.* ..... (O) 262

Blood,
Determination of antibodies in dried blood from earlobes of leprosy patients by enzyme-linked immunosorbent assay—a preliminary report. Wu, Q., *et al.* ..... (O) 565
Distribution of blood groups and finger patterns in the families with leprosy patients. Baranov, Y. N. and Podoplelov, I. I. ..... (A) 498
Effect of leprosy sera and foetal calf serum (FCS) on the T cell number of peripheral blood of leprosy patients. Patil, S. A., *et al.* ..... (A) 504
Thalidomide induces imbalances in T lymphocyte subpopulations in circulating blood of healthy males. Gad, S. M., *et al.* ..... (A) 502
The assessment of activity of leprosy process and effectiveness of antileprosy therapy by excess lactate in blood. Ryzhova, N. Y. ..... (A) 501
The relation between cell-mediated immunity and blood groups in leprosy patients. Selezneva, S. P., *et al.* ..... (A) 501
Tissue and blood T-lymphocyte subpopulations in erythema nodosum leprosum. Modlin, R. L., *et al.* ..... (A) 338
Ultrastructural and histophysiological studies on the blood-nerve barrier and perineurial barrier in leprosy neuropathy. Boddingius, J. ..... (A) 138

Bone,
Relationship between the loss of maxillary anterior alveolar bone and the duration of untreated lepromatous leprosy in Malaysia. Seang Hoo Nah, *et al.* ..... (A) 501

Borderline leprosy,
An electron microscopic study on macrophages and lymphocytes in lepromatous and borderline leprosy. Burchard, G.-D. and Bierther, M. ..... (O) 64
Borderline reactions treated with clofazimine and corticosteroids. Thirugnanam, T. and Rajan, M. A. ..... (A) 677

Immunostimulatory effect of levamisole in borderline leprosy cases. Arora, S. K., *et al.* ..... (A) 673
The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Kiran, K. U., *et al.* ..... (A) 674
Untreated borderline leprosy in the ulnar nerve: light and electron microscopical studies. Vieregge, P., *et al.* ..... (A) 506

C3,
Conversion of the C3 component of complement in sera of hanseniasis patients. Kliemann, T. A. E., *et al.* ..... (A) 142
Reduced expression of C3b receptors on erythrocytes from patients with lepromatous leprosy. Tausk, F., *et al.* ..... (A) 184

Canada,
Ten-year evaluation of a trial of chemoprophylaxis against tuberculosis in Frobisher Bay, Canada. Darken, E., *et al.* ..... (A) 149

Cells,
A case of squamous cell carcinoma in plantar ulcer in leprosy. Bobhate, S. K., *et al.* ... (A) 331
Adoptive transfer of cell-mediated immunity in *M. leprae*-infected nude mice with *M. leprae*-immunized allogeneic leukocytes depleted of Thy-1.2-bearing cells and Lyt-2.2-bearing cells. Chehl, S. K., *et al.* ..... (A) 720
Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., *et al.* ..... (A) 503
Cell envelope architectures of leprosy-related corynebacteria, *Mycobacterium leprae*, and related organisms: a comparative study. Rastogi, N., *et al.* ..... (A) 145
Concentration-dependent effects of mycobacteria on the stimulation of murine T-cell clones. Kingston, A. E. and Colston, M. J. ..... (A) 337
Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to *Mycobacterium leprae* is associated with defective expression of interleukin-2 receptors and is not reconstituted by interleukin-2. Mohagheghpour, N., *et al.* ..... (A) 680
Determination of inhibitory concentrations of antiviral agents in cell culture by use of an enzyme immunoassay with virus-specific, peroxidase-labeled monoclonal antibodies. van Tiel, F. H., *et al.* ..... (A) 699
Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., *et al.* ..... (A) 504
Effect of leprosy sera and foetal calf serum (FCS) on the T cell number of peripheral blood of leprosy patients. Patil, S. A., *et al.* ..... (A) 504
Effect of *Mycobacterium bovis* (BCG) infection on the kinetics of the mononuclear cell response within the lung. Collins, F. M. and Auclair, L. K. ..... (A) 149
Electron microscopic observations of cell wall and cytoplasmic membrane in murine and human leprosy bacilli. Hirata, T. ..... (O) 433
Freeze-etching and freeze-fracture structural features of cell envelopes in mycobacteria and leprosy-derived corynebacteria. Benedetti, E. L., *et al.* ..... (A) 343
Further studies of the use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. Matsuo, Y. ..... (A) 345
Immunochemical characterization of a protein associated with *Mycobacterium leprae* cell wall. Gillis, T. P., *et al.* ..... (A) 679
In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin-2 and its receptor. Modlin, R. L., *et al.* ..... (A) 503
In vitro lymphocyte stimulating ability of cell components of *Mycobacterium leprae*. Khandke, L., *et al.* ..... (A) 337
In vitro studies on dermal granulomas of human leprosy—cellular characteristics. Narayanan, R. B., *et al.* ..... (O) 39
Incorporation of [^{14}C]-acetate into the specific phenolic glycolipid *M. leprae* maintained within cultured cells. Mukherjee, R., *et al.* ..... (A) 508
Inhibition of interleukin-2 production by adherent cell factors from lepromatous leprosy patients. Nath, I., *et al.* ..... (A) 339
Interleukin-2-induced T-cell response to *M. leprae* in lepromatous leprosy: reversion of

a suppressor mechanism or expansion of a small *M. leprae*-reactive T-cell pool? Shankar, P., *et al.* ..... (C) 649
Low prevalence of serologic evidence of polyclonal B cell activation among Hansen's disease patients in Seattle. Miller, R. A., *et al.* ..... (A) 182
Mycobacterium leprae within a squamous cell carcinoma. Laing, A. B. G., *et al.* ..... (A) 333
Normal numbers of T6 positive epidermal Langerhans' cells across the leprosy spectrum. Narayanan, R. B., *et al.* ..... (A) 143
Parasitism of antigen presenting cells in hyperbacillary leprosy. Poulter, L. W., *et al.* ..... (A) 505
Persistence of Langhans' giant cells in rapidly downgrading leprosy lesions. Lyons, N. F., *et al.* ..... (C) 114
Proliferation of IgDx plasma cells after agranulocytosis induced by dapsone. Lahuerta-Palacios, J. J., *et al.* ..... (A) 669
Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., *et al.* ..... (A) 678
Rapid detection of mycobacterial contamination in batches of whole cells of purified *Mycobacterium leprae* by pyrolysis gas chromatography. Wieten, G., *et al.* ..... (A) 348
Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Martin, W. J., II, and Kachel, D. L. ..... (A) 696
Results from cation and mass fingerprint analysis of single cells and from ATP measurements of *M. leprae* for drug sensitivity testing: a comparison. Seydel, U., *et al.* ..... (O) 365
Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to *Mycobacterium leprae*. Haregewoin, A., *et al.* ..... (A) 141
Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Waldor, M. K., *et al.* ..... (A) 362
Specific suppression of responses to *Leishmania tropica* by a cloned T-cell line. Liew, F. Y. ..... (A) 362
Squamous cell carcinoma developing in trophic ulcers in leprosy—a case report. Kumar, K. and Kant, M. ..... (A) 333
T-cell responsiveness in *Mycobacterium lepraemurium* infections in a "resistant" (CBA) and a "susceptible" (BALB/c) mouse strain. Brett, S. J. ..... (A) 349
Thalidomide—effect on T cell subsets as a possible mechanism of action. Moncada, B., *et al.* ..... (O) 201
The cell interaction in lepromin test. Ibraimov, M. ..... (A) 502
The spectrum of *in vitro* T-cell responsiveness in lepromatous leprosy. Kaplan, G., *et al.* ..... (A) 708
Ultrastructural study of epidermal Langerhans' cells in leprosy. Mathur, N., *et al.* ..... (A) 503

Chemotherapy, see also Therapy,

A follow-up investigation of the Matla Project. Jopling, W. H., *et al.* ..... (A) 134
Ad Hoc Drug Development Subgroup of the SWG on the Chemotherapy of Leprosy meeting, 10–11 October 1983. ..... (N) 125
An anomalous response of *M. leprae* to dapsone chemotherapy in nude mice. Chehl, S. K. and Hastings, R. C. ..... (A) 167
Chemotherapy of Leprosy for Control Programs videotape available. ..... (N) 126
Chemotherapy of leprosy—a tool for leprosy control (The Kellersberger Memorial Lecture, 1984). Levy, L. ..... (A) 669
ELISA evaluation of phenolic glycolipid-I (PGI) and whole *M. leprae* with sera collected from leprosy patients during the course of chemotherapy. Douglas, J. T., *et al.* ..... (A) 180
Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Weldon, J. S., *et al.* ..... (A) 153
On a role of antileprotic agents as the scavengers of active oxygen radicals. Tsutsumi, S. and Gidoh, M. ..... (A) 714
Recent Ideas and "Progress in the Treatment" of Leprosy (Erwin Stindl Memorial Oration, 1985). Girdhar, B. K. ..... (N) 663
Role of dapsone in chemotherapy of leprosy—a comparison of responses to therapy in two cohorts in 1960s and 1970s. Reddy, B. N. and Neelan, P. N. ..... (A) 497
The chemotherapy of leprosy. Hooper, M. and Purohit, M. G. ..... (A) 134

Children,

A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal. Morton, A., *et al.* ..... (A) 143

An epidemiological study of leprosy among children in a rural area (India). Reddy, B. N. and Bansal, R. D. ..... (A) 148
Leprosy in children one year of age and under. Brubaker, M. L., *et al.* ..... (O) 517
Leprosy in young children—past, present and future. Duncan, M. E. ..... (E) 468
Multibacillary leprosy in an 18-month-old child: a case report. Nsibambi, J., *et al.* ..... (A) 333
Prevalence of leprosy in children of leprosy parents. Dave, D. S. and Agrawal, S. K. ..... (A) 354
Skin-test sensitization by tubercle bacilli and by other mycobacteria in Ethiopian school-children. Eshetu Lema and Stanford, J. ..... (A) 362

China, People's Republic of,
30th anniversary of the founding of the Institute of Dermatology, CAMS celebrated. Ye, G.-Y. ..... (N) 318
Experiences with phenazine dye, B628, in the treatment of leprosy in China. Li, F. T. ..... (A) 670
Former IJL Editor returns to China. ..... (N) 659
Institute of Dermatology, CAMS relocated. Ye, G.-Y. ..... (N) 122
Leprosy control in Shandong Province, China, 1955–1983; some epidemiological features. Li, H.-Y., *et al.* ..... (O) 79
National conference on Propaganda and Education of Leprosy held in Nanjing. Ye, G.-Y. ..... (N) 659
Understanding of leprosy in ancient China. Skinsnes, O. K. and Chang, P. H. C. ..... (E) 289

Cholesterol,
An *in vitro* test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of *Mycobacterium leprae.* Nair, I. and Mahadevan, P. R. ..... (A) 671

Chromatography,
Comparative study on the thin-layer chromatographic pattern of methyl mycolates of *M. leprae* and related species. Datta, A. K., *et al.* ..... (O) 45
Rapid detection of mycobacterial contamination in batches of whole cells of purified *Mycobacterium leprae* by pyrolysis gas chromatography. Wieten, G., *et al.* ..... (A) 348
Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. avium/intracellulare,* and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* ..... (O) 441

Chromosomes,
Chromosomal aberrations in cultures of skin fibroblasts of leprosy patients. Hackel, C. and Beiguelman, B. ..... (O) 533

Clinical
A retrospective study of leprosy in an industrial hospital. Ramanan, C., *et al.* ..... (A) 692
Absence of triradium d on the palm of a leprosy patient. Gupta, C. M., *et al.* ..... (A) 499
An analysis of leprosy incidence by patient age and the clinical form of the disease. Ferreira, J., *et al.* ..... (A) 691
Arteriography in leprosy. Agrawal, B. R. and Agrawal, R. I. ..... (A) 673
Clinical aspects. Jacobson, R. R. ..... (A) 162
Clinico-pathological study of nephrotic syndrome in leprosy. Jain, A. P., *et al.* ..... (A) 499
Electro-cardiographic changes in multibacillary leprosy. Agrawal, S. and Aggarwal, S. K. ..... (A) 331
Epidemiological and clinical aspects of leprosy in Indian Armed Forces. Tiwari, V. D. and Tutakne, M. A. ..... (A) 693
Hypercalcemia in leprosy. Ryzen, E. and Singer, F. R. ..... (A) 675
International Conference on Biomechanics and Clinical Kinesiology of Hand and Foot to be held 16–18 December 1985 (India). Patil, K. M. ..... (N) 319
NADH-Methemoglobin reductase and reticulocytosis. Caticha-Alfonso, O. ..... (C) 483
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., *et al.* ..... (A) 669
Some data on pharmakinetics of dimociphon in leprosy (experimental and clinical investigation). Gnenjuk, T. S. ..... (A) 494
Spontaneous healing in paucibacillary leprosy. Jesudasan, K. and Christian, M. ..... (A) 499
The patient with sensory loss. Coleman, W. C. and Madrigal, D. R. ..... (O) 255
The placenta in leprosy. Duncan, M. E., *et al.* ..... (A) 336

Untreated Hansen's disease of the eye: a clinicopathological report. Robertson, I., *et al.* . . . . . (A) 675
Value of pilocarpine test in early diagnosis of leprosy. Chattopadhyay, S. P., *et al.* . . . . (A) 498

Clofazimine,
Borderline reactions treated with clofazimine and corticosteroids. Thirugnanam, T. and Rajan, M. A. . . . . (A) 677
Clofazimine and the eye: preliminary communication. Negrel, A. D., *et al.* . . . . . (A) 330
Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes *in vitro*. Anderson, R. . . . . (A) 327
Evaluation of effectiveness of clofazimine therapy. I. Monitoring of absorption of clofazimine from gastrointestinal tract. Mathur, A., *et al.* . . . . . (A) 670
Exfoliative dermatitis after clofazimine. Pavithran, K. . . . . (C) 645
Lamprene (Clofazimine, B663) on Leprosy; Basic Information. . . . . . (N) 126
LDH isoenzymes subunit ratio in leprosy and the effect of clofazimine treatment on LDH isoenzymes subunit. Bulakh, P. M., *et al.* . . . . . (A) 673
Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine. Niwa, Y., *et al.* . . . (A) 330
Rapid, radiometric *in vitro* assay for the evaluation of the anti-leprosy activity of clofazimine and its analogues. Mittal, A., *et al.* . . . . . (A) 670
The pharmacology of intermittent clofazimine therapy in Hansen's disease. Morales, M. J., *et al.* . . . . . (A) 166

Complement,
Conversion of the C3 component of complement in sera of hanseniasis patients. Kliemann, T. A. E., *et al.* . . . . . (A) 142
Leprosy: altered complement receptors in disseminated disease. Tausk, F., *et al.* . . . . . (A) 683
Reduced complement-mediated immune complex solubilization in leprosy patients. Ramanathan, V. D., *et al.* . . . . . (A) 681

Control of leprosy,
Analysis of leprosy control program in Pakistan. Pfau, R. . . . . (A) 512
Chemotherapy of Leprosy for Control Programs videotape available. . . . . (N) 126
Chemotherapy of leprosy—a tool for leprosy control (The Kellersberger Memorial Lecture, 1984). Levy, L. . . . . (A) 669
Comparative value of dapsone "spot test" and dapsone "tile test" in leprosy control programme. Naik, S. S. . . . . (A) 496
Diagnostic efficiency of paramedical workers involved in leprosy case detection. Kumar, A., *et al.* . . . . . (A) 332
Epidemiology of Leprosy in Relation to Control. Report of a WHO Study Group. WHO Tech. Rpt. Ser. 716. . . . . (B) 491
. . . . . (N) 663
Leprosy case detection rates by age, sex and polar type under leprosy control conditions. de Vries, J. L. and Perry, B. H. . . . . (A) 355
Leprosy control in Shandong Province, China, 1955–1983; some epidemiological features. Li, H.-Y., *et al.* . . . . . (O) 79
Leprosy control in Sind. Pfau, R. . . . . (A) 358
Leprosy detection through non-survey techniques. Ganapati, R., *et al.* . . . . . (A) 355
Patient compliance in leprosy control: a necessity in old and new regimens. Huikeshoven, H. . . . . (E) 474
Proceedings of the 5th International Workshop on Leprosy Control in Asia. Leprosy Control in Urban Community. . . . . (B) 323
Risk of paucibacillary leprosy patients released from control relapsing with multibacillary leprosy. Jesudasan, J. and Christian, M. . . . . (O) 19
Social factors and leprosy in Lamjung, west central Nepal: implication for disease control. Pearson, M. . . . . (A) 358
Strategy for leprosy control. Lagrange, P. H. and Stach, J. L. . . . . (E) 278
Surveillance in leprosy. Jesudasan, K. and Christian, M. . . . . (A) 692

Corticosteroids,
Borderline reactions treated with clofazimine and corticosteroids. Thirugnanam, T. and Rajan, M. A. . . . . (A) 677

Immunomodulation with corticosteroids and levamisole in leprosy as gauged by *in vivo* lepromin and *in vitro* CMI responses. Kundu, S. K., *et al.* ..... (A) 679

Corynebacteria,
Cell envelope architectures of leprosy-related corynebacteria, *Mycobacterium leprae,* and related organisms: a comparative study. Rastogi, N., *et al.* ..... (A) 145
Comparative properties of *Mycobacterium leprae* and leprosy-derived corynebacteria. Cocito, C. ..... (A) 712
Description of *Corynebacterium tuberculostearicum* sp. nov., a leprosy-derived corynebacterium. Brown, S., *et al.* ..... (A) 343
Freeze-etching and freeze-fracture structural features of cell envelopes in mycobacteria and leprosy-derived corynebacteria. Benedetti, E. L., *et al.* ..... (A) 343
Occurrence of antigen BCG 60 in leprosy-derived corynebacteria and other coryneforms. Papa, F. P., *et al.* ..... (A) 345

Cultivation,
Cultivable mycobacteria isolated from organs of armadillos uninoculated and inoculated with *Mycobacterium leprae.* Portaels, F., *et al.* ..... (A) 687
Cultivation of *M. leprae* using perfluorocarbon beddings. Juscenko, A. A. and Irtuganova, O. A. ..... (A) 507
Further studies of the use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. Matsuo, Y. ..... (A) 345
In vitro cultivation of leprosy granulation tissue and the effect of rifampin on it. Anokhina, V. V. ..... (A) 493
Morphology and cytochemistry of cultivated monocyte-macrophage in leprosy. Yushin, M. Y. ..... (A) 506
Trials of culturing of *Mycobacterium leprae* using media enriched with thyroid hormones. Massalski, W., *et al.* ..... (A) 145
Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. aviun/intracellulare,* and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* ..... (O) 441

Cutaneous,
An electron microscopic study of the small cutaneous vessels in leprosy. Burchard, G.-D. and Bierther, M. ..... (O) 70
Cutaneous coccidioidomycosis simulating lepromatous leprosy. Hobbs, E. R. and Hempstead, R. W. ..... (A) 332
Cutaneous inoculation tuberculosis secondary to "jailhouse tatooing." Horney, D. A., *et al.* ..... (A) 514
Cutaneous *Mycobacterium szulgai* infection. Cross, G. M., *et al.* ..... (A) 361
Observations on local heat treatment for cutaneous leishmaniasis. Neva, F. A., *et al.* ..... (A) 151

Cycloheximide,
Further studies of the use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. Matsuo, Y. ..... (A) 345

Cycloserine,
Activity of the combination of fludalanine and cycloserine against mycobacteria *in vitro.* Dickinson, J. M. and Mitchison, D. A. ..... (A) 695

Dapsone (DDS),
An anomalous response of *M. leprae* to dapsone chemotherapy in nude mice. Chehl, S. K. and Hastings, R. C. ..... (A) 167
Chemical characterization of the dapsone binding site of lysozyme. Datta, G., *et al.* ..... (O) 428
Comparative value of dapsone "spot test" and dapsone "tile test" in leprosy control programme. Naik, S. S. ..... (A) 496
Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of *Mycobacterium leprae* sensitivity/resistance to dapsone. Sathish, M., *et al.* ..... (O) 378
Dapsone and aplastic anemia. Foucauld, J., *et al.* ..... (A) 327
Dapsone resistance in patients attending Central Leprosy Teaching and Research Institute, Chengalpattu (South India). Bhatia, V. N., *et al.* ..... (A) 327
DDS-resistant leprosy. Neelan, P. N. and Reddy, B. N. ..... (C) 115
Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes *in vitro.* Anderson, R. ..... (A) 327

Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Steffen, C. ..... (A) 608
Hypersensitivity reaction to dapsone: report from Malaysia. Mohammed, K. N. ..... (A) 329
Incidence of anemia in leprosy patients tested with dapsone. Puavilai, S., *et al.* ..... (A) 672
Negative observations on immunological side effects of rifampin and dapsone in mice. Nagata, Y., *et al.* ..... (O) 421
Norethisterone and ethinyl estradiol kinetics during dapsone therapy. Joshi, J. V., *et al.* ..... (A) 328
Prevalence of secondary dapsone resistance in Nepal. Samuel, N. M., *et al.* ..... (A) 497
Prevalence of secondary dapsone-resistant leprosy in Upper Volta. Pattyn, S. R., *et al.* ..... (A) 330
Primary dapsone resistant leprosy in Nepal. Samuel, N. M., *et al.* ..... (A) 497
Proliferation of IgDx plasma cells after agranulocytosis induced by dapsone. Lahuerta-Palacios, J. J., *et al.* ..... (A) 669
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., *et al.* ..... (A) 669
Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Martin, W. J., II, and Kachel, D. L. ..... (A) 696
Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. Warndorff van Diepen, T. and Mengistu, G. ..... (O) 189
Response to Drs. Neelan and Reddy (DDS-resistant leprosy). Almeida, J. G. and Chacko, C. J. G. ..... (C) 116
Role of dapsone in chemotherapy of leprosy—a comparison of responses to therapy in two cohorts in 1960s and 1970s. Reddy, B. N. and Neelan, P. N. ..... (A) 497
Synergistic activity of dapsone and brodimoprim (a dihydrofolate inhibitor) against *Mycobacterium leprae.* Jagannathan, R. and Mahadevan, P. R. ..... (A) 495
The dapsone syndrome. A case report. Gupta, C. M., *et al.* ..... (A) 668
The neurotoxicity of dapsone. Daneshmend, T. K. ..... (A) 494
Toxicity of prothiomide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. ..... (A) 134
Urine test for monitoring regular self-administration of dapsone and its application. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. ..... (A) 133
Vitamin E and dapsone-induced hemolysis. Kelly, J. W., *et al.* ..... (A) 135

Deformity(ies),
Deformities in leprosy patients attending urban leprosy clinic at Varanasi (India). Kaur, P. and Singh, G. ..... (A) 694
Extensor pollicis brevis deviation graft operation in case of Z-deformity of the thumb in ulnar palsy—a preliminary report. Beine, A. ..... (A) 693
Management of Paralytic Deformities in Leprosy. Andersen, J. G. and Brandsma, J. W. ..... (B) 129

Dermatology,
30th anniversary of the founding of the Institute of Dermatology, CAMS celebrated (China). Ye, G.-Y. ..... (N) 318
Cyclosporine and murine allergic contact dermatitis. Rullan, P. P., *et al.* ..... (A) 152
Differential diagnosis between leprosy and post-kala-azar dermal leishmaniasis. Ekambaram, V., *et al.* ..... (A) 331
Exfoliative dermatitis after clofazimine. Pavithran, K. ..... (C) 645
Fifth World Congress of Tropical Dermatology. Browne, S. G. ..... (N) 125
In vitro studies on dermal granulomas of human leprosy—cellular characteristics. Narayanan, R. B., *et al.* ..... (O) 39
Institute of Dermatology, CAMS relocated (China). Ye, G.-Y. ..... (N) 122

Dermatoglyphics,
Dermatoglyphics in leprosy (I. Finger patterns). Ghei, S. K., *et al.* ..... (A) 498
Digital dermatoglyphics in leprosy patients with severe nerve damage. Baranov, Y. N., *et al.* ..... (A) 498

Distribution of blood groups and finger patterns in the families with leprosy patients. Baranov, Y. N. and Podoplelov, I. I. ..... (A) 498
Results from cation and mass fingerprint analysis of single cells and from ATP measurements of *M. leprae* for drug sensitivity testing: a comparison. Seydel, U., *et al.* ..... (O) 365

Dharmendra,
Evaluation of standard Dharmendra lepromin. Sengupta, U., *et al.* ..... (A) 501

DNA,
Deoxyribonucleic acid relatedness among *Mycobacterium leprae, Mycobacterium lepraemurium,* and selected bacteria by dot blot and spectrophotometric deoxyribonucleic acid hybridization assays. Athwal, R. S., *et al.* ..... (A) 342
Dissection of *Mycobacterium tuberculosis* antigens using recombinant DNA. Young, R. A., *et al.* ..... (A) 699
DNA from *Mycobacterium leprae.* David, H. L., *et al.* ..... (A) 344
DNA relatedness among *Mycobacterium leprae,* leprosy-derived bacteria, and established mycobacterial species. Imaeda, T. and Portaels, F. ..... (A) 170
Double-stranded DNA inhibits cardiolipin-binding activity in lepromatous leprosy patients' sera. Furukawa, F., *et al.* ..... (C) 647
Expression of cloned *Mycobacterium leprae* DNA in *Escherichia coli* K-12. Jacobs, W. R., *et al.* ..... (A) 170
Molecular analysis of DNA and construction of genomic libraries of *Mycobacterium leprae.* Clark-Curtiss, J. E., *et al.* ..... (A) 344
Monoclonal antibodies and recombinant DNA technology: present and future uses in leprosy and tuberculosis. Seckl, M. J. ..... (E) 618
Recombinant DNA clones expressing *M. leprae* and *M. tuberculosis* antigens: potential new tools for immunodiagnosis and prophylaxis. Mehra, V., *et al.* ..... (A) 727
The study of antibodies to DNA in the patients with complicated lepromatous leprosy. Kuzina, Z. A. ..... (A) 499

Drug(s), see also specific drugs,
A comparative evaluation of levamisole in leprosy. Sharma, L., *et al.* ..... (A) 672
A series of new antileprosy compounds derived from serotonin. Mester de Parajd, L., *et al.* ..... (A) 670
A study of the immunological effects of cimetidine in patients with lepromatous leprosy. Brown, A. A., *et al.* ..... (O) 559
Activity of the combination of fludalanine and cycloserine against mycobacteria *in vitro.* Dickinson, J. M. and Mitchison, D. A. ..... (A) 695
Ad Hoc Drug Development Subgroup of the SWG on the Chemotherapy of Leprosy meeting, 10–11 October 1983. ..... (N) 125
An *in vitro* test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of *Mycobacterium leprae.* Nair, I. and Mahadevan, P. R. ..... (A) 671
Borderline reactions treated with clofazimine and corticosteroids. Thirugnanam, T. and Rajan, M. A. ..... (A) 677
Combined therapy of leprosy patients with solusulfone, rifampin, and prothionamide. Evstratova, V. A., *et al.* ..... (A) 494
Dimociphon in combined therapy of drug-resistant and relapsed leprosy patients. Gnenjuk, T. S. ..... (A) 494
Drug interactions in combined antileprosy therapy. Loginov, V. K., *et al.* ..... (A) 496
Drug sensitivity testing of *M. leprae.* Grosset, J., *et al.* ..... (C) 118
Effect of antacids on oral absorption of rifampicin. Khalil, S. A. H., *et al.* ..... (A) 669
Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Steffen, C. ..... (A) 608
Evaluation of effectiveness of clofazimine therapy. I. Monitoring of absorption of clofazimine from gastrointestinal tract. Mathur, A., *et al.* ..... (A) 670
Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Schroder, J. M. and Matthiesen, T. ..... (A) 672
Immunomodulation with corticosteroids and levamisole in leprosy as gauged by *in vivo* lepromin and *in vitro* CMI responses. Kundu, S. K., *et al.* ..... (A) 679
Immunostimulatory effect of levamisole in borderline leprosy cases. Arora, S. K., *et al.* ..... (A) 673

In vitro drug screening system using membrane alteration in macrophages by *Mycobacterium leprae*. Mankar, M. V., *et al.* ..... (A) 507
Incidence of anemia in leprosy patients tested with dapsone. Puavilai, S., *et al.* ..... (A) 672
Influence of levamisole on lymphocytes and *M. leprae* in mice. Ganguly, N. K., *et al.* ..... (A) 689
LDH isoenzymes subunit ratio in leprosy and the effect of clofazimine treatment on LDH isoenzymes subunit. Bulakh, P. M., *et al.* ..... (A) 673
Levamisole in cases of ENL. Arora, S. K., *et al.* ..... (A) 668
Pattern of drug resistance in tuberculosis. Hardas, U. D. and Jayaraman, V. S. ..... (A) 695
Proliferation of IgDx plasma cells after agranulocytosis induced by dapsone. Lahuerta-Palacios, J. J., *et al.* ..... (A) 669
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., *et al.* ..... (A) 669
Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. Schwab, B. W., *et al.* ..... (A) 330
Rapid, radiometric *in vitro* assay for the evaluation of the anti-leprosy activity of clofazimine and its analogues. Mittal, A., *et al.* ..... (A) 670
Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone. Martin, W. J., II, and Kachel, D. L. ..... (A) 696
Response to Dr. Grosset, *et al.* (drug sensitivity testing of *M. leprae*). Almeida, J. G. and Chacko, C. J. G. ..... (C) 120
Results from cation and mass fingerprint analysis of single cells and from ATP measurements of *M. leprae* for drug sensitivity testing: a comparison. Seydel, U., *et al.* ..... (O) 365
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. ..... (A) 697
Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae. Kurkcuoglu, N., *et al.* ..... (A) 696
The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Kiran, K. U., *et al.* ..... (A) 674
The search for new drugs for the treatment of leprosy. Hooper, M. ..... (A) 494
The usage of liposomes for directed transport of drugs in leprosy (a preliminary report). Juscenko, A. A., *et al.* ..... (A) 495
The use of "*M. lufu*" for initial screening of antileprosy drugs. Irtuganova, O. A. and Urlyapova, N. G. ..... (A) 494

Electron microscopy, see also Ultrastructure,

An electron microscopic study of the small cutaneous vessels in leprosy. Burchard, G.-D. and Bierther, M. ..... (O) 70
An electron microscopic study on macrophages and lymphocytes in lepromatous and borderline leprosy. Burchard, G.-D. and Bierther, M. ..... (O) 64
Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with *M. leprae*. Fukunishi, Y. ..... (O) 75
Electron microscopic findings of transverse fission of *M. leprae* by freeze-etching methods. Fukunishi, Y. ..... (O) 247
Electron microscopic observations of acid-fast bacilli in nasal mucosal biopsies of lepromatous leprosy patients. Hirata, T. ..... (O) 577
Electron microscopic observations of cell wall and cytoplasmic membrane in murine and human leprosy bacilli. Hirata, T. ..... (O) 433
Untreated borderline-leprosy in the ulnar nerve: light and electron microscopical studies. Vieregge, P., *et al.* ..... (A) 506

ELISA (enzyme-linked immunosorbent assay) tests,

A specific glucose oxidase immunoenzyme stain for *Mycobacterium leprae*. Long, E. G., *et al.* ..... (A) 176
An enzyme immunoassay for studying humoral immunity to tuberculosis. Castets, M., *et al.* ..... (A) 149
Antibodies to *Mycobacterium leprae* detected by enzyme linked (ELISA) and radio (RIA) immunoassay: comparison among families with leprosy patients. Chakinis, C., *et al.* ..... (A) 354
Determination of antibodies in dried blood from earlobes of leprosy patients by enzyme-linked immunosorbent assay—a preliminary report. Wu, Q., *et al.* ..... (O) 565

Determination of inhibitory concentrations of antiviral agents in cell culture by use of an enzyme immunoassay with virus-specific, peroxidase-labeled monoclonal antibodies. van Tiel, F. H., *et al.* ..... (A) 699
Diagnostic test systems based on enzyme-linked immunosorbent assay for detection of anti-*M. leprae* antibodies. Sukhenko, L. T., *et al.* ..... (A) 506
ELISA evaluation of phenolic glycolipid-I (PGI) and whole *M. leprae* with sera collected from leprosy patients during the course of chemotherapy. Douglas J. T., *et al.* ..... (A) 180
Enzyme immunoassay of serum β-2-microglobulin levels in various histological forms of leprosy with special reference to its elevation in type I and type II lepra reactions. Saha, K., *et al.* ..... (A) 505
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* ..... (A) 360

Endocrine,
Endocrine profile and seminal plasma composition in Hansen's disease. Sultan Sheriff, D. ..... (A) 138

Enzyme(s),
Hydrolytic enzymes in macrophages from leprosy patients in presence of *Mycobacterium leprae.* Marolia, J. and Mahadevan, P. R. ..... (A) 508
Serum angiotensin-converting enzyme and delayed hypersensitivity in pulmonary tuberculosis. Grange, J. M., *et al.* ..... (A) 151
Systemic changes in hydrolytic enzyme activities in mice affected with murine leprosy. Aoyagi, T., *et al.* ..... (A) 348

Eosinophilia,
Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Steffen, C. ..... (A) 608

Epidemiology,
An epidemiological study of leprosy among children in a rural area (India). Reddy, B. N. and Bansal, R. D. ..... (A) 148
Epidemiological and clinical aspects of leprosy in Indian Armed Forces. Tiwari, V. D. and Tutakne, M. A. ..... (A) 693
Epidemiology of Leprosy in Relation to Control. Report of a WHO Study Group. WHO Tech. Rpt. Ser. 716. ..... (B) 491
..... (N) 663
Leprosy control in Shandong Province, China, 1955–1983; some epidemiological features. Li, H.-Y., *et al.* ..... (O) 79
Simulation of vaccination and resistance in leprosy using an epidemiometric model. Lechat, M. F., *et al.* ..... (O) 461

Erythema nodosum leprosum (ENL),
[Erythema nodosum leprosum as the first manifestation of leprosy]. Bano Aracil, M., *et al.* ..... (A) 497
Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients. Andreoli, A., *et al.* ..... (O) 211
IgM antibodies against phenolic glycolipid I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* ..... (A) 341
In vitro cyclosporin A restoration of lepromin-induced suppressor activity in patients with erythema nodosum leprosum. Uyemura, K., *et al.* ..... (A) 709
Levamisole in cases of ENL. Arora, S. K., *et al.* ..... (A) 668
Standardized schemes for steroid treatment in ENL and reversal reactions. Imkamp, F. M. J. H. ..... (C) 313
The use of colchicine in the management of type 2 lepra reaction (erythema nodosum leprosum). Stanley, J. N. A., *et al.* ..... (A) 136
Tissue and blood T-lymphocyte subpopulations in erythema nodosum leprosum. Modlin, R. L., *et al.* ..... (A) 338
Use of colchicine in the management of erythema nodosum leprosum (ENL). Sarojini, P. A. and Mshana, R. N. ..... (A) 136

Ethiopia,
Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. Warndorff van Diepen, T. and Mengistu, G. ....(O) 189
Skin-test sensitization by tubercle bacilli and by other mycobacteria in Ethiopian school-children. Eshetu Lema and Stanford, J. ....(A) 362

Experimental leprosy,
An attempt to infect turtles (*Kinosternon leucostomum*) with *Mycobacterium leprae* and *M. lepraemurium*. Rojas-Espinosa, O., *et al.* ....(A) 691
Animal models of leprosy. Meyers, W. M., *et al.* ....(A) 352
Depression of lymphocyte responses to mitogens in mangabeys with disseminated experimental leprosy. Martin, L. N., *et al.* ....(A) 351
Experimental leprosy in nonhuman primates. Martin, L. N., *et al.* ....(A) 351
Experimental leprosy in the armadillo and nude mice: comparative histobacteriology and ultrastructure. Ravisse, P., *et al.* ....(A) 352
Experimental leprosy in the mangabey (*Cercocebus atys atys*): necropsy findings. Baskin, G. B., *et al.* ....(A) 175
Experimental leprosy in the mangabey (*Cercocebus atys*): necropsy findings. Baskin, G. B., *et al.* ....(O) 269
Experimental leprosy in three species of monkeys. Wolf, R. H., *et al.* ....(A) 353
Fatty acids in *M. leprae* purified from the tissues of the animals with experimental leprosy. Pinchuck, L. M., *et al.* ....(A) 508
Manifestation of experimental leprosy in the armadillo. Job, C. K., *et al.* ....(A) 350
Protective properties of some bacterial antigens in experimental leprosy. Zajcev, R. A. and Umerov, G. G. ....(A) 506
Relationship between depressed lymphocyte responsiveness to mitogens and the percentage of OKT8+ lymphocytes in experimental leprosy in the mangabey (*Cercocebus atys*). Martin, L. N., *et al.* ....(A) 169

Eye(s),
1984 Sixth Clayton Memorial Lecture: Leprosy and the Eye. ....(N) 127
A survey of the eye complications of leprosy in South Korea. Courtright, P., *et al.* ....(A) 137
Clofazimine and the eye: preliminary communication. Negrel, A. D., *et al.* ....(A) 330
Histopathological changes in the eye of a mangabey monkey with lepromatous leprosy. Malaty, R., *et al.* ....(A) 176
Intra-ocular tuberculosis associated with a penetrating injury. A case report. Murray, R. I. and Daya, H. ....(A) 697
Leprosy and the eye: a review. ffytche, T. J. and McDougall, A. C. ....(A) 674
Ocular complications in patients with leprosy in Karigiri, South India. Her Hsin Tsai and Suryawanshi, N. ....(A) 674
Ocular involvement from leprosy. Lamba, P. A. and Kumar, D. S. ....(A) 675
The American Peace Corps Survey of the ocular complications of leprosy in South Korea. ffytche, T. J. ....(A) 137
Untreated Hansen's disease of the eye: a clinicopathological report. Robertson, I., *et al.* ....(A) 675

Face,
Ultrastructural aspects of oral and facial lepromatous lesions. Reichart, P. A., *et al.* ....(A) 682

Family(ies),
Analysis of immunologic and genetic factors in multicase families with Hansen's disease in Hawaii. Ching, C. Y., *et al.* ....(A) 163
Antibodies to *Mycobacterium leprae* detected by enzyme-linked (ELISA) and radio (RIA) immunoassay: comparison among families with leprosy patients. Chakinis, C., *et al.* ....(A) 354
Distribution of blood groups and finger patterns in the families with leprosy patients. Baranov, Y. N. and Podoplelov, I. I. ....(A) 498

Fibronectin,
Fibronectin in leprosy lesions: observations using monoclonal antibodies to human fibronectin. Narayanan, R. B., *et al.* ....(A) 339

FLA-ABS,
The sensitivity and specificity of fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with *Mycobacterium leprae*. Ji, B., *et al.* .....(A) 357

Foot,
International Conference on Biomechanics and Clinical Kinesiology of Hand and Foot to be held 16–18 December 1985 (India). Patil, K. M. .....(N) 319
Neuropathic ulcers of the foot. Lang-Stevenson, A. I., *et al.* .....(A) 694

Foot pad(s),
Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of *Mycobacterium leprae* sensitivity/resistance to dapsone. Sathish, M., *et al.* .....(O) 378
Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with *Mycobacterium leprae*. Sebille, A., *et al.* .....(C) 481
Studies on antimicrobial activity against *M. leprae* infections of the mouse foot pad. Gelber, R. H. .....(A) 171

Freeze-etching technique,
Electron microscopic findings of transverse fission of *M. leprae* by freeze-etching methods. Fukunishi, Y. .....(O) 247
Freeze-etching and freeze-fracture structural features of cell envelopes in mycobacteria and leprosy-derived corynebacteria. Benedetti, E. L., *et al.* .....(A) 343

γ-Interferon,
Induction of γ-interferon with various mitogens in mice pretreated with *M. lepraemurium* and the effect of *in vivo* interferon production on the growth of *M. lepraemurium* in mice. Nomaguchi, H., *et al.* .....(A) 706

Genetic(s),
Analysis of immunologic and genetic factors in multicase families with Hansen's disease in Hawaii. Ching, C. Y., *et al.* .....(A) 163
Genetic resistance of mice to persistent infection with *Mycobacterium lepraemurium in vitro*: association with macrophage bactericidal responsiveness to lymphokines and dissociation from production of hydrogen peroxide by macrophages. Sankaran, K., *et al.* .....(A) 353
Segregation and linkage analyses of 72 leprosy pedigrees. Haile, R. W. C., *et al.* .....(A) 356
The athymic rodent as an experimental lepromatous leprosy model (continued): effect of genetic background of nude rats and age of ICR nude mice. Nakamura, K. and Yogi, Y. .....(A) 719

Genome,
Molecular analysis of DNA and construction of genomic libraries of *Mycobacterium leprae*. Clark-Curtiss, J. E., *et al.* .....(A) 344

Germany,
Malta Project completed. .....(N) 318

Granuloma(s),
Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., *et al.* .....(A) 503
Granuloma forming activity of mycolic acid-containing glycolipids in *Nocardia* and related taxa. Yano, I., *et al.* .....(A) 342
In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin-2 and its receptor. Modlin, R. L., *et al.* .....(A) 503
In vitro studies on dermal granulomas of human leprosy—cellular characteristics. Narayanan, R. B., *et al.* .....(O) 39
Plasminogen activator and plasminogen activator inhibitor associated with granulomatous inflammation: a study with murine leprosy. Izaki, S., *et al.* .....(A) 350
Plasminogen activator associated with hypersensitivity granulomas in murine leprosy. Izaki, S., *et al.* .....(A) 709
Quantitation of the granuloma fraction in leprosy skin biopsies by planimetry. Cree, I. A., *et al.* .....(O) 582

Hand(s),
Correction of intrinsic-minus hands associated with reversal of the transverse metacarpal arch. Palande, D. D. ..... (A) 352
Correction of ulnar claw hand by a loop of flexor digitorum superficialis motor for lumbrical replacement. Shah, A. ..... (A) 359
Extensor pollicis brevis deviation graft operation in case of Z-deformity of the thumb in ulner palsy—a preliminary report. Beine, A. ..... (A) 693
Hand function and leprosy. Cottler-Fox, M., *et al.* ..... (A) 359
International Conference on Biomechanics and Clinical Kinesiology of Hand and Foot to be held 16–18 December 1985 (India). Patil, K. M. ..... (N) 319
Primary defects of the hand with intrinsic paralysis. Brandsma, J. W. and Andersen, J. G. ..... (A) 359
Silastic implant of the first dorsal interosseous space. Zacharia, A. G. and Gelber, R. H. ..... (C) 643
Surgical reconstruction of the hand with triple nerve palsy. Sundararaj, G. D. and Mani, K. ..... (A) 513
Weight appreciation in the hand in normal subjects and in patients with leprous neuropathy. Raj, D. V., *et al.* ..... (A) 675

Heiser Program, The,
The Heiser Program for Research in Leprosy 1986. ..... (N) 662

Hepatitis,
A study of leprosy in relation with HBsAg. Jain, A. P., *et al.* ..... (A) 332

Hepatotoxicity,
Hepatitis and multidrug therapy in leprosy with special reference to prothionamide. Kar, H. K., *et al.* ..... (A) 669
Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy. Ji, B., *et al.* ..... (A) 134
Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin. Cartel, J.-L., *et al.* ..... (O) 15

Histoid leprosy,
Immunological status of histoid leprosy. Sehgal, V. N., *et al.* ..... (A) 505

Histology,
Enzyme immunoassay of serum β-2-microglobulin levels in various histological forms of leprosy with special reference to its elevation in type I and type II lepra reactions. Saha, K., *et al.* ..... (A) 505
Histological changes in the apparently normal skin at the periphery of leprosy lesions. Verma, R. N., *et al.* ..... (A) 683
Histology of the Mitsuda reaction of healthy adults with no known contacts with leprosy patients. Petri, V., *et al.* ..... (O) 540
Three histologic fixatives for the demonstration of *Mycobacterium leprae*. Jones, R. L. and McDougall, A. C. ..... (A) 337

Histopathology,
A sequential histopathological study of the lepromin reaction in leprosy patients. Mistry, N. F., *et al.* ..... (A) 680
Histopathological changes in the eye of a mangabey monkey with lepromatous leprosy. Malaty, R., *et al.* ..... (A) 176

History,
A brief history of Hansen's disease. Trautman, J. R. ..... (A) 326
Leprosy. Godal, T. ..... (A) 141
Leprosy. Reality and metaphor in literature. Prioleau, E. ..... (A) 132
Leprosy. The Moslem attitude. Mohammed, H. A. A. ..... (A) 513
Ma'i Ho'oka'awale—the Separating Sickness. Gugelyk, T. and Bloombaum, M. ..... (B) 129
The leper in medieval Islamic society. Dols, M. W. ..... (A) 132
Tuberculosis and leprosy in antiquity; an interpretation. Manchester, K. ..... (N) 326

HLA,
Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan population. Ottenhoff, T. H. M., *et al.* ..... (A) 118

HLA class-II immune response genes and products in leprosy. de Vries, R. R. P., *et al.* ..... (A) 502
HLA-linked control of predisposition to lepromatous leprosy. Xu, K., *et al.* ..... (O) 56
HLA-linked control of predisposition to lepromatous leprosy. van Eden, W., *et al.* ..... (A) 358
Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., *et al.* ..... (A) 678
Tuberculoid leprosy in Thailand is associated with HLA-DR2. Schauf, V., *et al.* ..... (A) 163

Hydrocortisone,
The production of endogenous hydrocortisone and functional activity of lymphocytes in lepromatous leprosy patients. Naumov, V. Z. and Balybin, E. S. ..... (A) 500

Hypersensitivity,
Delayed-type hypersensitivity after immunization with ultrasonicated *Mycobacterium lepraemurium* in C3H and C57BL mice. Lovik, M., *et al.* ..... (A) 351
Hypersensitivity reaction to dapsone: report from Malaysia. Mohammed, K. N. ..... (A) 329
Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. ..... (A) 502
Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. Kirkpatrick, C. H., *et al.* ..... (A) 514
Plasminogen activator associated with hypersensitivity granulomas in murine leprosy. Izaki, S., *et al.* ..... (A) 709

ICRC bacilli,
Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. ..... (A) 502

IgG,
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* ..... (A) 360
Serum immunoglobulins, including IgG subclasses, in Vietnamese leprosy patients. Wright, E. P., *et al.* ..... (O) 225

IgM,
Detection of IgM class on antibodies in armadillos to the phenolic glycolipid-I antigen of *M. leprae*. Truman, R. W., *et al.* ..... (A) 175
IgM antibodies against phenolic glycolipid-I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* ..... (A) 341

ILEP,
ILEP Catalogue on Training, 1985. ..... (N) 490
XV General Assembly of ILEP (Italy). ..... (N) 125

IMMLEP,
Phenolic glycolipid I now available in limited quantities (from IMMLEP Bank, London) ..... (N) 319

Immune complexes,
Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., *et al.* ..... (A) 137
Isolation and analysis of circulating immune complexes in leprosy. Ramanathan, V. D., *et al.* ..... (A) 144
Reduced complement-mediated immune complex solubilization in leprosy patients. Ramanathan, V. D., *et al.* ..... (A) 681
The molecular basis of positive treponemal antibody, antinuclear antibody, and immune complex tests among Hansen's disease patients. Miller, R. A., *et al.* ..... (A) 713

Immune responses,
Adoptive transfer of cell-mediated immunity in *M. leprae*-infected nude mice with *M. leprae*-immunized allogeneic leukocytes depleted of Thy-1.2-bearing cells and Lyt-2.2-bearing cells. Chehl, S. K., *et al.* ..... (A) 720

An enzyme immunoassay for studying humoral immunity to tuberculosis. Castets, M., *et al.* ..... (A) 149
Assessment of sensitin from *M. leprae* by cell-mediated and humoral immune reactions. Dyachina, M. N., *et al.* ..... (A) 502
Cell-mediated immune response in intestinal tuberculosis. Bhargava, D. K., *et al.* ..... (A) 360
Cell-mediated immunity in mice treated with *Mycobacterium leprae* or with macrophages harboring *M. leprae*. Ridel, P. R., *et al.* ..... (A) 340
Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to *Mycobacterium leprae* is associated with defective expression of interleukin-2 receptors and is not reconstituted by interleukin-2. Mohagheghpour, N., *et al.* ..... (A) 680
Effects of *Mycobacterium leprae* vaccinations on cell-mediated immune functions of Lewis rats: specific sensitization vs tolerance. Humphres, R. C. and Winters, M. A. ..... (A) 174
HLA class-II immune response genes and products in leprosy. de Vries, R. R. P., *et al.* ..... (A) 502
Hypothesis: possible idiotypic suppression of cell-mediated immunity in lepromatous leprosy. Ferluga, J., *et al.* ..... (A) 140
Immune response in BALB/c mice following immunization with heat-killed *Mycobacterium lepraemurium*. Graham, L. and Navalkar, R. G. ..... (A) 146
Immunomodulation with corticosteroids and levamisole in leprosy as gauged by *in vivo* lepromin and *in vitro* CMI responses. Kundu, S. K., *et al.* ..... (A) 679
In situ characterization of the cellular immune response in leprosy and leishmaniasis. Modlin, R. L., *et al.* ..... (A) 181
In vivo responses to *Mycobacterium leprae*: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., *et al.* ..... (O) 385
Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. ..... (A) 502
Phenolic glycolipid 1 of *Mycobacterium leprae* causes nonspecific inflammation but has no effect on cell-mediated responses in mice. Brett, S. J., *et al.* ..... (A) 139
Strain variation in murine immune response to the *M. leprae* glycolipid antigen, phenolic glycolipid-I. Tung, K. S. K., *et al.* ..... (A) 721
The relation between cell-mediated immunity and blood groups in leprosy patients. Selezneva, S. P., *et al.* ..... (A) 501
The role of lymphokines in cell-mediated immunity. Cohn, Z. A., *et al.* ..... (A) 725

Immunoglobulin(s),

Association between leprosy and immunoglobulin allotypes: Gm-A2m and Km frequencies in Vietnamese. de Lange, G., *et al.* ..... (A) 355
Immunoglobulins in leprosy. Chiewsilp, P., *et al.* ..... (O) 28
Serum immunoglobulins, including IgG subclasses, in Vietnamese leprosy patients. Wright, E. P., *et al.* ..... (O) 225

Immunology,

A study of the immunological effects of cimetidine in patients with lepromatous leprosy. Brown, A. A., *et al.* ..... (O) 559
An Overview of Immunological Aspects of Human Leprosy. Saha, K. ..... (B) 131
Analysis of immunologic and genetic factors in multicase families with Hansen's disease in Hawaii. Ching, C. Y., *et al.* ..... (A) 163
Hansen's disease as a research model. Kaplan, G. and Cohn, Z. ..... (A) 337
Immunologic assessment of *Mycobacterium leprae* antigens using isoelectric focusing and chromatofocusing separation. Navalkar, R. G. and Ibegbu, C. ..... (A) 173
Immunological status of histoid leprosy. Sehgal, V. N., *et al.* ..... (A) 505
Immunological unresponsiveness in leprosy. Bloom, B. R. and Mehra, V. ..... (A) 678
Immunology of leprosy. Bloom, B. R., *et al.* ..... (A) 335
Immunoregulatory defects in leprosy. Watson, S. R. and Bullock, W. E. ..... (A) 144
Negative observations on immunological side effects of rifampin and dapsone in mice. Nagata, Y., *et al.* ..... (O) 421
Numerical taxonomic and immunologic comparison of 36 leprosy-derived mycobacterial strains and 17 members of the MAIS complex. Skinsnes, O. K., *et al.* ..... (A) 167

The Biology of the Mycobacteria. Vol. 2. Immunological and Environmental Aspects. Ratledge, C. and Stanford, J. ..... (B) 664
The dynamics of immunological parameters in lepromatous leprosy patients as related with various methods of therapy. Kuzina, Z. A. ..... (A) 503

Immunopharmacology,
The immunopharmacology of antileprosy agents. Anderson, R. ..... (A) 133

Immunosuppression,
Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., *et al.* ..... (A) 146
Mechanism of immunosuppression in leprosy—macrophage membrane alterations. Salgame, P. R., *et al.* ..... (A) 144
Phagocytic and bactericidal activities of macrophages from *Mycobacterium leprae*-infected normal and immunosuppressed mice. Vaishnavi, C., *et al.* ..... (O) 233
The influence of immunosuppression and immunodeficiency on infections with leprosy and tuberculosis. Strickland, N. H. ..... (E) 86

Immunotherapy,
Prospects for early diagnosis, immunotherapy, and vaccination for leprosy. Buchanan, T. M. ..... (A) 335
The value of using T and B lymphocytes for assessment of immunotherapy in leprosy patients. Selezneva, S. P. ..... (A) 505

India,
1983–1984 Gandhi Memorial Leprosy Foundation report. ..... (N) 319
1984 ICMR awards. ..... (N) 659
1985 Magsaysay award to Baba Amte. Christian, M. ..... (N) 660
A study of knowledge, attitude and practice of leprosy among doctors of Bhopal, India. Sandhu, H. S., *et al.* ..... (A) 334
An epidemiological study of leprosy among children in a rural area. Reddy, B. N. and Bansal, R. D. ..... (A) 148
Central Leprosy Teaching and Research Institute, Chengalpattu, 1982 Annual Report. ..... (N) 123
Childhood leprosy and social response in South India. Berreman, J. M. ..... (A) 512
Community leaders' involvement in leprosy health education. Kumar, A., *et al.* ..... (A) 493
Dapsone resistance in patients attending Central Leprosy Teaching and Research Institute, Chengalpattu. Bhatia, V. N., *et al.* ..... (A) 327
Deformities in leprosy patients attending urban leprosy clinic at Varanasi. Kaur, P. and Singh, G. ..... (A) 694
Dr. B. R. Chatterjee awarded "Padma Shri." Christian, M. ..... (N) 660
Epidemiological and clinical aspects of leprosy in Indian Armed Forces. Tiwari, V. D. and Tutakne, M. A. ..... (A) 693
Formation of Karnataka State Anti-Leprosy Council. Marshall, J. T. ..... (N) 319
Gynaecomastia in leprosy in three districts of Tamil Nadu. Roy, R. G., *et al.* ..... (A) 334
International Conference on Biomechanics and Clinical Kinesiology of Hand and Foot to be held 16–18 December 1985. Patil, K. M. ..... (N) 319
Involvement of medical students in leprosy through video films and books. Ganapati, R. ..... (N) 123
Multidrug therapy for multibacillary cases in Wardha District, Maharastra. Nilakanta Rao, M. S. and Yellapurkar, M. V. ..... (A) 671
Nilayam report. Jagadisan, T. N. ..... (C) 658
Observations on the intrafamilial clustering of leprosy cases in Trivandrum City. Chidambaram Pillai, S., *et al.* ..... (A) 511
Ocular complications in patients with leprosy in Karigiri, South India. Her Hsin Tsai and Suryawanshi, N. ..... (A) 674
Padma Shri awarded to Dr. H. Srinivasan. ..... (N) 123
Schieffelin Leprosy Research and Training Center, Karigiri, 1985–1986 Course Schedule. ..... (N) 320
Second Erwin Stindl Memorial Oration given. ..... (N) 660
Socio-economic problems of leprosy patients and their relatives in Gujarat State. Kant, V. P. ..... (A) 511

Socio-environmental factors in relation to leprosy at Jaipur. Ojha, K. S., *et al.* .....(A) 512
State leprosy officers and regional directors hold conference. Christian, M. .....(N) 660
The Dr. Raghavendra Row Memorial Teaching Program in Leprosy—1985. Naik, S. S. .....(N) 490
The Macrophage in Leprosy proceedings available. Antia, N. H. .....(N) 660
Training workshop held. Christian, M. .....(N) 660
Treatment of leprosy in rural India as seen on a medical student elective. Riley, D. N. .....(A) 326
Video tapes and slides on leprosy now available. .....(N) 124
XIII Biennial Conference of the Indian Association of Leprologists held in Bombay. Pandya, S. S. .....(N) 123

Injection(s),
Anti-*Mycobacterium leprae* antibodies induced by lepromin injection as demonstrated by indirect immunofluorescence. Gonzalez-Abreu, E., *et al.* .....(A) 336

Inoculation,
Cutaneous inoculation tuberculosis secondary to "jailhouse tatooing." Horney, D. A., *et al.* .....(A) 514
Influence of dose and route of inoculation and of mouse strain on the production of interleukin 2 in mice infected with *Mycobacterium lepraemurium*. Hoffenbach, A., *et al.* .....(A) 349
Influence of dose and route of *Mycobacterium lepraemurium* inoculation on the production of interleukin-1 and interleukin-2 in C57BL/6 mice. Hoffenbach, A., *et al.* .....(A) 679
Inoculation leprosy subsequent to dog bite. A case report. Gupta, C. M., *et al.* .....(A) 499

Interleukin(s),
Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to *Mycobacterium leprae* is associated with defective expression of interleukin-2 receptors and is not reconstituted by interleukin-2. Mohagheghpour, N., *et al.* .....(A) 680
Human recombinant interleukin-2 is mitogenic to human lymphocytes. Mookerjee, B. K. and Pauly, J. L. .....(A) 697
In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin-2 and its receptor. Modlin, R. L., *et al.* .....(A) 503
In vivo responses to *Mycobacterium leprae*: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., *et al.* .....(O) 385
Influence of dose and route of inoculation and of mouse strain on the production of interleukin 2 in mice infected with *Mycobacterium lepraemurium*. Hoffenbach, A., *et al.* .....(A) 349
Influence of dose and route of *Mycobacterium lepraemurium* inoculation on the production of interleukin-1 and interleukin-2 in C57BL/6 mice. Hoffenbach, A., *et al.* .....(A) 679
Inhibition of interleukin-2 production by adherent cell factors from lepromatous leprosy patients. Nath, I., *et al.* .....(A) 339
Interleukin-2-induced T-cell response to *M. leprae* in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small *M. leprae*-reactive T-cell pool? Shankar, P., *et al.* .....(C) 649
Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to *Mycobacterium leprae*. Haregewoin, A., *et al.* .....(A) 141
Serum soluble interleukin-2 receptors in leprosy patients. Tung, K. S. K., *et al.* .....(A) 719

International Journal of Leprosy (IJL),
Former IJL Editor returns to China. .....(N) 659
IJL instructions to authors. .....(N) 498
Reviewers for Volume 53. .....(—) 729
Statement of financial condition. .....(—) 731
Statement of ownership, management, and circulation. .....(—) 735
The 1984 Journal—a continuing perspective. Hastings, R. C. .....(E) 101

International Leprosy Association (ILA),
Officers and councillors. .....(—) 730

Iron,
Diphenoloxidase of *Mycobacterium leprae* is not iron-dependent. Prabhakaran, K. and Harris, E. B. ..... (A) 508

Isoenzyme(s),
Isoenzyme patterns of mycobacteria. I. Factors influencing LDH isoenzymes of mycobacteria. Sharma, V. D., *et al.* ..... (A) 688
Isoenzymes of mycobacteria. II. Relevance of LDH zymograms in taxonomy and identification. Katoch, V. M., *et al.* ..... (A) 686
LDH isoenzymes subunit ratio in leprosy and the effect of clofazimine treatment on LDH isoenzymes subunit. Bulakh, P. M., *et al.* ..... (A) 673

Italy,
XV General Assembly of ILEP. ..... (N) 125

Kellersberger Memorial Lecture, 1984,
Chemotherapy of leprosy—a tool for leprosy control. Levy, L. ..... (A) 669

Kidney(s),
Associated hepatic and renal damages in lepromatous leprosy patients. Loginev, V. K. and Vishnevetsky, F. E. ..... (A) 500
Clinico-pathological study of nephrotic syndrome in leprosy. Jain, A. P., *et al.* ..... (A) 499
Phagocytosis of *Mycobacterium leprae* and *M. avium* by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. ..... (A) 340
Renal functional status in leprosy. Kanwar, A. J., *et al.* ..... (A) 332
Renal lesions and other major findings in necropsies of 133 patients with leprosy. Date, A., *et al.* ..... (O) 455
Reversible acute renal failure due to monthly administration of rifampicin in a leprosy patient. Kar, H. K. and Roy, R. G. ..... (A) 495
Successful kidney transplantation in leprosy and transitory recurrence of the disease. Tervel, J. L., *et al.* ..... (O) 410

Kinetics,
Effect of *Mycobacterium bovis* (BCG) infection on the kinetics of the mononuclear cell response within the lung. Collins, F. M. and Auclair, L. K. ..... (A) 149
Norethisterone and ethinyl estradiol kinetics during dapsone therapy, Joshi, J. V., *et al.* ..... (A) 328

Korea,
A survey of the eye complications of leprosy in South Korea. Courtright, P., *et al.* ..... (A) 137
Posthumous award for Erwin Stindl. ..... (N) 659
The American Peace Corps Survey of the ocular complications of leprosy in South Korea. ffytche, T. J. ..... (A) 137

Lactic acid,
The assessment of activity of leprosy process and effectiveness of antileprosy therapy by excess lactate in blood. Ryzhova, N. Y. ..... (A) 501

Lamprene® (see Clofazimine),

Langerhans' cells,
Normal numbers of T6 positive epidermal Langerhans' cells across the leprosy spectrum. Narayanan, R. B., *et al.* ..... (A) 143
Ultrastructural study of epidermal Langerhans' cells in leprosy. Mathur, N., *et al.* ..... (A) 503

Leishmaniasis,
Differential diagnosis between leprosy and post-kala-azar dermal leishmaniasis. Ekambaram, V., *et al.* ..... (A) 331
In situ characterization of the cellular immune response in leprosy and leishmaniasis. Modlin, R. L., *et al.* ..... (A) 181
Leprosy and leishmaniasis. Berger, T. G. ..... (A) 148
Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Weldon, J. S., *et al.* ..... (A) 153
Observations on local heat treatment for cutaneous leishmaniasis. Neva, F. A., *et al.* ..... (A) 151

Specific suppression of responses to *Leishmania tropica* by a cloned T-cell line. Liew, F. Y. ..... (A) 362
Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes. Reed, S. G., *et al.* ..... (A) 152

Lepromatous leprosy,
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability. Gelber, R. H., *et al.* ..... (A) 349
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability and optimal bactericidal therapy. Gelber, R. H., *et al.* ..... (A) 172
A single skin lesion—an unusual presentation of lepromatous leprosy. Yoder, L. J., *et al.* ..... (O) 554
A study of the immunological effects of cimetidine in patients with lepromatous leprosy. Brown, A. A., *et al.* ..... (O) 559
Adrenal cortical function and reserve in lepromatous leprosy. Durairaj, V., *et al.* ..... (A) 498
An electron microscopic study on macrophages and lymphocytes in lepromatous and borderline leprosy. Burchard, G.-D. and Bierther, M. ..... (O) 64
An unusual case of untreated polar lepromatous leprosy associated with rare *M. leprae.* Gelber, R. H. ..... (C) 311
Anti-*Mycobacterium leprae* antibodies in urine from lepromatous patients examined by crossed immunoelectrophoresis and radioimmunoassay. Olcén, P., *et al.* ..... (A) 144
Armadillo exposure among Mexican-born patients with lepromatous leprosy. Thomas, D. A., *et al.* ..... (A) 724
Associated hepatic and renal damages in lepromatous leprosy patients. Loginov, V. K. and Vishnevetsky, F. E. ..... (A) 500
Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan population. Ottenhoff, T. H. M., *et al.* ..... (A) 148
Cardiac dysautonomia in lepromatous leprosy. Kale, H. D., *et al.* ..... (A) 332
Cutaneous coccidioidomycosis simulating lepromatous leprosy. Hobbs, E. R. and Hempstead, R. W. ..... (A) 332
Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to *Mycobacterium leprae* is associated with defective expression of interleukin-2 receptors and is not reconstituted by interleukin-2. Mohagheghpour, N., *et al.* ..... (A) 680
Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., *et al.* ..... (A) 504
Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., *et al.* ..... (A) 137
Double-stranded DNA inhibits cardiolipin-binding activity in lepromatous leprosy patients' sera. Furukawa, F., *et al.* ..... (C) 647
Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., *et al.* ..... (C) 113
Electron microscopic observations of acid-fast bacilli in nasal mucosal biopsies of lepromatous leprosy patients. Hirata, T. ..... (O) 577
Evidence for the presence of *M. leprae* reactive T lymphocytes in patients with lepromatous leprosy. Nath, I., *et al.* ..... (A) 340
Giant reactions to tuberculin in lepromatous leprosy patients. Waters, M. F. R. and Stanford, J. L. ..... (O) 546
Histopathological changes in the eye of a mangabey monkey with lepromatous leprosy. Malaty, R., *et al.* ..... (A) 176
HLA-linked control of predisposition to lepromatous leprosy. Xu, K., *et al.* ..... (O) 56
HLA-linked control of predisposition to lepromatous leprosy. von Eden, W., *et al.* ..... (A) 358
Hypothesis: possible idiotypic suppression of cell-mediated immunity in lepromatous leprosy. Ferluga, J., *et al.* ..... (A) 140
Inhibition of antibody-dependent, cell-mediated cytotoxicity by serum from lepromatous leprosy patients. de la Barrera, S. S., *et al.* ..... (O) 218

Inhibition of interleukin-2 production by adherent cell factors from lepromatous leprosy patients. Nath, I., *et al.* ..... (A) 339
Interleukin-2-induced T-cell response to *M. leprae* in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small *M. leprae*-reactive T-cell pool? Shankar, P., *et al.* ..... (C) 649
Isolation of phenolic glycolipid-I from human lepromatous nodules. Vemuri, N., *et al.* ..... (C) 487
Lepromatous leprosy complicated with systemic lupus erythematosus. Ohkawa, S., *et al.* ..... (A) 675
Mechanism of unresponsiveness in lepromatous leprosy. Mehra, V., *et al.* ..... (A) 180
Phosphatidyl inosito mannosides in lepromatous leprosy nodules. Khande, L., *et al.* ..... (A) 142
Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., *et al.* ..... (A) 678
Reduced expression of C3b receptors on erythrocytes from patients with lepromatous leprosy. Tausk, F., *et al.* ..... (A) 184
Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. Warndorff van Diepen, T. and Mengistu, C. ..... (O) 189
Relationship between the loss of maxillary anterior alveolar bone and the duration of untreated lepromatous leprosy in Malaysia. Seang Hoo Nah, *et al.* ..... (A) 501
Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to *Mycobacterium leprae*. Haregewoin, A., *et al.* ..... (A) 141
Thalidomide enhances defective monocyte function in lepromatous leprosy. Nielsen, H. and Bennike, T. ..... (A) 135
The athymic rodent as an experimental lepromatous leprosy model (continued): effect of genetic background of nude rats and age of ICR nude mice. Nakamura, K. and Yogi, Y. ..... (A) 719
The changes in upper respiratory organs in the discharged patients with "burnt out" lepromatous leprosy. Kaipbergenov, U. K. ..... (A) 499
The dynamics of immunological parameters in lepromatous leprosy patients as related with various methods of therapy. Kuzina, Z. A. ..... (A) 503
The *in vitro* dynamics of cyclic adenosine monophosphate levels in lymphocytes from lepromatous leprosy patients (the first report). Balybin, E. S. ..... (A) 501
The production of endogenous hydrocortisone and functional activity of lymphocytes in lepromatous leprosy patients. Naumov, V. Z. and Balybin, E. S. ..... (A) 500
The spectrum of *in vitro* T-cell responsiveness in lepromatous leprosy. Kaplan, G., *et al.* ..... (A) 708
The study of antibodies to DNA in the patients with complicated lepromatous leprosy. Kuzina, Z. A. ..... (A) 499
Ultrastructural aspects of oral and facial lepromatous lesions. Reichart, P. A., *et al.* ..... (A) 682
Use of human skin to demonstrate antinuclear antibodies in lepromatous leprosy patients. Lamas-Robles, C., *et al.* ..... (O) 373

Lepromin,

A sequential histopathological study of the lepromin reaction in leprosy patients. Mistry, N. F., *et al.* ..... (A) 680
Anti-*Mycobacterium leprae* antibodies induced by lepromin injection as demonstrated by indirect immunofluorescence. Gonzalez-Abreu, E., *et al.* ..... (A) 336
Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., *et al.* ..... (C) 113
Evaluation of standard Dharmendra lepromin. Sengupta, U., *et al.* ..... (A) 501
Immunomodulation with corticosteroids and levamisole in leprosy as gauged by *in vivo* lepromin and *in vitro* CMI responses. Kundu, S. K., *et al.* ..... (A) 679
In vitro cyclosporin A restoration of lepromin-induced suppressor activity in patients with erythema nodosum leprosum. Uyemura, K., *et al.* ..... (A) 709
Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., *et al.* ..... (A) 707
The cell interaction in lepromin test. Ibraimov, M. ..... (A) 502

Lesions,
A single skin lesion—an unusual presentation of lepromatous leprosy. Yoder, L. J., *et al.* ..... (O) 554
Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., *et al.* ..... (A) 504
Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with *M. leprae*. Fukunishi, Y. ..... (O) 75
Fibronectin in leprosy lesions: observations using monoclonal antibodies to human fibronectin. Narayanan, R. B., *et al.* ..... (A) 339
First lesion in experimental armadillo leprosy. Job, C. K., *et al.* ..... (A) 690
Histological changes in the apparently normal skin at the periphery of leprosy lesions. Verma, R. N., *et al.* ..... (A) 683
In vivo responses to *Mycobacterium leprae*: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., *et al.* ..... (O) 385
Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., *et al.* ..... (A) 707
Lysozyme as a measure of cellular dynamics in the lesions of leprosy. Ridley, M. J., *et al.* ..... (A) 341
Persistence of Langhans' giant cells in rapidly downgrading leprosy lesions. Lyons, N. F., *et al.* ..... (C) 114
Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., *et al.* ..... (A) 678
Renal lesions and other major findings in necropsies of 133 patients with leprosy. Date, A., *et al.* ..... (O) 455
Ultrastructural aspects of oral and facial lepromatous lesions. Reichart, P. A., *et al.* ..... (A) 682

Leukocytes,
Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes *in vitro*. Anderson, R. ..... (A) 327
The effect of *Mycobacterium leprae* on PHA- and PPD-induced inhibition of leukocyte migration in leprosy patients. Dharma Rao, T., *et al.* ..... (A) 679

Levamisole,
A comparative evaluation of levamisole in leprosy. Sharma, L., *et al.* ..... (A) 672
Effect of levamisole on bacterial index in BL and LL leprosy. Bera, D. K. and Sen, P. C. ..... (O) 198
Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., *et al.* ..... (C) 113
Immunomodulation with corticosteroids and levamisole in leprosy as gauged by *in vivo* lepromin and *in vitro* CMI responses. Kundu, S. K., *et al.* ..... (A) 679
Immunostimulatory effect of levamisole in borderline leprosy cases. Arora, S. K., *et al.* ..... (A) 673
Influence of levamisole on lymphocytes and *M. leprae* in mice. Ganguly, N. K., *et al.* ..... (A) 689
Levamisole in cases of ENL. Arora, S. K., et al. ..... (A) 668

Lipid(s),
Characterization of *Mycobacterium leprae* by lipid analysis. Minnikin, D. E., *et al.* ..... (A) 345
Lipids as taxonomic markers for bacteria derived from leprosy infections. Asselineau, C., *et al.* ..... (A) 342
Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of *Mycobacterium tuberculosis*. Goren, M. B., *et al.* ..... (A) 150
The free lipids of *Mycobacterium leprae* harvested from experimentally infected nine-banded armadillos. Minnikin, D. E., *et al.* ..... (A) 686

Liposome,
The usage of liposomes for directed transport of drugs in leprosy (a preliminary report). Juscenko, A. A., *et al.* ..... (A) 495
Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes. Reed, S. G., *et al.* ..... (A) 152

Lymphocyte(s),
An electron microscopic study on macrophages and lymphocytes in lepromatous and borderline leprosy. Burchard, G.-D. and Bierther, M. ....(O) 64
Depression of lymphocyte responses to mitogens in mangabeys with disseminated experimental leprosy. Martin, L. N., *et al.* ....(A) 351
Evidence for the presence of *M. leprae* reactive T lymphocytes in patients with lepromatous leprosy. Nath, I., *et al.* ....(A) 340
Human recombinant interleukin-2 is mitogenic to human lymphocytes. Mookerjee, B. K. and Pauly, J. L. ....(A) 697
Immunity to leprosy. 1. The proliferative response of murine T lymphocytes to *Mycobacterium leprae.* Douglas-Jones, A. G. and Watson, J. D. ....(O) 412
Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., *et al.* ....(A) 146
In vitro lymphocyte stimulating ability of cell components of *Mycobacterium leprae.* Khandke, L., *et al.* ....(A) 337
Influence of levamisole on lymphocytes and *M. leprae* in mice. Ganguly, N. K., *et al.* ....(A) 689
Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., *et al.* ....(A) 707
Lymphocyte suppression in leprosy induced by unique *M. leprae* glycolipid. Mehra, V., *et al.* ....(A) 680
Relationship between depressed lymphocyte responsiveness to mitogens and the percentage of OKT8+ lymphocytes in experimental leprosy in the mangabey (*Cercocebus atys*). Martin, L. N., *et al.* ....(A) 169
Thalidomide induces imbalances in T lymphocyte subpopulations in circulating blood of healthy males. Gad, S. M., *et al.* ....(A) 502
The *in vitro* dynamics of cyclic adenosine monophosphate levels in lymphocytes from lepromatous leprosy patients (the first report). Balybin, E. S. ....(A) 501
The production of endogenous hydrocortisone and functional activity of lymphocytes in lepromatous leprosy patients. Naumov, V. Z. and Balybin, E. S. ....(A) 500
The value of using T and B lymphocytes for assessment of immunotherapy in leprosy patients. Selezneva, S. P. ....(A) 505
Tissue and blood T-lymphocyte subpopulations in erythema nodosum leprosum. Modlin, R. L., *et al.* ....(A) 338

Lysozyme,
Chemical characterization of the dapsone binding site of lysozyme. Datta, G., *et al.* ....(O) 428
Lysozyme as a measure of cellular dynamics in the lesions of leprosy. Ridley, M. J., *et al.* ....(A) 341
Muramidase (lysozyme) findings in sural and radial nerve biopsies in leprosy patients after varying periods of treatment. Haimanot, R. T., *et al.* ....(O) 238

Macrophage(s),
Alternate radiolabeled markers for detecting metabolic activity of *Mycobacterium leprae* residing in murine macrophages. Prasad, H. K. and Hastings, R. C. ....(A) 688
An electron microscopic study on macrophages and lymphocytes in lepromatous and borderline leprosy. Burchard, G.-D. and Bierther, M. ....(O) 64
An *in vitro* test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of *Mycobacterium leprae.* Nair, I. and Mahadevan, P. R. ....(A) 671
Cell-mediated immunity in mice treated with *Mycobacterium leprae* or with macrophages harboring *M. leprae.* Ridel, P. R., *et al.* ....(A) 340
Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of *Mycobacterium leprae* sensitivity/resistance to dapsone. Sathish, M., *et al.* ....(O) 378
Exchange of material between the extracellular medium and macrophage phagosomes containing different species of bacteria including mycobacteria. de Chastellier, C. and Lang, T. ....(A) 336
Functionality of secondary lysosomes in murine resident peritoneal macrophages. Goren, M. B., *et al.* ....(A) 726

Genetic resistance of mice to persistent infection with *Mycobacterium lepraemurium in vitro*: association with macrophage bactericidal responsiveness to lymphokines and dissociation from production of hydrogen peroxide by macrophages. Sankaran, K., *et al.* ....(A) 353
Hydrolytic enzymes in macrophages from leprosy patients in presence of *Mycobacterium leprae*. Marolia, J. and Mahadevan, P. R. ....(A) 508
Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., *et al.* ....(A) 146
In vitro drug screening system using membrane alteration in macrophages by *Mycobacterium leprae*. Mankar, M. V., *et al.* ....(A) 507
Macrophage activation in mice infected with *Mycobacterium lepraemurium*. Brett, S. J. ....(A) 349
Macrophage activity in *Mycobacterium leprae* infection. Sharp, A. K. and Banerjee, D. K. ....(A) 341
Macrophage interaction with mycobacteria including *M. leprae*. Ryter, A., *et al.* ....(A) 346
Mechanism of immunosuppression in leprosy—macrophage membrane alterations. Salgame, P. R., *et al.* ....(A) 144
Morphology and cytochemistry of cultivated monocyte-macrophage in leprosy. Yushin, M. Y. ....(A) 506
Phagocytic and bactericidal activities of macrophages from *Mycobacterium leprae*-infected normal and immunosuppressed mice. Vaishnavi, C., *et al.* ....(D) 233
Susceptibility of *Mycobacterium leprae* to bactericidal activity of mouse peritoneal macrophages and to hydrogen peroxide. Sharp, A. K., *et al.* ....(A) 342
"The Macrophage in Leprosy" proceedings available. Antia, N. H. ....(N) 660

Malaysia,
Hypersensitivity reaction to dapsone: report from Malaysia. Mohammed, K. N. ....(A) 329
Leprosy in Malaysia; Past, Present and Future. Joshua-Raghavar, A. ....(B) 323
Relationship between the loss of maxillary anterior alveolar bone and the duration of untreated lepromatous leprosy in Malaysia. Seang Hoo Nah, *et al.* ....(A) 501

Metabolism,
Alternate radiolabeled markers for detecting metabolic activity of *Mycobacterium leprae* residing in murine macrophages. Prasad, H. K. and Hastings, R. C. ....(A) 688
An *in vitro* test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of *Mycobacterium leprae*. Nair, I. and Mahadevan, P. R. ....(A) 671
Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine. Niwa, Y., *et al.* ....(A) 330

Mexico,
Fifth World Congress of Tropical Dermatology. Browne, S. G. ....(N) 125

Mice,
A dual effect of tilorone on multiplication of *Mycobacterium leprae* in mice. Levy, L. and Aizer, F. ....(A) 350
An experimental study of the antileprosy activity of a series of thioamides in the mouse. Shepard, C. C., *et al.* ....(O) 587
Antibody response to phenolic glycolipid I in inbred mice immunized with *Mycobacterium leprae*. Teuscher, C., *et al.* ....(A) 683
Cell-mediated immunity in mice treated with *Mycobacterium leprae* or with macrophages harboring *M. leprae*. Ridel, P. R., *et al.* ....(A) 340
Delayed-type hypersensitivity after immunization with ultrasonicated *Mycobacterium lepraemurium* in C3H and C57BL mice. Lovik, M., *et al.* ....(A) 351
Effect of thalidomide on induction of antibody synthesis in mice to a T-independent antigen. Shannon, E. J., *et al.* ....(A) 165
Efficacy of *Mycobacterium bovis* BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Orme, I. M. and Collins, F. M. ....(A) 697
Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with *Mycobacterium leprae*. Sebille, A., *et al.* ....(C) 481
Experimental mycobacterial infections of CBA/N mice. Levy, L., *et al.* ....(A) 690
Genetic resistance of mice to persistent infection with *Mycobacterium lepraemurium in*

vitro: association with macrophage bactericidal responsiveness to lymphokines and dissociation from production of hydrogen peroxide by macrophages. Sankaran, K., *et al.* ..... (A) 353
H-2-linked genes which modify resistance of C57BL/10 mice to subcutaneous infection with *Mycobacterium lepraemurium*. Curtis, J., *et al.* ..... (A) 146
Immune response in BALB/c mice following immunization with heat-killed *Mycobacterium lepraemurium*. Graham, L. and Navalkar, R. G. ..... (A) 146
Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. ..... (A) 502
Induction of gamma-interferon with various mitogens in mice pretreated with *M. lepraemurium* and the effect of *in vivo* interferon production on the growth of *M. lepraemurium* in mice. Nomaguchi, H., *et al.* ..... (A) 706
Influence of dose and route of inoculation and of mouse strain on the production of interleukin 2 in mice infected with *Mycobacterium lepraemurium*. Hoffenbach, A., *et al.* ..... (A) 349
Influence of dose and route of *Mycobacterium lepraemurium* inoculation on the production of interleukin-1 and interleukin-2 in C57BL/6 mice. Hoffenbach, A., *et al.* ..... (A) 679
Influence of levamisole on lymphocytes and *M. leprae* in mice. Ganguly, N. K., *et al.* ..... (A) 689
Macrophage activation in mice infected with *Mycobacterium lepraemurium*. Brett, S. J. ..... (A) 349
Negative observations on immunological side effects of rifampin and dapsone in mice. Nagata, Y., *et al.* ..... (O) 421
Phagocytic and bactericidal activities of macrophages from *Mycobacterium leprae*-infected normal and immunosuppressed mice. Vaishnavi, C., *et al.* ..... (O) 233
Phenolic glycolipid 1 of *Mycobacterium leprae* causes nonspecific inflammation but has no effect on cell-mediated responses in mice. Brett, S. J., *et al.* ..... (A) 139
Prophylactic effect in mice of BCG vaccination against nontuberculous mycobacterial infections. Orme, I. and Collins, F. M. ..... (A) 698
Serum enzymatic changes following infection of mice with *Mycobacterium lepraemurium*. Rojas-Espinosa, O., *et al.* ..... (O) 258
Strain variation of lymphokine production and specific antibody secretion in mice infected with *Mycobacterium lepraemurium*. Hoffenbach, A., *et al.* ..... (A) 510
Susceptibility of *Mycobacterium leprae* to bactericidal activity of mouse peritoneal macrophages and to hydrogen peroxide. Sharp, A. K., *et al.* ..... (A) 342
Systemic changes in hydrolytic enzyme activities in mice affected with murine leprosy. Aoyagi, T., *et al.* ..... (A) 348
T-cell responsiveness in *Mycobacterium lepraemurium* infections in a "resistant" (CBA) and a "susceptible" (BALB/c) mouse strain. Brett, S. J. ..... (A) 349
The bactericidal activity of various aminoglycoside antibiotics against *Mycobacterium leprae* in mice. Gelber, R. H., *et al.* ..... (A) 328
Trophic changes and extensive dissemination in normal mice with human *Mycobacterium leprae*. Vaishnavi, C., *et al.* ..... (A) 510
Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Mackett, M., *et al.* ..... (A) 353

Mice, nude,
Adoptive transfer of cell-mediated immunity in *M. leprae*-infected nude mice with *M. leprae*-immunized allogeneic leukocytes depleted of Thy-1.2-bearing cells and Lyt-2.2-bearing cells. Chehl, S. K., *et al.* ..... (A) 720
An anomalous response of *M. leprae* to dapsone chemotherapy in nude mice. Chehl, S. K. and Hastings, R. C. ..... (A) 167
Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with *M. leprae*. Fukunishi, Y. ..... (O) 75
Experimental infection with *Mycobacterium kansasii* in athymic nude mice. Kubin, M., *et al.* ..... (A) 362
Experimental leprosy in the armadillo and nude mice: comparative histobacteriology and ultrastructure. Ravisse, P., *et al.* ..... (A) 352
Mycobacterium lepraemurium infection of nude athymic (nu/nu) mice. Lefford, M. J. ..... (A) 690

The athymic rodent as an experimental lepromatous leprosy model (continued): effect of genetic background of nude rats and age of ICR nude mice. Nakamura, K. and Yogi, Y. ..... (A) 719

Microscopy,

Microscopic findings of delayed reactions elicited by the skin test reagent leprosin A derived from *M. leprae*. Samuel, N. M., *et al.* ..... (O) 395

Untreated borderline-leprosy in the ulnar nerve: light and electron microscopical studies. Vieregge, P., *et al.* ..... (A) 506

Mitsuda reaction,

An *in situ* immunohistological study of Mitsuda reactions. Dugan, E., *et al.* ..... (O) 404

Histology of the Mitsuda reaction of healthy adults with no known contacts with leprosy patients. Petri, V., *et al.* ..... (O) 540

Phenolic glycolipid-I: an immunogen for a Mitsuda response. Job, C. K., *et al.* ..... (A) 179

Monkey(s),

Animal models of leprosy. Meyers, W. M., *et al.* ..... (A) 352

Depression of lymphocyte responses to mitogens in mangabeys with disseminated experimental leprosy. Martin, L. N., *et al.* ..... (A) 351

Experimental leprosy in nonhuman primates. Martin, L. N., *et al.* ..... (A) 351

Experimental leprosy in the mangabey (*Cercocebus atys atys*): necropsy findings. Baskin, G. B., *et al.* ..... (A) 175

Experimental leprosy in the mangabey (*Cercocebus atys*): necropsy findings. Baskin, G. B., *et al.* ..... (O) 269

Experimental leprosy in three species of monkeys. Wolf, R. H., *et al.* ..... (A) 353

Histopathological changes in the eye of a mangabey monkey with lepromatous leprosy. Malaty, R., *et al.* ..... (A) 176

Leprosy in a mangabey monkey—naturally acquired infection. Meyers, W. M., *et al.* ..... (O) 1

Leprosy in sub-human primates: potential risk for transfer of *M. leprae* to humans. Hagstad, H. V. ..... (A) 147

Relationship between depressed lymphocyte responsiveness to mitogens and the percentage of OKT8+ lymphocytes in experimental leprosy in the mangabey (*Cercocebus atys*). Martin, L. N., *et al.* ..... (A) 169

Monoclonal antibodies,

A monoclonal antibody against *Mycobacterium lepraemurium* which recognizes a cross-reacting mycobacterial antigen. Bach, M.-A. and Hoffenbach, A. ..... (A) 138

Affinity purification of a 65,000 dalton protein of *Mycobacterium gordonae* using a monoclonal antibody which recognizes a shared epitope on the homologous protein of *Mycobacterium leprae*. Gillis, T. P. ..... (A) 718

Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthews, R. C., *et al.* ..... (A) 503

Characterization of a competitive-antibody-binding assay with a radiolabeled monoclonal antibody specific for *Mycobacterium leprae*. Gillis, T. P., *et al.* ..... (A) 178

Determination of inhibitory concentrations of antiviral agents in cell culture by use of an enzyme immunoassay with virus-specific, peroxidase-labeled monoclonal antibodies. van Tiel, F. H., *et al.* ..... (A) 699

Fibronectin in leprosy lesions: observations using monoclonal antibodies to human fibronectin. Narayanan, R. B., *et al.* ..... (A) 339

Human monoclonal antibodies against *Mycobacterium leprae*. Atlaw, T., *et al.* ..... (A) 677

In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin-2 and its receptor. Modlin, R. L., *et al.* ..... (A) 503

Monoclonal antibodies and recombinant DNA technology: present and future uses in leprosy and tuberculosis. Seckl, M. J. ..... (E) 618

Monoclonal antibodies to a 28,000 mol. wt protein antigen of *Mycobacterium leprae*. Young, D. B., *et al.* ..... (A) 684

Production and characterization of monoclonal antibodies to *Mycobacterium tuberculosis*. Kolk, A. H. J., *et al.* ..... (A) 338

Production of human monoclonal antibodies to *Mycobacterium leprae*. Mohagheghpour, N., *et al.* ..... (A) 178

Results of a World Health Organization-sponsored workshop on monoclonal antibodies to *Mycobacterium leprae*. ....(A) 682
Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Waldor, M. K., *et al.* ....(A) 363
Serological survey of leprosy and control subjects by a monoclonal antibody-based immunoassay. Sinha, S., *et al.* ....(O) 33
Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. ....(A) 715
Serological survey of leprosy and control subjects by a monoclonal antibody-based immunoassay. Sinha, S., *et al.* ....(O) 33
Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. ....(A) 715

Mononuclear cells,
Activation of human monocytes in leprosy. Ohkawa, S. ....(A) 681
Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., *et al.* ....(A) 503
Effect of *Mycobacterium bovis* (BCG) infection on the kinetics of the mononuclear cell response within the lung. Collins, F. M. and Auclair, L. K. ....(A) 149

Morphology,
Correlation viability/morphology in *Mycobacterium leprae*. Silva, M. T., *et al.* ....(A) 347
Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Schroder, J. M. and Matthiesen, T. ....(A) 672
Morphological changes induced by β-lactum antibiotics in *Mycobacterium avium-intracellulare* complex. Mizuguchi, Y., *et al.* ....(A) 696
Morphology and cytochemistry of cultivated monocyte-macrophage in leprosy. Yushin, M. Y. ....(A) 506

Multidrug therapy (MDT),
Hepatitis and multidrug therapy in leprosy with special reference to prothionamide. Kar, H. K., *et al.* ....(A) 669
Leprosy treatment in Nepal with multidrug regimens. Birch, M. C. ....(A) 133
Managerial implications of multidrug therapy. Askew, A. D. ....(A) 668
Multidrug regime in management of leprosy. Paradkar, S., *et al.* ....(A) 496
Multidrug therapy for leprosy in Trinidad and Tobago: a preliminary report. Keeler, R. F. ....(A) 329
Multidrug therapy for multibacillary cases in Wardha District, Maharastra, India. Nilakanta Rao, M. S. and Yellapurkar, M. V. ....(A) 671
Multidrug treatment of leprosy—practical application in Nepal. Samuel, N. M., *et al.* ....(A) 136
WHO meeting on multidrug therapy. ....(N) 126

Murine,
Alternate radiolabeled markers for detecting metabolic activity of *Mycobacterium leprae* residing in murine macrophages. Prasad, H. K. and Hastings, R. C. ....(A) 688
Antimycobacteria antibodies in *M. lepraemurium* murine infection. Bach, M. A. and Hoffenbach, A. ....(A) 348
Electron microscopic observations of cell wall and cytoplasmic membrane in murine and human leprosy bacilli. Hirata, T. ....(O) 433
Immunity to leprosy. 1. The proliferative response of murine T lymphocytes to *Mycobacterium leprae*. Douglas-Jones, A. G. and Watson, J. D. ....(O) 412
Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., *et al.* ....(A) 146
Plasminogen activator and plasminogen activator inhibitor associated with granulomatous inflammation: a study with murine leprosy. Izaki, S., *et al.* ....(A) 350
Plasminogen activator associated with hypersensitivity granulomas in murine leprosy. Izaki, S., *et al.* ....(A) 709
Systemic changes in hydrolytic enzyme activities in mice affected with murine leprosy. Aoyagi, T., *et al.* ....(A) 348

Mycobacteria,
Activity of the combination of fludalanine and cycloserine against mycobacteria *in vitro.* Dickinson, J. M. and Mitchison, D. A. ..... (A) 695
Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., *et al.* ..... (A) 503
Concentration-dependent effects of mycobacteria on the stimulation of murine T-cell clones. Kingston, A. E. and Colston, M. J. ..... (A) 337
Cultivable mycobacteria isolated from organs of armadillos uninoculated and inoculated with *Mycobacterium leprae.* Portaels, F., *et al.* ..... (A) 687
Cytochemical characterization of mycobacterial outer surfaces. Picard, B., *et al.* ..... (A) 346
DNA relatedness among *Mycobacterium leprae,* leprosy-derived bacteria, and established mycobacterial species. Imaeda, T. and Portaels, F. ..... (A) 170
Does infection with environmental mycobacteria suppress the protective response to subsequent vaccination with BCG? Smith, D., *et al.* ..... (A) 363
Efficacy of *Mycobacterium bovis* BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Orme, I. M. and Collins, F. M. ..... (A) 697
Exchange of material between the extracellular medium and macrophage phagosomes containing different species of bacteria including mycobacteria. de Chastellier, C. and Lang, T. ..... (A) 336
Experimental mycobacterial infections of CBA/N mice. Levy, L., *et al.* ..... (A) 690
Freeze-etching and freeze-fracture structural features of cell envelopes in mycobacteria and leprosy-derived corynebacteria. Benedetti, E. L., *et al.* ..... (A) 343
Further observations on the mycobacteriophage D29—mycobacterial interactions. David, H. L., *et al.* ..... (A) 344
Inhibition of mycobacteria by garlic extract (*Allium sativum*). Delaha, E. C. and Garagusi, V. F. ..... (A) 695
Intracellular multiplication of leprosy-derived mycobacteria in Schwann cells of dorsal root ganglion cultures. Mukherjee, R. and Antia, N. H. ..... (A) 687
Isoenzyme patterns of mycobacteria. I. Factors influencing LDH isoenzymes of mycobacteria. Sharma, V. D., *et al.* ..... (A) 688
Isoenzymes of mycobacteria. II. Relevance of LDH zymograms in taxonomy and identification. Katoch, V. M., *et al.* ..... (A) 686
Isolation of mycobacterial phage from the laboratory strain *Mycobacterium lepraemurium* "Douglas." Sula, L., *et al.* ..... (A) 509
Lytic potency against various mycobacterial strains of the phage isolated from *Mycobacterium lepraemurium* "Douglas." Sula, L. and Sulova, J. ..... (A) 509
Macrophage interaction with mycobacteria including *M. leprae.* Ryter, A., *et al.* ..... (A) 346
New-found glycolipid antigens of mycobacteria. Brennan, P. J. ..... (A) 343
Numerical taxonomic and immunologic comparison of 36 leprosy-derived mycobacterial strains and 17 members of the MAIS complex. Skinsnes, O. K., *et al.* ..... (A) 167
Presence of "difficult-to-grow" mycobacteria in armadillos. Dhople, A. M., *et al.* ..... (A) 166
Prophylactic effect in mice of BCG vaccination against nontuberculous mycobacterial infections. Orme, I. and Collins, F. M. ..... (A) 698
Rapid detection of mycobacterial contamination in batches of whole cells of purified *Mycobacterium leprae* by pyrolysis gas chromatography. Wieten, G., *et al.* ..... (A) 348
Rapid methods for counting mycobacteria—comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assay. Prioli, R. P., *et al.* ..... (A) 698
Skin-test sensitisation by tubercle bacilli and by other mycobacteria in Ethiopian schoolchildren. Eshetu Lema and Stanford, J. ..... (A) 362
The Biology of the Mycobacteria. Vol. 2. Immunological and Environmental Aspects. Ratledge, C. and Stanford, J. ..... (B) 664
Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. avium/intracellulare,* and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* ..... (O) 441

Mycobacterium aurum,
Antibacterial action of colistin (polymyxin E) against *Mycobacterium aurum.* David, H. L. and Rastogi, N. ..... (A) 685

Mycobacterium avium,
Phagocytosis of *Mycobacterium leprae* and *M. avium* by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. ..... (A) 340

Mycobacterium avium-intracellulare,
Intra- and extracellular susceptibility of *Mycobacterium avium-intracellulare* complex to aminoglycoside antibiotics. Nozawa, R. T., *et al.* ..... (A) 152
Morphological changes induced by β-lactum antibiotics in *Mycobacterium avium-intracellulare* complex. Mizuguchi, Y., *et al.* ..... (A) 696
Susceptibility of intra- and extracellular *Mycobacterium avium-intracellulare* to cephem antibiotics. Nozawa, R. T., *et al.* ..... (A) 363
Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. avium/intracellulare,* and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* ..... (O) 441

Mycobacterium bovis,
Effect of *Mycobacterium bovis* (BCG) infection on the kinetics of the mononuclear cell response within the lung. Collins, F. M. and Auclair, L. K. ..... (A) 149
Efficacy of *Mycobacterium bovis* BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Orme, I. M. and Collins, F. M. ..... (A) 697

Mycobacterium chelonei,
In vitro susceptibility of *Mycobacterium fortuitum* and *Mycobacterium chelonei* to cefmetazole. Casal, M. J., *et al.* ..... (A) 361
Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis, M. leprae, M. ulcerans, M. chelonei (abscessus),* and *M. kansasii.* Wear, D. J., *et al.* ..... (A) 684

Mycobacterium fortuitum,
In vitro susceptibility of *Mycobacterium fortuitum* and *Mycobacterium chelonei* to cefmetazole. Casal, M. J., *et al.* ..... (A) 361

Mycobacterium gordonae,
Affinity purification of a 65,000 dalton protein of *Mycobacterium gordonae* using a monoclonal antibody which recognizes a shared epitope on the homologous protein of *Mycobacterium leprae.* Gillis, T. P. ..... (A) 718
Quantitative comparison of the mycolic and fatty acid compositions of *Mycobacterium leprae* and *M. gordonae.* Minnikin, D. E., *et al.* ..... (A) 687

Mycobacterium kansasii,
Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis, M. leprae, M. ulcerans, M. chelonei (abscessus),* and *M. kansasii.* Wear, D. J., *et al.* ..... (A) 684

Mycobacterium leprae,
A comparative study of antigens from human peripheral nerves and *M. leprae* antigens. Umerov, G. G. ..... (A) 506
A dual effect of tilorone on multiplication of *Mycobacterium leprae* in mice. Levy, L. and Aizer, F. ..... (A) 350
A specific glucose oxidase immunoenzyme stain for *Mycobacterium leprae.* Long, E. G., *et al.* ..... (A) 176
Absence of mycobactin in *Mycobacterium leprae*; probably a microbe dependent microorganism. Implications. Kato, L. ..... (A) 686
Adoptive transfer of cell-mediated immunity in *M. leprae*-infected nude mice with *M. leprae*-immunized allogeneic leukocytes depleted of Thy-1.2-bearing cells and Lyt-2.2-bearing cells. Chehl, S. K., *et al.* ..... (A) 720
Affinity purification of a 65,000 dalton protein of *Mycobacterium gordonae* using a monoclonal antibody which recognizes a shared epitope on the homologous protein of *Mycobacterium leprae.* Gillis, T. P. ..... (A) 718
Alternate radiolabeled markers for detecting metabolic activity of *Mycobacterium leprae* residing in murine macrophages. Prasad, H. K. and Hastings, R. C. ..... (A) 688
An anomalous response of *M. leprae* to dapsone chemotherapy in nude mice. Chehl, S. K. and Hastings, R. C. ..... (A) 167

An attempt to infect turtles (*Kinosternon leucostomum*) with *Mycobacterium leprae* and *M. lepraemurium*. Rojas-Espinosa, O., *et al.* ..... (A) 691
An *in vitro* test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of *Mycobacterium leprae*. Nair, I. and Mahadevan, P. R. ..... (A) 671
An unusual case of untreated polar lepromatous leprosy associated with rare *M. leprae*. Gelber, R. H. ..... (C) 311
Antibodies to *Mycobacterium leprae* detected by enzyme linked (ELISA) and radio (RIA) immunoassay: comparison among families with leprosy patients. Chakinis, C., *et al.* ..... (A) 354
Antibody response to phenolic glycolipid I in inbred mice immunized with *Mycobacterium leprae*. Teuscher, C., *et al.* ..... (A) 683
Anti-*Mycobacterium leprae* antibodies in urine from lepromatous patients examined by cross immunoelectrophoresis and radioimmunoassay. Olcén, P., *et al.* ..... (A) 144
Anti-*Mycobacterium leprae* antibodies induced by lepromin injection as demonstrated by indirect immunofluorescence. Gonzalez-Abreu, E., *et al.* ..... (A) 336
Assessment of sensitin from *M. leprae* by cell-mediated and humoral immune reactions. Dyachina, M. N., *et al.* ..... (A) 502
Biochemical alterations in the serum of armadillos (*Dasypus novemcinctus*) infected with *Mycobacterium leprae*. A preliminary report. Rojas-Espinosa, O., *et al.* ..... (O) 262
Cell envelope architectures of leprosy-related corynebacteria, *Mycobacterium leprae*, and related organisms: a comparative study. Rastogi, N., *et al.* ..... (A) 145
Cell-mediated immunity in mice treated with *Mycobacterium leprae* or with macrophages harboring *M. leprae*. Ridel, P. R., *et al.* ..... (A) 340
Characterization of a competitive-antibody-binding assay with a radiolabeled monoclonal antibody specific for *Mycobacterium leprae*. Gillis, T. P., *et al.* ..... (A) 178
Characterization of *Mycobacterium leprae* by lipid analysis. Minnikin, D. E., *et al.* ..... (A) 345
Comparative properties of *Mycobacterium leprae* and leprosy-derived corynebacteria. Cocito, C. ..... (A) 712
Comparative study on the thin-layer chromatographic pattern of methyl mycolates of *M. leprae* and related species. Datta, A. K., *et al.* ..... (O) 45
Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of *Mycobacterium leprae* sensitivity/resistance to dapsone. Sathish, M., *et al.* ..... (O) 378
Correlation viability/morphology in *Mycobacterium leprae*. Silva, M. T., *et al.* ..... (A) 347
Cultivable mycobacteria isolated from organs of armadillos uninoculated and inoculated with *Mycobacterium leprae*. Portaels, F., *et al.* ..... (A) 687
Cultivation of *M. leprae* using perfluorocarbon beddings. Juscenko, A. A. and Irtuganova, O. A. ..... (A) 507
Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to *Mycobacterium leprae* is associated with defective expression of interleukin-2 receptors and is not reconstituted by interleukin-2. Mohagheghpour, N., *et al.* ..... (A) 680
Deoxyribonucleic acid relatedness among *Mycobacterium leprae, Mycobacterium lepraemurium,* and selected bacteria by dot blot and spectrophotometric deoxyribonucleic acid hybridization assays. Athwal, R. S., *et al.* ..... (A) 342
Detection of an antigen (MY4) common to *M. tuberculosis* and *M. leprae* by "tandem" immunoassay. Praputpittaya, K. and Ivanyi, J. ..... (A) 681
Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of *M. leprae*. Truman, R. W., *et al.* ..... (A) 175
Diagnostic test systems based on enzyme-linked immunosorbent assay for detection of anti-*M. leprae* antibodies. Sukhenko, L. T., *et al.* ..... (A) 506
Diphenoloxidase of *Mycobacterium leprae* is not iron-dependent. Prabhakaran, K. and Harris, E. B. ..... (A) 508
Distribution of *Mycobacterium leprae* in circular counting films. Humber, D. P. ..... (C) 656
Distribution of *Mycobacterium leprae* in the circles of counting slides. Shepard, C. C. and Levy, L. ..... (C) 653
DNA from *Mycobacterium leprae*. David, H. L., *et al.* ..... (A) 344
DNA relatedness among *Mycobacterium leprae,* leprosy-derived bacteria, and established mycobacterial species. Imaeda, T. and Portaels, F. ..... (A) 170
Drug sensitivity testing of *M. leprae*. Grosset, J., *et al.* ..... (C) 118

Effects of *Mycobacterium leprae* vaccinations on cell-mediated immune functions of Lewis rats: specific sensitization vs tolerance. Humphres, R. C. and Winters, M. A. ...(A) 174
Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with *M. leprae*. Fukunishi, Y. ...(O) 75
Electron microscopic findings of transverse fission of *M. leprae* by freeze-etching methods. Fukunishi, Y. ...(O) 247
ELISA evaluation of phenolic glycolipid-I (PGI) and whole *M. leprae* with sera collected from leprosy patients during the course of chemotherapy. Douglas, J. T., *et al.* ...(A) 180
Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with *Mycobacterium leprae*. Sebille, A., *et al.* ...(C) 481
Evidence for the presence of *M. leprae* reactive T lymphocytes in patients with lepromatous leprosy. Nath, I., *et al.* ...(A) 340
Expression of cloned *Mycobacterium leprae* DNA in *Escherichia coli* K-12. Jacobs, W. R., *et al.* ...(A) 170
Fatty acids in *M. leprae* purified from the tissues of the animals with experimental leprosy. Pinchuck, L. M., *et al.* ...(A) 508
Fixation of *Mycobacterium leprae* in unstained smears prior to shipment or storage: evaluation of formaldehyde using *Mycobacterium tuberculosis* as indicator of efficacy. Allen, B. W. ...(A) 685
Fluorescence of *Mycobacterium leprae*. Padilla, M. A. and Sanchez, J. L. ...(A) 340
Growth of *Mycobacterium leprae* in a redox system. Chatterjee, B. R. ...(A) 685
Host-grown *Mycobacterium leprae*. A credible microorganism. Draper, P. ...(A) 345
Host responses to the phenolic glycolipid-I antigen of *M. leprae*. Truman, R. W., *et al.* ...(A) 710
Human monoclonal antibodies against *Mycobacterium leprae*. Atlaw, T., *et al.* ...(A) 677
Hydrolytic enzymes in macrophages from leprosy patients in presence of *Mycobacterium leprae*. Marolia, J. and Mahadevan, P. R. ...(A) 508
Incorporation of [^{14}C]-acetate into the specific phenolic glycolipid of *M. leprae* maintained within cultured cells. Mukherjee, R., *et al.* ...(A) 508
Identification of cloned *Mycobacterium leprae* genes in *Escherichia coli*. Jacobs, W. R., *et al.* ...(A) 711
IgM antibodies against phenolic glycolipid I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* ...(A) 341
Immunity to leprosy. 1. The proliferative response of murine T lymphocytes to *Mycobacterium leprae*. Douglas-Jones, A. G. and Watson, J. D. ...(O) 412
Immunochemical characterization of a protein associated with *Mycobacterium leprae* cell wall. Gillis, T. P., *et al.* ...(A) 679
Immunofluorescence studies on *Mycobacterium leprae* in fixed tissues. Krotoski, W. A. and McCormick, G. T. ...(A) 177
Immunologic assessment of *Mycobacterium leprae* antigens using isoelectric focusing and chromatofocusing separation. Navalkar, R. G. and Ibegbu, C. ...(A) 173
In vitro drug screening system using membrane alteration in macrophages by *Mycobacterium leprae*. Mankar, M. V., *et al.* ...(A) 507
In vitro lymphocyte stimulating ability of cell components of *Mycobacterium leprae*. Khandke, L., *et al.* ...(A) 337
In vivo responses to *Mycobacterium leprae*: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., *et al.* ...(O) 385
Influence of levamisole on lymphocytes and *M. leprae* in mice. Ganguly, N. K., *et al.* ...(A) 689
Interleukin-2-induced T-cell response to *M. leprae* in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small *M. leprae*-reactive T-cell pool? Shankar, P., *et al.* ...(C) 649
Isolation and preliminary characterization of the major intracellular carbohydrate-containing antigens of *Mycobacterium leprae*. Hunter, S. W., *et al.* ...(A) 712
Isolation of characteristic glycolipids possibly included in spherical droplets around *M. leprae*. Fukunishi, Y., *et al.* ...(O) 447

Leprosy in sub-human primates: potential risk for transfer of *M. leprae* to humans. Hagstad, H. V. ..... (A) 147
Lipase and penicillinase activity in *Mycobacterium leprae*. Talati, S. and Mahadevan, P. R. ..... (A) 509
Lymphocyte suppression in leprosy induced by unique *M. leprae* glycolipid. Mehra, V., *et al.* ..... (A) 680
Macrophage activity in *Mycobacterium leprae* infection. Sharp, A. K. and Banerjee, D. K. ..... (A) 341
Macrophage interaction with mycobacteria including *M. leprae*. Ryter, A., *et al.* ..... (A) 346
Malonyl-CoA decarboxylase activity in *Mycobacterium leprae*. Harris, E. B. and Prabhakaran, K. ..... (A) 165
Microscopic findings of delayed reactions elicited by the skin test reagent leprosin A derived from *M. leprae*. Samuel, N. M., *et al.* ..... (O) 395
Molecular analysis of DNA and construction of genomic libraries of *Mycobacterium leprae*. Clark-Curtiss, J. E., *et al.* ..... (A) 344
Monoclonal antibodies to a 28,000 mol. wt protein antigen of *Mycobacterium leprae*. Young, D. B., *et al.* ..... (A) 684
Morphometrical characteristics of *M. leprae* and *M. lepraemurium* intracytoplasmatic inclusions. Maslov, A. K. ..... (A) 508
Mycobacterium leprae in seminal fluid: a case report. Pareek, S. S. and Al-Nozha, M. ..... (A) 500
Mycobacterium leprae—the outer lipoidal surface. Brennan, P. J. ..... (A) 685
Mycobacterium leprae within a squamous cell carcinoma. Laing, A. B. G., *et al.* ..... (A) 333
Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis, M. leprae, M. ulcerans, M. chelonei* (*abscessus*), and *M. kansasii*. Wear, D. J., *et al.* ..... (A) 684
Phagocytic and bactericidal activities of macrophages from *Mycobacterium leprae*-infected normal and immunosuppressed mice. Vaishnavi, C., *et al.* ..... (O) 233
Phagocytosis of *Mycobacterium leprae* and *M. avium* by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. ..... (A) 340
Phenolic glycolipid 1 of *Mycobacterium leprae* causes nonspecific inflammation but has no effect on cell-mediated responses in mice. Brett, S. J., *et al.* ..... (A) 139
Production of human antibodies to *Mycobacterium leprae*. Mohagheghpour, N., *et al.* ..... (A) 717
Production of human monoclonal antibodies to *Mycobacterium leprae*. Mohagheghpour, N., *et al.* ..... (A) 178
Quantitative comparison of the mycolic and fatty acid compositions of *Mycobacterium leprae* and *M. gordonae*. Minnikin, D. E., *et al.* ..... (A) 687
Rapid detection of mycobacterial contamination in batches of whole cells of purified *Mycobacterium leprae* by pyrolysis gas chromatography. Wieten, G., *et al.* ..... (A) 348
Recombinant DNA clones expressing *M. leprae* and *M. tuberculosis* antigens: potential new tools for immunodiagnosis and prophylaxis. Mehra, V., *et al.* ..... (A) 727
Respiration in *Mycobacterium leprae*. Mori, T., *et al.* ..... (O) 600
Response to Dr. Grosset, *et al.* (drug sensitivity testing of *M. leprae*). Almeida, J. G. and Chacko, C. J. G. ..... (C) 120
Results from cation and mass fingerprint analysis of single cells and from ATP measurements of *M. leprae* for drug sensitivity testing: a comparison. Seydel, U., *et al.* ..... (O) 365
Results of a World Health Organization-sponsored workshop on monoclonal antibodies to *Mycobacterium leprae*. ..... (A) 682
Reversal by interleukin-2 of the T cell unresponsiveness of lepromatous leprosy to *Mycobacterium leprae*. Haregewoin, A., *et al.* ..... (A) 141
Reversal reactions in *M. leprae*-infected nine-banded armadillos. Juscenko, A. A. ..... (A) 510
Salivary anti-*M. leprae* antibodies of household contacts and inhabitants in a leprosy-endemic area. Abe, M., *et al.* ..... (A) 715
Some new data on *Mycobacterium leprae* biology. Juscenko, A. A. ..... (A) 507
Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. ..... (A) 715
Strain variation in murine immune response to the *M. leprae* glycolipid antigen, phenolic glycolipid-I. Tung, K. S. K., *et al.* ..... (A) 721
Studies on antimicrobial activity against *M. leprae* infections of the mouse foot pad. Gelber, R. H. ..... (A) 171

Study on the micromorphology of *Mycobacterium leprae*. Burchard, G.-D. and Bierther, M. ..... (A) 685
Susceptibility of *Mycobacterium leprae* to bactericidal activity of mouse peritoneal macrophages and to hydrogen peroxide. Sharp, A. K., *et al.* ..... (A) 342
Synergistic activity of dapsone and brodimoprim (a dihydrofolate inhibitor) against *Mycobacterium leprae*. Jagannathan, R. and Mahadevan, P. R. ..... (A) 495
Temperature effects on viability, diphenoloxidase, and permeability of *Mycobacterium leprae*. Prabhakaran, K. and Harris, E. B. ..... (A) 168
Temperature-induced changes in viability, diphenoloxidase and permeability of *Mycobacterium leprae*. Prabhakaran, K. and Harris, E. B. ..... (A) 688
The adenosine triphosphate content and death rate of *Mycobacterium leprae* isolated from armadillo tissue by Percoll buoyant density centrifugation. Kvach, J. T., *et al.* ..... (A) 169
The bactericidal activity of various aminoglycoside antibiotics against *Mycobacterium leprae* in mice. Gelber, R. H., *et al.* ..... (A) 328
The discovery of *Mycobacterium leprae*. A medical achievement in the light of evolving scientific methods. Irgens, L. M. ..... (A) 326
The effect of *Mycobacterium leprae* on PHA- and PPD-induced inhibition of leucocyte migration in leprosy patients. Dharma Rao, T., *et al.* ..... (A) 679
The free lipids of *Mycobacterium leprae* harvested from experimentally infected nine-banded armadillos. Minnikin, D. E., *et al.* ..... (A) 686
The influence of ultrasonication of *M. leprae* growth. Badovskaya, Z. V. ..... (A) 507
The sensitivity and specificity of fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with *Mycobacterium leprae*. Ji, B., *et al.* ..... (A) 357
The synthesis and activity of the sugar derivatives to phenolic glycolipids of *Mycobacterium leprae* and preparation of sugar-protein conjugates. Fujiwara, T., *et al.* ..... (A) 727
Three histologic fixatives for the demonstration of *Mycobacterium leprae*. Jones, R. L. and McDougall, A. C. ..... (A) 337
Trials of culturing of *Mycobacterium leprae* using media enriched with thyroid hormones. Massalski, W., *et al.* ..... (A) 145
Trophic changes and extensive dissemination in normal mice with human *Mycobacterium leprae*. Vaishnavi, C., *et al.* ..... (A) 510
Ultrastructure of sciatic nerve of armadillo infected with *Mycobacterium leprae*. Mehta, L. N. and Antia, N. H. ..... (A) 338
Use of a polysulfone membrane support for immunochemical analysis of a glycolipid from *Mycobacterium leprae*. Young, D. B., *et al.* ..... (A) 684
Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. avium/intracellulare*, and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* ..... (O) 441

Mycobacterium lepraemurium,
A monoclonal antibody against *Mycobacterium lepraemurium* which recognizes a cross-reacting mycobacterial antigen. Bach, M.-A. and Hoffenbach, A. ..... (A) 138
An attempt to infect turtles (*Kinosternon leucostomum*) with *Mycobacterium leprae* and *M. lepraemurium*. Rojas-Espinosa, O., *et al.* ..... (A) 691
Antimycobacteria antibodies in *M. lepraemurium* murine infection. Bach, M. A. and Hoffenbach, A. ..... (A) 348
Delayed-type hypersensitivity after immunization with ultrasonicated *Mycobacterium lepraemurium* in C3H and C57BL mice. Lovik, M., *et al.* ..... (A) 351
Deoxyribonucleic acid relatedness among *Mycobacterium leprae, Mycobacterium lepraemurium,* and selected bacteria by dot blot and spectrophotometric deoxyribonucleic acid hybridization assays. Athwal, R. S., *et al.* ..... (A) 342
Further studies of the use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. Matsuo, Y. ..... (A) 345
Genetic resistance of mice to persistent infection with *Mycobacterium lepraemurium in vitro*: association with macrophage bactericidal responsiveness to lymphokines and dissociation from production of hydrogen peroxide by macrophages. Sankaran, K., *et al.* ..... (A) 353
H-2-linked genes which modify resistance of C57BL/10 mice to subcutaneous infection with *Mycobacterium lepraemurium*. Curtis, J., *et al.* ..... (A) 146

Immune response in BALB/c mice following immunization with heat-killed *Mycobacterium lepraemurium.* Graham, L. and Navalkar, R. G. ....(A) 146
Induction of gamma interferon with various mitogens in mice pretreated with *M. lepraemurium* and the effect of *in vivo* interferon production on the growth of *M. lepraemurium* in mice. Nomaguchi, H., *et al.* ....(A) 706
Influence of dose and route of inoculation and of mouse strain on the production of interleukin 2 in mice infected with *Mycobacterium lepraemurium.* Hoffenbach, A., *et al.* ....(A) 349
Influence of dose and route of *Mycobacterium lepraemurium* inoculation on the production of interleukin-1 and interleukin-2 in C57BL/6 mice. Hoffenbach, A., *et al.* ....(A) 679
Intrinsic energy potential of *Mycobacterium lepraemurium* essential for growth in MC-5 medium. Nakamura, M. and Dhople, A. M. ....(A) 687
Isolation of mycobacterial phage from the laboratory strain *Mycobacterium lepraemurium* "Douglas." Sula, L., *et al.* ....(A) 509
Lytic potency against various mycobacterial strains of the phage isolated from *Mycobacterium lepraemurium* "Douglas." Sula, L. and Sulova, J. ....(A) 509
Macrophage activation in mice infected with *Mycobacterium lepraemurium.* Brett, S. J. ....(A) 349
Morphometrical characteristics of *M. leprae* and *M. lepraemurium* intracytoplasmatic inclusions. Maslov, A. K. ....(A) 508
Mycobacterium lepraemurium infection of nude athymic (nu/nu) mice. Lefford, M. J. ....(A) 690
Serum enzymatic changes following infection of mice with *Mycobacterium lepraemurium.* Rojas-Espinosa, O., *et al.* ....(O) 258
Strain variation of lymphokine production and specific antibody secretion in mice infected with *Mycobacterium lepraemurium.* Hoffenbach, A., *et al.* ....(A) 510
Survival of *Mycobacterium lepraemurium in vitro* for thirty years by lyophilization. Nakamura, M. ....(O) 52
T-cell responsiveness in *Mycobacterium lepraemurium* infections in a "resistant" (CBA) and a "susceptible" (BALB/c) mouse strain. Brett, S. J. ....(A) 349
Use of fluorescent staining method for determining the viability of *Mycobacterium lepraemurium.* Tsukiyama, F., *et al.* ....(A) 347
Use of gas chromatography to differentiate *Mycobacterium leprae* from cultivable armadillo-derived mycobacteria, *M. avium/intracellulare,* and *M. lepraemurium* by analysis of secondary alcohols. Larsson, L., *et al.* ....(O) 441

"Mycobacterium lufu,"
The use of "*M. lufu*" for initial screening of antileprosy drugs. Irtuganova, O. A. and Urlyapova, N. G. ....(A) 494

Mycobacterium szulgai,
Cutaneous *Mycobacterium szulgai* infection. Cross, G. M., *et al.* ....(A) 361

Mycobacterium tuberculosis,
Detection of an antigen (MY4) common to *M. tuberculosis* and *M. leprae* by "tandem" immunoassay. Praputpittaya, L. and Ivanyi, J. ....(A) 681
Determination of *in vitro* susceptibility of *Mycobacterium tuberculosis* to cephalosporins by radiometric and conventional methods. Heifets, L. B., *et al.* ....(A) 361
Dissection of *Mycobacterium tuberculosis* antigens using recombinant DNA. Young, R. A., *et al.* ....(A) 699
Fixation of *Mycobacterium leprae* in unstained smears prior to shipment or storage: evaluation of formaldehyde using *Mycobacterium tuberculosis* as indicator of efficacy. Allen, B. W. ....(A) 685
In vitro activity of ampicillin compared to ampicillin and sulbactam against *Mycobacterium tuberculosis.* Cynamon, M. H., *et al.* ....(A) 165
Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis, M. leprae, M. ulcerans, M. chelonei* (*abscessus*), and *M. kansasii.* Wear, D. J., *et al.* ....(A) 684
Recombinant DNA clones expressing *M. leprae* and *M. tuberculosis* antigens: potential new tools for immunodiagnosis and prophylaxis. Mehra, V., *et al.* ....(A) 727

Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of *Mycobacterium tuberculosis*. Goren, M. B., *et al.* ..... (A) 150
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* ..... (A) 360
Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. ..... (A) 715

Mycobacterium ulcerans,
Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis, M. leprae, M. ulcerans, M. chelonei* (*abscessus*), and *M. kansasii*. Wear, D. J., *et al.* ..... (A) 684

Mycobactin,
Absence of mycobactin in *Mycobacterium leprae*; probably a microbe dependent microorganism. Implications. Kato, L. ..... (A) 686

Nepal,
A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal. Morton, A., *et al.* ..... (A) 143
Leprosy treatment in Nepal with multidrug regimens. Birch, M. C. ..... (A) 133
Multidrug treatment of leprosy—practical application in Nepal. Samuel, N. M., *et al.* ..... (A) 136
Prevalence of secondary dapsone resistance in Nepal. Samuel, N. M., *et al.* ..... (A) 497
Primary dapsone resistant leprosy in Nepal. Samuel, N. M., *et al.* ..... (A) 497
Social factors and leprosy in Lamjung, west central Nepal: implication for disease control. Pearson, M. ..... (A) 358

Nerve(s),
A comparative study of antigens from human peripheral nerves and *M. leprae* antigens. Umerov, G. G. ..... (A) 506
Digital dermatoglyphics in leprosy patients with severe nerve damage. Baranov, Y. N., *et al.* ..... (A) 498
Electron microscopic findings of the peripheral nerve lesions of nude mice inoculated with *M. leprae*. Fukunishi, Y. ..... (O) 75
Median nerve function after tendon transfer for ulnar paralysis. Brandsma, J. W. and Brand, P. W. ..... (A) 513
Muramidase (lysozyme) findings in sural and radial nerve biopsies in leprosy patients after varying periods of treatment. Haimanot, R. T., *et al.* ..... (O) 238
Neural auto-antibodies in leprosy. Eustis-Turf, E. P., *et al.* ..... (A) 722
Neurolysis of the common peroneal nerve in leprosy. A report on 22 patients. Chaise, F. and Roger, B. ..... (A) 694
Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. Schwab, B. W., *et al.* ..... (A) 330
Surgical decompression of the ulnar nerve. Srinivasan, H. ..... (A) 359
Surgical reconstruction of the hand with triple nerve palsy. Sundararaj, G. D. and Mani, K. ..... (A) 513
The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Kiran, K. U., *et al.* ..... (A) 674
The treatment of early nerve damages due to leprosy. Alamdarov, I. N., *et al.* ..... (A) 512
Ultrastructural and histophysiological studies on the blood-nerve barrier and perineurial barrier in leprosy neuropathy. Boddingius, J. ..... (A) 138
Ultrastructure of sciatic nerve of armadillo infected with *Mycobacterium leprae*. Mehta, L. N. and Antia, N. H. ..... (A) 338
Untreated borderline-leprosy in the ulnar nerve: light and electron microscopical studies. Vieregge, P., *et al.* ..... (A) 506

Neuropathy,
Acute severe peripheral neuropathy due to thiacetazone. Gupta, P. K., *et al.* ..... (A) 328
Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with *Mycobacterium leprae*. Sebille, A., *et al.* ..... (C) 481

Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Schroder, J. M. and Matthiesen, T. ....(A) 672
Neuropathic plantar ulceration. Kumar, K., *et al.* ....(A) 694
Nueropathic ulcers of the foot. Lang-Stevenson, A. I., *et al.* ....(A) 694
Thalidomide-induced peripheral neuropathy. Aronson, I. K., *et al.* ....(A) 148
Ultrastructural and histophysiological studies on the blood-nerve barrier and perineurial barrier in leprosy neuropathy. Boddingius, J. ....(A) 138
Weight appreciation in the hand in normal subjects and in patients with leprous neuropathy. Raj, D. V., *et al.* ....(A) 675

New Zealand,
Leprosy in New Zealand. Woodward, W. ....(A) 667

Nigeria,
Social aspects of leprosy: a case study in Zaria, northern Nigeria. Reddy, N. B. B., *et al.* (A) 513

Nose,
Electron microscopic observations of acid-fast bacilli in nasal mucosal biopsies of lepromatous leprosy patients. Hirata, T. ....(O) 577

Nutrition,
Geographical variations in the occurrence of leprosy: possible roles played by nutrition and some other environmental factors. Sommerfelt, H., *et al.* ....(O) 524
Nutritional aspects of leprosy. Mester de Parajd, L. and Garnier, J.-P. ....(A) 329

Obituaries,
Nishiura, Mitsugu. .... (Ob) 308
Pedley, James Cecil. .... (Ob) 641
Shepard, Charles C. .... (Ob) 309

Pakistan,
Analysis of leprosy control program. Pfau, R. ....(A) 512

Pathology,
Clinico-pathological study of nephrotic syndrome in leprosy. Jain, A. P., *et al.* ....(A) 499

Peroxidase,
Determination of inhibitory concentrations of antiviral agents in cell culture by use of an enzyme immunoassay with virus-specific, peroxidase-labeled monoclonal antibodies. van Tiel, F. H., *et al.* ....(A) 699

Peru,
Operational evaluation of treatment for tuberculosis: results of a "standard" 12-month regimen in Peru. Hopewell, P. C., *et al.* ....(A) 696

Phagocytes,
Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies. Matthew, R. C., *et al.* ....(A) 503
Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine. Niwa, Y., *et al.* ...(A) 330
Phagocytic and bactericidal activities of macrophages from *Mycobacterium leprae*-infected normal and immunosuppressed mice. Vaishnavi, C., *et al.* ....(O) 233
Phagocytosis of *Mycobacterium leprae* and *M. avium* by armadillo lung fibroblasts and kidney epithelial cells. Rastogi, N. and David, H. L. ....(A) 340

Phenolic glycolipid(s),
A diverse approach to the serodiagnosis of leprosy based on the phenolic glycolipid-I. Cho, S.-N., *et al.* ....(A) 715
Antibody response to phenolic glycolipid I in inbred mice immunized with *Mycobacterium leprae*. Teuscher, C., *et al.* ....(A) 683
Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients. Andreoli, A., *et al.* ....(O) 211
Detection of IgM class antibodies in armadillos to the phenolic glycolipid-I antigen of *M. leprae*. Truman, R. W., *et al.* ....(A) 175

ELISA evaluation of phenolic glycolipid-I (PGI) and whole *M. leprae* with sera collected from leprosy patients during the course of chemotherapy. Douglas, J. T., *et al.* .....(A) 180
Host responses to the phenolic glycolipid-I antigen of *M. leprae.* Truman, R. W., *et al.* .....(A) 710
IgM antibodies against phenolic glycolipid I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* .....(A) 341
Incorporation of [^{14}C]-acetate into the specific phenolic glycolipid of *M. leprae* maintained within cultured cells. Mukherjee, R., *et al.* .....(A) 508
Isolation of phenolic glycolipid-I from human lepromatous nodules. Vemuri, N., *et al.* .....(C) 487
Phenolic glycolipid-I: an immunogen for a Mitsuda response. Job, C. K., *et al.* .....(A) 179
Phenolic glycolipid I now available in limited quantities (from IMMLEP Bank, London). .....(N) 319
Phenolic glycolipid I of *Mycobacterium leprae* causes nonspecific inflammation but has no effect on cell-mediated responses in mice. Brett, S. J., *et al.* .....(A) 139
Purification of phenolic glycolipid-I from armadillo and human sources. Hunter, S. W., *et al.* .....(C) 484
Strain variation in murine immune response to the *M. leprae* glycolipid antigen, phenolic glycolipid-I. Tung, K. S. K., *et al.* .....(A) 721
The synthesis and activity of the sugar derivatives to phenolic glycolipids of *Mycobacterium leprae* and preparation of sugar-protein conjugates. Fujiwara, T., *et al.* .....(A) 727

Phenotypes,
Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., *et al.* .....(A) 504
In vivo responses to *Mycobacterium leprae*: antigen presentation, interleukin-2 production, and immune cell phenotypes in naturally occurring leprosy lesions. Longley, J., *et al.* .....(O) 385

Phospholipids,
Essential fatty acids in the plasma phospholipids of patients with leprosy. Wright, S. ..(A) 677

Prostaglandin,
Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes *in vitro.* Anderson, R. .....(A) 327

Protein(s),
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. .....(O) 22
Affinity purification of a 65,000 dalton protein of *Mycobacterium gordonae* using a monoclonal antibody which recognizes a shared epitope on the homologous protein of *Mycobacterium leprae.* Gillis, T. P. .....(A) 718
Immunochemical characterization of a protein associated with *Mycobacterium leprae* cell wall. Gillis, T. P., *et al.* .....(A) 679
Monoclonal antibodies to a 28,000 mol. wt protein antigen of *Mycobacterium leprae.* Young, D. B., *et al.* .....(A) 684
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* .....(A) 360
Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. .....(A) 715
The synthesis and activity of the sugar derivatives to phenolic glycolipids of *Mycobacterium leprae* and preparation of sugar-protein conjugates. Fujiwara, T., *et al.* .....(A) 727

Prothionamide,
Combined therapy of leprosy patients with solusulfone, rifampin, and prothionamide. Evstratova, V. A., *et al.* .....(A) 494
Hepatitis and multidrug therapy in leprosy with special reference to prothionamide. Kar, H. K., *et al.* .....(A) 669
Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy. Ji, B., *et al.* .....(A) 134

Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin. Cartel, J.-L., *et al.* ..... (O) 15
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., *et al.* ..... (A) 669
Toxicity of prothiomide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. ..... (A) 134

Prurigo nodularis,
Thalidomide treatment of prurigo nodularis. Winkelmann, R. K., *et al.* ..... (A) 153

Psychosocial,
Psychosocial stress in Hansen's disease: a comparison with other chronic illness patients. Bahlinger, V. M., *et al.* ..... (O) 251

Purification,
Affinity purification of a 65,000 dalton protein of *Mycobacterium gordonae* using a monoclonal antibody which recognizes a shared epitope on the homologous protein of *Mycobacterium leprae.* Gillis, T. P. ..... (A) 718
Purification of phenolic glycolipid-I from armadillo and human sources. Hunter, S. W., *et al.* ..... (C) 484

Purified protein derivative (PPD),
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* ..... (A) 360
The effect of *Mycobacterium leprae* on PHA- and PPD-induced inhibition of leucocyte migration in leprosy patients. Dharma Rao, T., *et al.* ..... (A) 679

Radioimmunoassay,
Anti-*Mycobacterium leprae* antibodies in urine from lepromatous patients examined by crossed immunoelectrophoresis and radioimmunoassay. Olcén, P., *et al.* ..... (A) 144
Radioimmunoassay of serum cortisol levels in leprosy patients with special reference to type I and type II reaction. Saha, K., *et al.* ..... (A) 676

Radiolabel,
Alternate radiolabeled markers for detecting metabolic activity of *Mycobacterium leprae* residing in murine macrophages. Prasad, H. K. and Hastings, R. C. ..... (A) 688
Characterization of a competitive-antibody-binding assay with a radiolabeled monoclonal antibody specific for *Mycobacterium leprae.* Gillis, T. P., *et al.* ..... (A) 178

Rat(s),
Effects of *Mycobacterium leprae* vaccinations on cell-mediated immune functions of Lewis rats: specific sensitization vs tolerance. Humphres, R. C. and Winters, M. A. ..... (A) 174
The athymic rodent as an experimental lepromatous leprosy model (continued): effect of genetic background of nude rats and age of ICR nude mice. Nakamura, K. and Yogi, Y. ..... (A) 719

Reaction(s),
A new method for testing tuberculin skin reactivity—chamber test. Backman, A., *et al.* ..... (A) 360
A sequential histopathological study of the lepromin reaction in leprosy patients. Misty, N. F., *et al.* ..... (A) 680
An *in situ* immunohistological study of Mitsuda reactions. Dugan, E., *et al.* ..... (O) 404
Assessment of sensitin from *M. leprae* by cell-mediated and humoral immune reactions. Dyachina, M. N., *et al.* ..... (A) 502
Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., *et al.* ..... (C) 113
Evidence for the presence of *M. leprae* reactive T lymphocytes in patients with lepromatous leprosy. Nath, I., *et al.* ..... (A) 340
Giant reactions to tuberculin in lepromatous leprosy patients. Waters, M. F. R. and Stanford, J. L. ..... (O) 546

Histology of the Mitsuda reaction of healthy adults with no known contacts with leprosy patients. Petri, V., *et al.* ..... (O) 540
Hypersensitivity reaction to dapsone: report from Malaysia. Mohammed, K. N. ..... (A) 329
Interleukin-2-induced T-cell response to *M. leprae* in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small *M. leprae*-reactive T-cell pool? Shankar, P., *et al.* ..... (C) 649
Microscopic findings of delayed reactions elicited by the skin test reagent leprosin A derived from *M. leprae.* Samuel, N. M., *et al.* ..... (O) 395
Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis, M. leprae, M. ulcerans, M. chelonei* (*abscessus*), and *M. kansasii.* Wear, D. J., *et al.* ..... (A) 684
Qualitative differences in tuberculin reactivity in patients with tuberculosis, occupational contacts and non-contacts. El-Ansary, E. H. and Grange, J. M. ..... (A) 149

Reaction, leprosy,
A case of type 2 leprosy reactions accompanied by purpura. Chen, J., *et al.* ..... (A) 136
Borderline reactions treated with clofazimine and corticosteroids. Thirugnanan, T. and Rajan, M. A. ..... (A) 677
Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., *et al.* ..... (A) 504
Enzyme immunoassay of serum β-2-microglobulin levels in various histological forms of leprosy with special reference to its elevation in type I and type II lepra reactions. Saha, K., *et al.* ..... (A) 505
Late reversal reaction after combined treatment of a patient with multibacillary leprosy. Pattyn, S. R., *et al.* ..... (A) 334
Radioimmunoassay of serum cortisol levels in leprosy patients with special reference to type I and type II reaction. Saha, K., *et al.* ..... (A) 676
Reversal reactions in *M. leprae*-infected nine-banded armadillos. Juscenko, A. A. ..... (A) 510
Standardized schemes for steroid treatment in ENL and reversal reactions. Imkamp, F. M. J. H. ..... (C) 313
Successful plasma exchange in type 1 leprosy reversal reaction. Lucht, F., *et al.* ..... (A) 500
The use of colchicine in the management of type 2 lepra reaction (erythema nodosum leprosum). Stanley, J. N. A., *et al.* ..... (A) 136

Refugees,
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. ..... (A) 697
Specific health problems of Southeast Asian refugees in middle Tennessee (U.S.A.). Dao, A. H., *et al.* ..... (A) 132

Rehabilitation,
Surgical Reconstruction and Rehabilitation in Leprosy. Fritschi, E. P. ..... (B) 129

Relapse(s),
A study of relapse in nonlepromatous and intermediate groups of leprosy. Pandian, T. D., *et al.* ..... (A) 671
Dimociphon in combined therapy of drug-resistant and relapsed leprosy patients. Gnenjuk, T. S. ..... (A) 494
Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment. Warndorff van Diepen, T. and Mengistu, G. ..... (O) 189
Risk of paucibacillary leprosy patients released from control relapsing with multibacillary leprosy. Jesudasan, J. and Christian, M. ..... (O) 19
The analysis of causes of relapses in leprosy. Kadantsev, N. D. and Kogan, V. R. ..... (A) 495

Respiration,
Respiratory dysautonomia in leprosy. Gupta, O. P., *et al.* ..... (A) 499
The changes in upper respiratory organs in the discharged patients with "burnt out" lepromatous leprosy. Kaipbergenov, U. K. ..... (A) 499

Rifampin,
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. ..... (O) 22

Acute rifampin overdose: a pharmacokinetic study and review of the literature. Wong, P., *et al.* ..... (A) 497
Combined therapy of leprosy patients with solusulfone, rifampin, and prothionamide. Evstratova, V. A., *et al.* ..... (A) 494
Effect of antacids on oral absorption of rifampicin. Khalil, S. A. H., *et al.* ..... (A) 669
Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with *Mycobacterium leprae*. Sebille, A., *et al.* ..... (C) 481
Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy. Ji, B., *et al.* ..... (A) 134
Hepatotoxicity of the daily combination of 5 mg/kg prothionamide + 10 mg/kg rifampin. Cartel, J.-L., *et al.* ..... (O) 15
In vitro cultivation of leprosy granulation tissue and the effect of rifampin on it. Anokhina, V. V. ..... (A) 493
Negative observations on immunological side effects of rifampin and dapsone in mice. Nagata, Y., *et al.* ..... (O) 421
Reversible acute renal failure due to monthly administration of rifampicin in a leprosy patient. Kar, H. K. and Roy, R. G. ..... (A) 495
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. ..... (A) 697
Toxicity of prothiomide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. ..... (A) 134

Rifamycin,
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. ..... (O) 22
Novel rifamycins. IV. 3-Aminomethylazino-methylrifamycins, a new class of rifamycins, endowed with remarkable antibacterial activity. Marsili, I., *et al.* ..... (A) 135
Toxicity of prothiomide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. ..... (A) 134

Saliva,
Salivary anti-*M. leprae* antibodies of household contacts and inhabitants in a leprosy-endemic area. Abe, M., *et al.* ..... (A) 715

Screening: for leprosy,
In vitro drug screening system using membrane alteration in macrophages by *Mycobacterium leprae*. Mankar, M. V., *et al.* ..... (A) 507
The use of "*M. lufu*" for initial screening of antileprosy drugs. Irtuganova, O. A. and Urlyapova, N. G. ..... (A) 494

Sensation(s),
Minimum temperature felt as hot (MTH)—a new concept for grading the loss of temperature sensation in leprosy patients. Jain, G. L., *et al.* ..... (O) 206

Sensitivity, drug,
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability. Gelber, R. H., *et al.* ..... (A) 349
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability and optimal bactericidal therapy. Gelber, R. H., *et al.* ..... (A) 172
An *in vitro* test using cholesterol metabolism of macrophages to determine drug sensitivity and resistance of *Mycobacterium leprae*. Nair, I. and Mahadevan, P. R. ..... (A) 671
Comparison of radiometric macrophage assay and the mouse foot pad infection for the evaluation of *Mycobacterium leprae* sensitivity/resistance to dapsone. Sathish, M., *et al.* ..... (O) 378
Drug sensitivity testing of *M. leprae*. Grosset, J., *et al.* ..... (C) 118
Response to Dr. Grosset, *et al.* (drug sensitivity testing of *M. leprae*). Almeida, J. G. and Chacko, C. J. G. ..... (C) 120

Results from cation and mass fingerprint analysis of single cells and from ATP measurements of *M. leprae* for drug sensitivity testing: a comparison. Seydel, U., *et al.* .....(O) 365

Serodiagnosis,

A diverse approach to the serodiagnosis of leprosy based on the phenolic glycolipid-I. Cho, S.-N., *et al.* .....(A) 715

Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* .....(A) 360

Use of an artificial antigen containing the 3,6-di-*O*-methyl-β-D-glucopyranosyl epitope for the serodiagnosis of leprosy. Cho, S.-N., *et al.* .....(A) 139

Serum,

Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. .....(O) 22

Biochemical alterations in the serum of armadillos (*Dasypus novemcinctus*) infected with *Mycobacterium leprae.* A preliminary report. Rojas-Espinosa, O., *et al.* .....(O) 262

Conversion of the C3 component of complement in sera of hanseniasis patients. Kliemann, T. A. E., *et al.* .....(A) 142

Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., *et al.* .....(A) 137

Double-stranded DNA inhibits cardiolipin-binding activity in lepromatous leprosy patients' sera. Furukawa, F., *et al.* .....(C) 647

Effect of leprosy sera and foetal calf serum (FCS) on the T cell number of peripheral blood of leprosy patients. Patil, S. A., *et al.* .....(A) 504

ELISA evaluation of phenolic glycolipid-I (PGI) and whole *M. leprae* with sera collected from leprosy patients during the course of chemotherapy. Douglas, J. T., *et al.* .....(A) 180

Enzyme immunoassay of serum β-2-microglobulin levels in various histological forms of leprosy with special reference to its elevation in type I and type II lepra reactions. Saha, K., *et al.* .....(A) 505

IgM antibodies against phenolic glycolipid I from *Mycobacterium leprae* in leprosy sera: relationship to bacterial index and erythema nodosum leprosum. Schwerer, B., *et al.* .....(A) 341

Inhibition of antibody-dependent, cell-mediated cytotoxicity by serum from lepromatous leprosy patients. de la Barrera, S. S., *et al.* .....(O) 218

Myelinotoxic effect of serum antibodies from leprosy patients. Umerov, G. G., *et al.* ..(A) 506

Radioimmunoassay of serum cortisol levels in leprosy patients with special reference to type I and type II reaction. Saha, K., *et al.* .....(A) 676

Serum angiotensin-converting enzyme and delayed hypersensitivity in pulmonary tuberculosis. Grange, J. M., *et al.* .....(A) 151

Serum enzymatic changes following infection of mice with *Mycobacterium lepraemurium.* Rojas-Espinosa, O., *et al.* .....(O) 258

Serum immunoglobulins, including IgG subclasses, in Vietnamese leprosy patients. Wright, E. P., *et al.* .....(O) 225

Serum soluble interleukin-2 receptors in leprosy patients. Tung, K. S. K., *et al.* .....(A) 719

Sexual dysfunction,

Behavioral analysis of sexual dysfunction in Hansen's disease. Faulstich, M. E. .....(A) 674

Skin,

A new method for testing tuberculin skin reactivity—chamber test. Backman, A., *et al.* .....(A) 360

A single skin lesion—an unusual presentation of lepromatous leprosy. Yoder, L. J., *et al.* .....(O) 554

Chromosomal aberrations in cultures of skin fibroblasts of leprosy patients. Hackel, C. and Beiguelman, B. .....(O) 533

Comparison of S-100 and OKT6 antisera in human skin. Modlin, R. L., *et al.* .....(A) 389

Histological changes in the apparently normal skin at the periphery of leprosy lesions. Verma, R. N., *et al.* .....(A) 683

Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., *et al.* .....(A) 707

Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., *et al.* ..... (A) 678
Quantitation of the granuloma fraction in leprosy skin biopsies by planimetry. Cree, I. A., *et al.* ..... (O) 582
Use of human skin to demonstrate antinuclear antibodies in lepromatous leprosy patients. Lamas-Robles, C., *et al.* ..... (O) 373

Skin tests,
A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal. Morton, A., *et al.* ..... (A) 143
Microscopic findings of delayed reactions elicited by the skin test reagent leprosin A derived from *M. leprae.* Samuel, N. M., *et al.* ..... (O) 395
Skin-test sensitisation by tubercle bacilli and by other mycobacteria in Ethiopian schoolchildren. Eshetu Lema and Stanford, J. ..... (A) 362

Social,
The relationship between perceived social support and illness reports in Hansen's disease patients. Williams, K., *et al.* ..... (A) 162

Southeast Asia,
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. ..... (A) 697
Specific health problems of Southeast Asian refugees in middle Tennessee (U.S.A.). Dao, A. H., *et al.* ..... (A) 132

Spain,
El Doctor Jose Terencio de las Aguas, experto en lepra de la Organizacion Mundial de la Salud. ..... (N) 125
Fontilles celebrates 75th anniversary. ..... (N) 125

Spleen,
Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., *et al.* ..... (A) 146

Stain(s),
A specific glucose oxidase immunoenzyme stain for *Mycobacterium leprae.* Long, E. G., *et al.* ..... (A) 176
Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis, M. leprae, M. ulcerans, M. chelonei* (*abscessus*), and *M. kansasii.* Wear, D. J., *et al.* ..... (A) 684
Use of fluorescent staining method for determining the viability of *Mycobacterium lepraemurium.* Tsukiyama, F., *et al.* ..... (A) 347

Steroid(s),
Standardized schemes for steroid treatment in ENL and reversal reactions. Imkamp, F. M. J. H. ..... (C) 313
The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen. Kiran, K. U., *et al.* ..... (A) 674

Subclinical,
Extended studies on subclinical infection in leprosy. Bharadwaj, V. P., *et al.* ..... (A) 510
The sensitivity and specificity of fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with *Mycobacterium leprae.* Ji, B., *et al.* ..... (A) 357

Superoxide dismutase,
Oxygen metabolism in phagocytes of leprotic patients: enhanced endogenous superoxide dismutase activity and hydroxyl radical generation by clofazimine. Niwa, Y., *et al.* ..... (A) 330

Supidimide,
Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. Schwab, B. W., *et al.* ..... (A) 330

Suppression,
A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal. Morton, A., *et al.* ..... (A) 143
Hypothesis: possible idiotypic suppression of cell-mediated immunity in lepromatous leprosy. Ferluga, J., *et al.* ..... (A) 140

In vitro cyclosporin A restoration of lepromin-induced suppressor activity in patients with erythema nodosum leprosum. Uyemura, K., *et al.* ..... (A) 709
Interleukin-2-induced T-cell response to *M. leprae* in lepromatous leprosy: reversion of a suppressor mechanism or expansion of a small *M. leprae*-reactive T-cell pool? Shankar, P., *et al.* ..... (C) 649
Lepromin-induced suppressor activity in lymphocytes cultured from leprosy skin lesions. Modlin, R. L., *et al.* ..... (A) 707
Lymphocyte suppression in leprosy induced by unique *M. leprae* glycolipid. Mehra, V., *et al.* ..... (A) 680
Specific suppression of responses to *Leishmania tropica* by a cloned T-cell line. Liew, F. Y. ..... (A) 362

Surgery,
Reconstruction of the heel with chronic ulceration with flexor digitorum brevis myocutaneous flap. Shuh, A. and Pandit, S. ..... (A) 513
Silastic imprint of the first dorsal interosseous space. Zacharia, A. G. and Gelber, R. H. ..... (C) 643
Surgical decompression of the ulnar nerve. Srinivasan, H. ..... (A) 359
Surgical Reconstruction and Rehabilitation in Leprosy. Fritschi, E. P. ..... (B) 129
Surgical reconstruction of the hand with triple nerve palsy. Sundararaj, G. D. and Mani, K. ..... (A) 513

Switzerland,
Ad Hoc Drug Development Subgroup of the SWG on the Chemotherapy of Leprosy meeting, 10–11 October 1983. ..... (N) 125
Tropical Disease Research Program seventh report published. ..... (N) 660
WHO meeting on multidrug therapy. ..... (N) 126

Systemic lupus erythematosus (SLE),
Different mode of circulating immune complexes and anti-ssDNA antibodies in sera of lepromatous leprosy and systemic lupus erythematosus. Furukawa, F., *et al.* ..... (A) 137
Lepromatous leprosy complicated with systemic lupus erythematosus. Ohkawa, S., *et al.* ..... (A) 675

Temperature,
Minimum temperature felt as hot (MTH)—a new concept for grading the loss of temperature sensation in leprosy patients. Jain, G. L., *et al.* ..... (O) 206
Temperature effects on viability, diphenoloxidase, and permeability of *Mycobacterium leprae.* Prabhakaran, L. and Harris, E. B. ..... (A) 168
Temperature-induced changes in viability, diphenoloxidase and permeability of *Mycobacterium leprae.* Prabhakaran, K. and Harris, E. B. ..... (A) 688

Thailand,
Tuberculoid leprosy in Thailand is associated with HLA-DR2. Schauf, V., *et al.* ..... (A) 163

Thalidomide,
Development of polyneuropathy during thalidomide therapy. Wulff, C. H., *et al.* ..... (A) 514
Effect of thalidomide on induction of antibody synthesis in mice to a T-independent antigen. Shannon, E. J., *et al.* ..... (A) 165
Experimental thalidomide neuropathy: the morphological correlate of reduced conduction velocity. Schroder, J. M. and Matthiesen, T. ..... (A) 672
Rabbit sural nerve responses to chronic treatment with thalidomide and supidimide. Schwab, B. W., *et al.* ..... (A) 330
Thalidomide. A promising new treatment for rheumatoid arthritis. Gutierrez-Rodriguez, O. ..... (A) 151
Thalidomide enhances defective monocyte function in lepromatous leprosy. Nielsen, H. and Bennike, T. ..... (A) 135
Thalidomide in severe orogenital ulceration. Jenkins, J. S., *et al.* ..... (A) 362
Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae. Kurkcuoglu, N., *et al.* ..... (A) 696
Thalidomide induces imbalances in T lymphocyte subpopulations in circulating blood of healthy males. Gad, S. M., *et al.* ..... (A) 502
Thalidomide treatment of prurigo nodularis. Winkelmann, R. K., *et al.* ..... (A) 153

Thalidomide—effect on T cell subsets as a possible mechanism of action. Moncada, B., *et al.* ....(O) 201
Thalidomide-induced peripheral neuropathy. Aronson, I. K., *et al.* ....(A) 148

The Leprosy Mission (TLM),
The Leprosy Mission International's Teaching and Learning Materials in Leprosy. Neville, J. ....(N) 321

THELEP,
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. ....(O) 22

Therapy, see also Chemotherapy,
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability. Gelber, R. H., *et al.* ....(A) 349
A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability and optimal bactericidal therapy. Gelber, R. H., *et al.* ....(A) 172
Combined therapy of leprosy patients with solusulfone, rifampin, and prothionamide. Evstratova, V. A., *et al.* ....(A) 494
Development of polyneuropathy during thalidomide therapy. Wulff, C. H., *et al.* ....(A) 514
Dimociphon in combined therapy of drug-resistant and relapsed leprosy patients. Gnenjuk, T. S. ....(A) 494
Drug interactions in combined antileprosy therapy. Loginov, V. K., *et al.* ....(A) 496
Effect of levamisole therapy on lepromin reaction in lepromatous leprosy cases. Arora, S. K., *et al.* ....(C) 113
Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Steffen, C. ....(A) 608
Evaluation of effectiveness of clofazimine therapy. I. Monitoring of absorption of clofazimine from gastrointestinal tract. Mathur, A., *et al.* ....(A) 670
Hepatitis and multidrug therapy in leprosy with special reference to prothionamide. Kar, H. K., *et al.* ....(A) 669
Hepatotoxicity of combined therapy with rifampicin and daily prothionamide for leprosy. Ji, B., *et al.* ....(A) 134
Managerial implications of multidrug therapy. Askew, A. D. ....(A) 668
Monitoring compliance with anti-tuberculosis therapy. Pitchenik, A. E. ....(A) 135
Multidrug therapy for leprosy in Trinidad and Tobago: a preliminary report. Keeler, R. F. ....(A) 329
Multidrug therapy for multibacillary cases in Wardha District, Maharastra, India. Nilakanta Rao, M. S. and Yellapurkar, M. V. ....(A) 671
Norethisterone and ethinyl estradiol kinetics during dapsone therapy. Joshi, J. V., *et al.* ....(A) 328
Prothionamide and dapsone therapy in leprosy—a clinical study. Kundu, S. K., *et al.* ....(A) 669
The assessment of activity of leprosy process and effectiveness of antileprosy therapy by excess lactate in blood. Ryzhova, N. Y. ....(A) 501
The dynamics of immunological parameters in lepromatous leprosy patients as related with various methods of therapy. Kuzina, Z. A. ....(A) 503
The pharmacology of intermittent clofazimine therapy in Hansen's disease. Morales, M. J., *et al.* ....(A) 166
WHO meeting on multidrug therapy. ....(N) 126

Thiacetazone,
Acute severe peripheral neuropathy due to thiacetazone. Gupta, P. K., *et al.* ....(A) 328

Thioamide,
An experimental study of the antileprosy activity of a series of thioamides in the mouse. Shepard, C. C., *et al.* ....(O) 587

Tilorone,
A dual effect of tilorone on multiplication of *Mycobacterium leprae* in mice. Levy, L. and Aizer, F. ....(A) 350

Tissue(s),
Fatty acids in *M. leprae* purified from the tissues of the animals with experimental leprosy. Pinchuck, L. M., *et al.* ..... (A) 508
Immunofluorescence studies on *Mycobacterium leprae* in fixed tissues. Krotoski, W. A. and McCormick, G. T. ..... (A) 177
In vitro cultivation of leprosy granulation tissue and the effect of rifampin on it. Anokhina, V. V. ..... (A) 493
The adenosine triphosphate content and death rate of *Mycobacterium leprae* isolated from armadillo tissue by Percoll buoyant density centrifugation. Kvach, J. T., *et al.* ..... (A) 169
Tissue and blood T-lymphocyte subpopulations in erythema nodosum leprosum. Modlin, R. L., *et al.* ..... (A) 338

Tobago,
Multidrug therapy for leprosy in Trinidad and Tobago: a preliminary report. Keeler, R. F. ..... (A) 329

Toxicity,
Toxicity of prothiomide plus rifampicin (or isobutylpiperazinyl rifamycin) and dapsone in the treatment of multibacillary leprosy. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. ..... (A) 134

Training,
Hansenologia (textbook on leprosy). Talhari, S. and Neves, R. G. ..... (B) 131
ILEP Catalogue on Training, 1985. ..... (N) 490
Schieffelin Leprosy Research and Training Centre, Karigiri, 1985–1986 Course Schedule (India). ..... (N) 320
Teaching and Learning in Leprosy. O'Connor, R. J. ..... (N) 664
Training workshop held (India). Christian, M. ..... (N) 660

Transfer,
Adoptive transfer of cell-mediated immunity in *M. leprae*-infected nude mice with *M. leprae*-immunized allogeneic leukocytes depleted of Thy-1.2-bearing cells and Lyt-2.2-bearing cells. Chehl, S. K., *et al.* ..... (A) 720
Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. ..... (A) 502
Median nerve function after tendon transfer for ulnar paralysis. Brandsma, J. W. and Brand, P. W. ..... (A) 513
Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens. Kirkpatrick, C. H., *et al.* ..... (A) 514

Trial(s),
Absence from sera from normal individuals or from rifampin-treated leprosy patients (THELEP trials) of antibody to rifamycin-protein or rifamycin-membrane conjugates. Rook, G. A. W. ..... (O) 22
Antileprosy vaccines—field trials and future prospects. Deo, M. G. ..... (A) 502
New leprosy vaccine trial. ..... (N) 661
Ten year evaluation of a trial of chemoprophylaxis against tuberculosis in Frobisher Bay, Canada. Dorken, E., *et al.* ..... (A) 149

Trinidad,
Multidrug therapy for leprosy in Trinidad Tobago: a preliminary report. Keeler, R. F. ..... (A) 329

Tuberculin,
A new method for testing tuberculin skin reactivity—chamber test. Backman, A., *et al.* ..... (A) 360
Giant reactions to tuberculin in lepromatous leprosy patients. Waters, M. F. R. and Stanford, J. L. ..... (O) 546
Qualitative differences in tuberculin reactivity in patients with tuberculosis, occupational contacts and non-contacts. El-Ansary, E. H. and Grange, J. M. ..... (A) 149
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* ..... (A) 360

Tuberculoid leprosy,
Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R. B., *et al.* .....(A) 504
Quantitation of HLA-DR expression by cells involved in the skin lesions of tuberculoid and lepromatous leprosy. Collings, L. A., *et al.* .....(A) 678
Short course treatment of tuberculoid cases—a feasibility study. Girdhar, B. K., *et al.* .....(A) 668
Tuberculoid leprosy in Thailand is associated with HLA-DR2. Schauf, V., *et al.* .....(A) 163
Vitiligo on tuberculoid patches—a case report. Misra, R. S., *et al.* .....(A) 333

Tuberculosis,
An enzyme immunoassay for studying humoral immunity to tuberculosis. Castets, M., *et al.* .....(A) 149
Cell-mediated immune response in intestinal tuberculosis. Bhargava, D. K., *et al.* .....(A) 360
Cutaneous inoculation tuberculosis secondary to "jailhouse tatooing." Horney, D. A., *et al.* .....(A) 514
Detection of an antigen (MY4) common to *M. tuberculosis* and *M. leprae* by "tandem" immunoassay. Praputpittaya, K. and Ivanyi, J. .....(A) 681
Determination of *in vitro* susceptibility of *Mycobacterium tuberculosis* to cephalosporins by radiometric and conventional methods. Heifets, L. B., *et al.* .....(A) 361
Dissection of *Mycobacterium tuberculosis* antigens using recombinant DNA. Young, R. A., *et al.* .....(A) 699
Fixation of *Mycobacterium leprae* in unstained smears prior to shipment or storage: evaluation of formaldehyde using *Mycobacterium tuberculosis* as indicator of efficacy. Allen, B. W. .....(A) 685
Haptoglobin: an immunoregulatory role in tuberculosis? Grange, J. M., *et al.* .....(A) 361
In vitro activity of ampicillin compared to ampicillin and sulbactam against *Mycobacterium tuberculosis.* Cynamon, M. H., *et al.* .....(A) 165
Intra-ocular tuberculosis associated with a penetrating injury. A case report. Murray, R. I. and Daya, H. .....(A) 697
Molecular biology of host-parasite relationship in infectious diseases, especially in salmonellosis, tuberculosis, and leprosy. Akiyama, T. .....(A) 334
Monitoring compliance with anti-tuberculosis therapy. Pitchenik, A. E. .....(A) 135
Monoclonal antibodies and recombinant DNA technology: present and future uses in leprosy and tuberculosis. Seckl, M. J. .....(E) 618
Operational evaluation of treatment for tuberculosis; results of a "standard" 12-month regimen in Peru. Hopewell, P. C., *et al.* .....(A) 696
Pattern of drug resistance in tuberculosis. Hardas, U. D. and Jayaraman, V. S. .....(A) 695
Periodic acid-Schiff reaction stains *Mycobacterium tuberculosis, M. leprae, M. ulcerans, M. chelonei* (*abscessus*), and *M. kansasii.* Wear, D. J., *et al.* .....(A) 684
Production and characterization of monoclonal antibodies to *Mycobacterium tuberculosis.* Kolk, A. H. J., *et al.* .....(A) 338
Qualitative differences in tuberculin reactivity in patients with tuberculosis, occupational contacts and non-contacts. El-Ansary, E. H. and Grange, J. M. .....(A) 149
Recombinant DNA clones expressing *M. leprae* and *M. tuberculosis* antigens: potential new tools for immunodiagnosis and prophylaxis. Mehra, V., *et al.* .....(A) 727
Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of *Mycobacterium tuberculosis.* Goren, M. B., *et al.* .....(A) 150
Safety of thrice-weekly rifampin for tuberculosis in Southeast Asian refugees. Mukerjee, C. M. and McKenzie, D. K. .....(A) 697
Serodiagnosis of pulmonary tuberculosis in Argentina by enzyme-linked immunosorbent assay (ELISA) of IgG antibody to *Mycobacterium tuberculosis* antigen 5 and tuberculin purified protein derivative. Balestrino, E. A., *et al.* .....(A) 360
Serum angiotensin-converting enzyme and delayed hypersensitivity in pulmonary tuberculosis. Grange, J. M., *et al.* .....(A) 151
Species-specific epitopes on protein molecules of *Mycobacterium leprae* or *M. tuberculosis*: elucidation with monoclonal antibodies. Buchanan, T. M. .....(A) 715
Ten year evaluation of a trial of chemoprophylaxis against tuberculosis in Frobisher Bay, Canada. Dorken, E., *et al.* .....(A) 149
The influence of immunosuppression and immunodeficiency on infections with leprosy and tuberculosis. Strickland, N. H. .....(E) 86
Tuberculosis and leprosy in antiquity: an interpretation. Manchester, K. .....(N) 326

Tumor(s),
Immunosuppressive activities of peritoneal and splenic macrophages in murine leprosy: effect on lymphocyte transformation and tumor growth. Ha, D. K. K., *et al.* ....(A) 146

Tunisia,
Tendences nouvelles en leprologie, 4–6 Novembre 1985, Sousse. ....(N) 122

Turtle(s),
An attempt to infect turtles (*Kinosternon leucostomum*) with *Mycobacterium leprae* and *M. lepraemurium.* Rojas-Espinosa, O., *et al.* ....(A) 691

U.K.
1984 Sixth Clayton Memorial Lecture: Leprosy and the Eye. ....(N) 127
Chemotherapy of Leprosy for Control Programs videotape available. ....(N) 126
ILEP Catalogue on Training, 1985. ....(N) 490
"Learn About Leprosy," new Leprosy Mission International booklet. ....(N) 127
New edition of Dr. Browne's "Leprosy." ....(N) 127
OXFAM Mini Pack available. ....(N) 661
Robert Cochrane Fund for Leprosy. ....(N) 128
The Leprosy Mission International's Teaching and Learning Materials in Leprosy. Neville, J. ....(N) 321

Ulcer(s),
A case of squamous cell carcinoma in plantar ulcer in leprosy. Bobhate, S. K., *et al.* ..(A) 331
Carcinoma in plantar ulcers in leprosy. Fleury, R. N. and Opromolla, D. V. A. ....(A) 331
Neuropathic plantar ulceration. Kumar, K., *et al.* ....(A) 694
Neuropathic ulcers of the foot. Lang-Stevenson, A. I., *et al.* ....(A) 694
Reconstruction of the heel with chronic ulceration with flexor digitorum brevis myocutaneous flap. Shuh, A. and Pandit, S. ....(A) 513
Squamous cell carcinoma developing trophic ulcers in leprosy—a case report. Kumar, K. and Kant, M. ....(A) 333

Ultrastructure, see also Electron microscopy,
Experimental leprosy in the armadillo and nude mice: comparative histobacteriology and ultrastructure. Ravisse, P., *et al.* ....(A) 352
Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Weldon, J. S., *et al.* ....(A) 153
Ultrastructural and histophysiological studies on the blood-nerve barrier and perineurial barrier in leprosy neuropathy. Boddingius, J. ....(A) 138
Ultrastructural aspects of oral and facial lepromatous lesions. Reichart, P. A., *et al.* ...(A) 682
Ultrastructural study of epidermal Langerhans' cells in leprosy. Mathur, N., *et al.* .....(A) 503
Ultrastructure of leprous phlebitis. Mukherjee, A., *et al.* ....(O) 571
Ultrastructure of sciatic nerve of armadillo infected with *Mycobacterium leprae.* Mehta, L. N. and Antia, N. H. ....(A) 338

Upper Volta,
Prevalence of secondary dapsone-resistant leprosy in Upper Volta. Pattyn, S. R., *et al.* ..(A) 330

Urine,
Anti-*Mycobacterium leprae* antibodies in urine from lepromatous patients examined by crossed immunoelectrophoresis and radioimmunoassay. Olcén, P., *et al.* ....(A) 144
Urine test for monitoring regular self-administration of dapsone and its application. Department of Leprology, Institute of Dermatology, Chinese Academy of Medical Sciences. ....(A) 133

U.S.A.
12th Annual Conference of the National Council for International Health (NCIH) scheduled. ....(N) 128
Analysis of immunologic and genetic factors in multicase families with Hansen's disease in Hawaii. Ching, C. Y., *et al.* ....(A) 163
Centers for Disease Control (CDC) position opening. ....(N) 490
Dates for major 1986 seminars at Carville. ....(N) 128
First U.S. Hansen's Disease Research Conference, 13–15 August 1984, Carville, Louisiana. ....(A) 154

Hansen's disease in Arizona. Campos-Outcalt, D. and Pust, R. E. ..... (A) 493
Leprosy in the U.S.; risks, recognition, regimens, resources. Pust, R. E. and Campos-Outcalt, D. ..... (A) 666
Leprosy in wild armadillos (*Dasypus novemcinctus*) of the Texas Gulf Coast. Smith, J. H., *et al.* ..... (A) 358
Low prevalence of serologic evidence of polyclonal B cell activation among Hansen's disease patients in Seattle. Miller, R. A., *et al.* ..... (A) 182
New leprosy cases in the U.S. in 1984. ..... (N) 319
Specific health problems of Southeast Asian refugees in middle Tennessee. Dao, A. H., *et al.* ..... (A) 132
The Heiser Program for Research in Leprosy 1986. ..... (N) 662
Treatment of leprosy in the United States. Levis, W. R. ..... (A) 329
Twentieth Joint Leprosy Research Conference, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 12–13 August 1985. ..... (A) 700

U.S.-Japan Cooperative Medical Science Program,
Twentieth Joint Leprosy Research Conference, Bethesda, Maryland, U.S.A. ..... (—) 700

Vaccination,
Antileprosy vaccines—field trials and future prospects. Deo, M. G. ..... (A) 502
Does infection with environmental mycobacteria suppress the protective response to subsequent vaccination with BCG? Smith, D., *et al.* ..... (A) 363
Effects of *Mycobacterium leprae* vaccinations on cell-mediated immune functions of Lewis rats: specific sensitization vs tolerance. Humphres, R. C. and Winters, M. A. ..... (A) 174
Efficacy of *Mycobacterium bovis* BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Orme, I. M. and Collins, F. M. ..... (A) 697
Induction of delayed-type hypersensitivity by ICRC antileprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan, A. and Bapat, C. V. ..... (A) 502
Leprosy—in pursuit of a vaccine. Stewart-Tull, D. E. S. ..... (A) 666
New leprosy vaccine trial. ..... (N) 661
Prophylactic effect in mice of BCG vaccination against nontuberculous mycobacterial infections. Orme, I. and Collins, F. M. ..... (A) 698
Prospects for early diagnosis, immunotherapy, and vaccination for leprosy. Buchanan, T. M. ..... (A) 335
Recombinant vaccinia virus: immunization against multiple pathogens. Perkus, M. E., *et al.* ..... (A) 698
Simulation of vaccination and resistance in leprosy using an epidemiometric model. Lechat, M. F., *et al.* ..... (O) 461
Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Mackett, M., *et al.* ..... (A) 353

Venezuela,
Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan population. Ottenhoff, T. H. M., *et al.* ..... (A) 148

Vietnam,
Association between leprosy and immunoglobulin allotypes: Gm-A2m and Km frequencies in Vietnamese. de Lange, G., *et al.* ..... (A) 355
Serum immunoglobulins, including IgG subclasses, in Vietnamese leprosy patients. Wright, E. P., *et al.* ..... (O) 225

Vitamin(s),
Vitamin E and dapsone-induced hemolysis. Kelly, J. W., *et al.* ..... (A) 135

World Health Organization (WHO),
Epidemiology of Leprosy in Relation to Control. Report of a WHO Study Group. WHO Tech. Rpt. Ser. 716. ..... (B) 491
..... (N) 663

Results of a World Health Organization-sponsored workshop on monoclonal antibodies to *Mycobacterium leprae*. ..... **(A)** 682
WHO meeting on multidrug therapy. ..... **(N)** 126